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Notations
• x: scalar x
• x: vector x
• {xa:b}: set of vectors {xa,xa+1, . . . ,xb 1,xb}
• X: matrix X
• X 0: X transpose
• p(A): probability of A
• p(A|B): probability of A conditional on B
• E(X): expectation of random variable X
• X / Y : X is proportional to Y
•  2
(k): chi-square distribution with k degrees of freedom
• Mult(⇡): multinomial distribution of probability parameter ⇡
• NiW (µ
0
,
0
,⇤
0
, 
0
): Normal inverse-Wishart distribution of parameters (µ
0
,
0
,⇤
0
, 
0
)
• sNiW (⇠
0
, 
0
,B
0
,⇤
0
, 
0
): structured Normal inverse-Wishart distribution of pa-
rameters (⇠
0
, 
0
,B
0
,⇤
0
, 
0
) [Frühwirth-Schnatter and Pyne, 2010]
•  d(x): the d-dimensional gamma function
• zd(x): the d-dimensional digamma function
Abbreviations
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cRNA: complementary Ribonucleic Acid
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NOTATIONS AND ABBREVATIONS
CRP: Chinese restaurant process
DNA: Deoxyribonucleic Acid
DP: Dirichlet Process
DPM: Dirichlet Process Mixture
EM: Estimation-Maximisation algorithm
FDR: False Discovery Rate
FWER: Family Wise Error Rate
GEM: Griffiths-Engen-McCloskey distribution [Pitman, 2006]
GO: Gene Ontology [Ashburner et al., 2000]
KEGG: Kyoto Encyclopedia of Genes and Genomes [Kanehisa and Goto, 2000]
MAP: Maximum a posteriori
MCMC: Monte-Carlo Markov Chain
MLE: Maximum Likelihood Estimation
mRNA: messenger Ribonucleic Acid
MSEP: Mean Squared Error of Prediction
NiW: Normal inverse-Wishart distribution
OLS: Ordinary Least Squares
OR: Odds Ratio
PLS: Partial Least Squares
PRESS: PRediction Error Sum of Squares
RMSEP: Root Mean Squared Error of Prediction
RSS: Residual Sum of Squares
sPLS: sparse Partial Least Squares
sNiW: structured Normal inverse-Wishart distribution [Frühwirth-Schnatter and Pyne,
2010]
TcGSA: Time-course Gene Set Analysis
TIV: Trivalent Inactivated seasonal influenza Vaccine
Thi: Testosterone level high
Tlo Testosterone level low
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Résumé substantiel
1 Introduction
L’analyse de données d’expression génique est bien identifiée comme un problème où
la grande dimension des données nécessite des outils statistiques spécifiques et sophis-
tiqués. Néanmoins, les mesures phénotypiques effectuées dans le cadre d’essais cliniques
vaccinaux sont à l’heure actuelle également devenues des données de grande dimension.
Ainsi, la biologie et les études cliniques sont également sujettes à la multiplication des
données dans le phénomène actuel représenté par les « Données Massives » (Big Data).
Par exemple, les populations de cellules immunitaires sont mesurées via des cytomètres à
8 ou 16 couleurs, permettant de distinguer jusqu’à 216 populations de cellules différentes,
qui sont elles-mêmes bien souvent suivies sur plusieurs intervalles de temps. Par ailleurs,
il existe plusieurs techniques afin d’évaluer la fonction des cellules prélevées : l’ELISPOT,
la cytométrie avec marquage intracellulaire et le luminex (quantification de la production
de multiples cytokines). . . Ces méthodes conduisent à obtenir plusieurs centaines d’obser-
vations pour un individu donné, pour un temps de mesure donné. Une analyse intégrative
a pour enjeu de relier tous ces différents types de données, données qui sont toutes de
grande dimension.
2 Analyse par groupe de gènes de données d’expression
génique au cours du temps
Introduction
L’expression génique est un processus dynamique à la racine de tout mécanisme mé-
tabolique, qui repose sur les mécanismes de transcription et de traduction de l’ADN. De
nombreuses technologies existent à l’heure actuelle pour étudier ce mécanisme, à diffé-
rents niveaux biologiques. Mais étant de moins en moins chères, les expériences de puces
à ADN (microarray) sont de plus en plus utilisées pour l’évaluation de l’expression gé-
nique au cours du temps. L’analyse de changements temporels de l’expression génique
contribue à une meilleure compréhension des mécanismes de régulation des gènes. Plu-
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sieurs approches ont été proposées pour analyser ces données longitudinales de grande
dimension, gène-par-gène [Storey et al., 2005], en réduisant leur dimension [Liquet et al.,
2012], ou bien par groupes de gènes [Wang et al., 2009]. Un groupe de gènes est un
ensemble de gènes a priori co-régulés ou liés de manière fonctionnelle. Les processus bio-
logiques définis par KEGG ou Gene Ontology, ainsi que les modules fonctionnels définis
par Chaussabel et al. [2008] sont des exemples de groupes de gènes. L’analyse par groupes
de gènes [Subramanian et al., 2005; Efron and Tibshirani, 2007] est supposée être plus
puissante que l’analyse gène-par-gène, car elle peut détecter le changement coordonné de
l’expression d’un groupe de gènes sans qu’aucun d’entre eux ne rencontre individuellement
un changement très significatif. De plus, le changement de l’ensemble des gènes au sein
d’un processus biologique particulier peut avoir plus d’importance sur le plan biologique
qu’une modification importante d’un seul gène. Enfin, et à condition que les groupes de
gènes soient bien définis, les résultats d’une analyse par groupes de gènes devraient être
plus interprétables et plus reproductibles que ceux obtenus par une analyse gène-par-gène
[Subramanian et al., 2005].
L’analyse de données d’expression génique répétées au cours du temps par groupes de
gènes présente un certain nombre de spécificités. L’une d’entre elles est que les change-
ments dans l’expression génique peuvent être hétérogènes au sein d’un groupe de gènes
donné [Efron and Tibshirani, 2007; Ackermann and Strimmer, 2009]. La fréquence de ce
phénomène [Ackermann and Strimmer, 2009] nous empêche de l’ignorer, d’autant que l’on
ne s’attend pas à ce que les gènes impliqués dans un même processus biologique varient
de manière synchrone.
Le choix de l’hypothèse nulle est un des éléments déterminants dans une méthode
d’analyse par groupe de gènes. On peut les répartir en deux grandes classes [Goeman and
Bühlmann, 2007] : i) les hypothèses nulles compétitives, qui testent les gènes d’un groupe
contre tous les gènes en dehors de ce groupe ; ii) les hypothèses autonomes, qui n’utilisent
que les gènes à l’intérieur du groupe. Ici nous nous intéressons à un sous-type d’hypothèse
autonome, « l’hypothèse nulle mixte » : H
0
: les gènes à l’intérieur d’un groupe de gènes
sont stables au cours du temps. Cette hypothèse nulle mixte permet de détecter à la fois
les groupes de gènes aux changements homogènes, et ceux aux changements hétérogènes.
A noter que la modification de l’expression d’un gène au cours du temps pourra ne pas
être correctement capturée par la modélisation mais de toute façon sera diagnostiquée via
l’hétérogénéité engendrée au sein d’un groupe de gènes.
Nous proposons ici une méthode d’analyse longitudinale par groupe de gènes Time-
course Gene Set Analysis (TcGSA) basée sur la vérification d’hypothèses utilisant des
effets aléatoires pour tester directement la significativité de groupes de gènes définis a
priori. Elle tient compte de la possible hétérogénéité des groupes de gènes et est robuste
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aux designs déséquilibrés dus à des valeurs manquantes aléatoirement grâce aux estima-
tions du maximum de vraisemblance.
Méthodes
Modèles mixtes pour l’expression d’un groupe de gènes
Soit S un groupe de gènes d’intérêt. Dans le cas d’un seul groupe de traitement (où
chaque patient est son propre contrôle), l’expression génique est modélisée au cours du
temps via la fonction f :
Pour tous les gènes g 2 S, ygpi = µ+  g + cgp + fg(ti) + "gpi (1)
où ygpi est l’expression du gène g du patient p mesuré au temps i, µ est le niveau moyen
d’expression dans le groupe de gènes S,  g est l’effet fixe du gène g, cgp ⇠ N (0,  c) est
un effet aléatoire, ti est le ième temps de mesure, "gpi ⇠ N (0,  ) est un terme d’erreur, et
fg(ti) est une fonction du temps (linéaire, polynomiale, splines, etc). Chaque coefficient
de f est en réalité composé de deux parties : un effet fixe du temps et un effet aléatoire
(permettant de tenir compte de l’hétérogénéité) du temps. Des variations autour de ce
modèle sont proposées dans l’implémentation de TcGSA.
Test de la significativité d’un groupe de gènes
On veut alors tester l’ensemble des coefficients de fg(·) simultanément afin de pouvoir
détecter à la fois les groupes de gènes changeant de façon homogène et les groupes de
gènes changeant de façon hétérogène. Un Test du Rapport de Vraisemblance (TRV) est
la manière la plus naturelle de le faire, en estimant le modèle (1) sous l’hypothèse nulle
(fg(·) = 0) et sous l’alternative (fg(·) 6= 0). Néanmoins, la distribution du TRV sous l’hy-
pothèse nulle n’est pas triviale lorsque l’on teste simultanément plusieurs effets aléatoires
et fixes. Il est possible de l’approximer [Self and Liang, 1987; Molenberghs and Verbeke,
2007] par un mélange de lois du  2 dépendant du nombre d’effets fixes et du nombre
d’effets aléatoires à tester :
LRTH0 ⇠
q+rX
k=q
✓
r
k   q
◆
2
 r 2
(k)
où q est le nombre d’effets fixes et r le nombre d’effets aléatoires à tester simultanément.
Habituellement, on va s’intéresser à plusieurs groupes de gènes dans une même analyse,
et de nombreux TRV vont être calculés. Il est alors indispensable de corriger pour la
multiplicité des tests.
19
RÉSUMÉ SUBSTANTIEL
Visualisation
Une fois qu’un groupe de gènes S a été identifié comme significatif, on veut résumer sa
dynamique temporelle. Néanmoins, à cause de la possible hétérogénéité de S, ce n’est pas
évident. Nous proposons d’identifier automatiquement le nombre de tendances différentes
à l’intérieur de S grâce à la statistique gap développée par Tibshirani et al. [2001]. Par
ailleurs, on s’intéresse souvent à un grand nombre de groupes de gènes (quelques centaines
à quelques milliers) à la fois. Une conséquence supplémentaire de cette multiplicité (outre
la nécessité de corriger le niveau de significativité du TRV) est de rendre la visualisation
des résultats difficile. Nous proposons de représenter l’ensemble des différentes tendances
que peuvent contenir chacun des groupes de gènes significatifs au sein d’une même repré-
sentation (carte de chaleur ou heatmap). Les tendances ayant une dynamique semblable
sont rapprochées par une classification hiérarchique. Les dynamiques générales animant
les données sont alors visibles, et des interactions entre diverses fonctions biologiques
peuvent apparaître.
Applications
Simulations
Une étude de simulation a démontré d’excellentes propriétés de l’approche TcGSA,
tant au niveau du contrôle de l’erreur de type-I que de la puissance statistique dans le cas
de données longitudinales.
L’essai DALIA-1
L’essai DALIA-1 est un essai de vaccin thérapeutique contre le VIH de phase 1 (détails
sur http ://clinicaltrials.gov/ct2/show/NCT00796770). Le candidat vaccin est basé sur
des cellules dendritiques productrices d’interféron-↵ générées ex-vivo, chargées avec des
lipopéptides de VIH-1, et activées avec du lipopolysaccharide. Nous nous intéressons ici
aux mesures de l’expression génique durant cet essai (mesuré en sang total avec des puces
Illumina HumanHT-12 v4 Expression BeadChips). Les patients, infectés par le VIH, ont
reçu le vaccin alors qu’ils étaient traités par un traitement antirétroviral (ARV) durant la
phase de vaccination, avant d’interrompre leur traitement ARV durant la seconde phase
de l’essai.
Après pré-traitement des données (modèle de mélange normal-exponentiel [Shi et al.,
2010], suivi de la méthode ComBat [Johnson et al., 2007] pour corriger les effets tech-
niques), on dispose finalement dans cet essai de 14 temps de mesure chez 18 patients
infectés par le VIH. Les données se repartissent sur deux phases distinctes, et séparées
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pour cette analyse : i) la phase de vaccination (5 mesures) ; ii) la phase après l’arrêt de
traitement antirétroviral (9 mesures). Dans cette analyse, nous nous sommes intéressés à
des groupes de gènes relatifs au système immunitaire définis par Chaussabel et al. [2008].
La méthode TcGSA, appliquée à ces 260 modules fonctionnels, a nettement amélioré
les résultats par rapport à une analyse gène-par-gène de l’expression différentielle au
cours de la phase de vaccination. En effet, une analyse gène-par-gène n’avait révélé aucun
changement significatif après correction pour la multiplicité des tests, alors que TcGSA a
identifié 69 groupes de gènes significatifs. Par ailleurs, après l’interruption du traitement
ARV, TcGSA détecte un changement significatif de nombreux modules. Ce second résultat
était attendu puisque l’arrêt du traitement ARV représente une source de perturbation
importante pour le système immunitaire.
Étude vaccinale
TcGSA a également été appliqué à une étude comparant le vaccin anti-pneumocoque
et le vaccin anti-grippe à un placebo [Obermoser et al., 2013]. Une analyse par groupe de
gènes de l’expression génique répétée suite à la vaccination, testant également les modules
de Chaussabel et al. [2008], y a originellement été menée à l’aide d’un modèle linéaire plus
simple (de manière transversale, sans tenir compte des données répétées). Les résultats ob-
tenus par TcGSA d’une part ont confirmé ceux de Obermoser et al. [2013], et d’autre part
les ont complété, notamment grâce à la puissance statistique accrue de l’approche TcGSA.
L’un des principaux apports de TcGSA a été la double identification d’un ensemble de
cinq modules (M3.2, M4.2, M4.13, M5.1 et M5.7) liés aux voies biologiques (pathway) de
l’inflammation. Ces derniers, qui n’étaient identifiés que dans le vaccin anti-pneumocoque
par Obermoser et al. [2013], ont été identifiés dans les deux vaccins par TcGSA.
Conclusion
Les mesures répétées d’expression génique sont de plus en plus courantes. Appli-
quée dans des études transversales, l’analyse par groupe de gènes a démontré ses qua-
lités en termes de sensibilité et d’interprétation. Nous étendons ici cet outil aux données
longitudinales d’expression génique, en tenant compte de la possible hétérogénéité des
groupes de gènes. Notre approche TcGSA teste si les gènes appartenant à un groupe
donné ont une expression stable au cours du temps, grâce aux estimations du maxi-
mum de vraisemblance. Cette approche peut s’appliquer dans le cas de données déséqui-
librées dues à des données manquantes aléatoirement. Une classification non supervisée
des dynamiques estimées pour les gènes appartenant à un groupe de gènes est ensuite
réalisée, afin d’y exhiber les principales tendances. Nous avons appliqué TcGSA dans
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l’essai DALIA-1, un essai de vaccin thérapeutique contre le VIH au cours duquel des
patients infectés par le VIH-1 ont reçu un vaccin à base de cellules dendritiques, avant
d’arrêter temporairement leur traitement antirétroviral. La méthode TcGSA, appliquée
à 260 modules fonctionnels, a nettement amélioré les résultats par rapport à une ana-
lyse gène-par-gène au cours de la phase de vaccination en identifiant 69 modules aux
dynamiques significatives. D’autres résultats encourageant ont également été obtenus
par TcGSA sur une étude comparant deux vaccins préventifs à un placebo. Une étude
de simulations a démontré la puissance statistique de l’approche TcGSA pour des don-
nées d’expression génique longitudinales. La méthode TcGSA a été implémentée sous
dans le package TcGSA, dont la dernière version est disponible sur le CRAN repository
(http://cran.r-project.org/web/packages/TcGSA/index.html).
3 Analyse intégrative de l’expression génique dans deux
essais vaccinaux
Ce chapitre présente deux analyses intégratives dans le cadre d’essais vaccinaux. La
première concerne l’essai de vaccin thérapeutique contre le VIH DALIA-1 déjà présenté
dans la section précédente, la seconde une étude de la différence de la réponse au vaccin
anti-grippale trivalent. L’enjeu de ces deux analyses est à chaque fois de révéler une
partie des mécanismes sous-jacents qui expliqueraient pourquoi certains patients ont une
meilleure réponse immunitaire que d’autres à la suite de la vaccination.
Analyse intégrative de l’essai DALIA-1
Au cours de l’essai DALIA-1, en plus de la mesure répétée de l’expression génique,
différents marqueurs immunologiques ont été mesurés. Notamment, le maximum de la
charge virale lors du rebond observé suite à l’interruption thérapeutique. Selon Lévy et al.
[2014], les 16 patients suivis peuvent être séparés en deux groupes de même taille selon leur
maximum de charge virale, avec d’une part ceux dont le logarithme (en base décimale)
de ce maximum est inférieur à 5 et qui sont considérés comme de bons répondeurs, et
d’autre part ceux pour qui il est supérieur à 5 et qui sont considérés comme de mauvais
répondeurs. Afin d’identifier une signature d’expression génique associée à ce maximum
d’intensité du rebond viral suite à l’interruption thérapeutique, nous avons effectué une
analyse sparse Partial Least Squares (sPLS) [Le Cao et al., 2008] associant des marqueurs
immunologiques à l’expression génique des 5 399 gènes participant aux modules identifiés
comme actifs durant la phase de vaccination par TcGSA.
La méthode Partial Least Squares (PLS) recherche pour chacune des deux matrices de
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données mises en relation, des variables latentes qui sont des combinaisons linéaires des
variables originales, et qui maximisent la covariance entre elles. Cette recherche est répétée
dans un processus itératif (similaire à celui de la construction des composantes principales
lors d’une ACP par exemple), afin de construire des variables latentes orthogonales deux à
deux pour une même matrice de données, qui maximisent à chaque fois la covariance avec
la variable latente correspondante pour l’autre matrice de données. La méthode sPLS est
une extension de la PLS où les variables latentes sont creuses (sparse), c’est-à-dire que peu
de variables originales contribuent à une variable latente, grâce à l’ajout d’une pénalité
de type LASSO par exemple dans la maximisation de la covariance.
On a effectué une analyse sPLS mettant en relation l’expression génique ayant évo-
luée au cours de la vaccination (69 modules identifiés par TcGSA) avec la production de
cytokines (interféron- , IL-2, IL-13, I-L21), la polyfonctionnalité des cellules CD4, deux
scores calculés à partir des données Luminex [Lévy et al., 2014], et le rebond viral maxi-
mum dichotomisé. Cette analyse a permis d’associer une plus faible expression des voies
biologiques inflammatoires suite à la vaccination à une meilleure réponse immunitaire
lors de l’interruption thérapeutique. Des analyses de sensibilité ont confirmé la signature
identifiée au niveau des Modules de Chaussabel et al. [2008]
Analyse systémique des différences entre les sexes dans la réponse
au vaccin anti-grippal
Le sexe est connu pour être une source importante de variabilité immunologique entre
les individus. Ainsi, les hommes sont plus fréquemment sujets à des infections que les
femmes, ces dernières montrant également une meilleure réponse aux vaccins [Klein, 2000;
Klein and Poland, 2013]. Néanmoins les mécanismes biologiques à l’œuvre derrière ces
différences sont encore mal compris. A l’heure actuelle, aucune association claire n’a été
établie entre de telles différences biologiques et cliniques entre les sexes. Dans une étude,
Klein et al. [2010] a montré que la plupart des gènes différentiellement exprimés lors
de la vaccination contre la fièvre jaune [Gaucher et al., 2008], étaient en réalité activés
préférentiellement chez les femmes. Néanmoins, ces différences n’ont pour l’instant pas
été associées à de faibles taux d’anticorps.
Afin d’étudier les différences dans le système immunitaire entre les hommes et les
femmes, nous avons analysé des données provenant d’une étude récente portant sur 91
individus (37 hommes et 54 femmes) répartis dans deux groupes d’âge (de 20 à 30 ans et
de 60 à 89 ans) [Furman et al., 2013]. Un grand nombre de marqueurs immunologiques a
été mesuré avant la vaccination dans le sang circulant tels que la production de cytokines,
chemokines, diverses fréquences de populations cellulaires, ainsi que l’expression génique
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en sang total. L’expression des gènes avait auparavant été résumée en 109 variables re-
présentant 109 groupes de gènes définis à partir de ces mêmes données [Furman et al.,
2013]. Par ailleurs, quatre individus furent retirés de l’analyse à cause de prélevements
manquants.
La réponse au vaccin est évaluée par le rapport entre le taux d’anticorps micro-
neutralisants avant et après la vaccination. Les individus sont considérés bons répondeurs
si ce rapport est supérieur ou égal à quatre. Parmi les trois souches de virus contenues dans
le vaccin (H1N1, H3N2, B), la différence la plus marquée entre les sexes a été observée
pour la souche H3N2, sur laquelle la suite des analyses s’est concentrée.
Afin d’évaluer l’association entre le sexe et la probabilité d’être un bon ou un mauvais
répondeur au vaccin pour la souche H3N2, on a utilisé un modèle de régression logistique.
Dans un premier temps, deux variables potentiellement confondantes pour l’effet du sexe
sur la probabilité d’être un bon répondeur ont été identifiées, à l’aide d’une stratégie
ascendante d’inclusion des variables modifiant le coefficient lié au sexe de plus de 20%
dans la régression logistique. Il s’agit d’un groupe de gènes lié à la production de protéines
ribosomales, ainsi que du marqueur d’inflammation aiguë CRP (C Reactive Protein).
Ensuite, on a appliqué une méthode innovante développée par Simon and Tibshirani [2012]
pour l’identification d’interactions significatives dans un modèle linéaire où la variable
réponse est binaire, qui permet d’assurer un contrôle du taux de faux positifs (FDR)
correct dans un contexte de grande dimension. On a ainsi identifié l’effet différentiel selon
le sexe d’un groupe de gènes lié au métabolisme lipidique sur la réponse au vaccin.
Finalement, il s’avère que cette interaction est d’autant plus importante lorsqu’on
stratifie les hommes selon leur niveau de testostérone (une hormone dont la concentration
est très basse chez les femmes) : plus leur niveau de testostérone est élevé, plus l’influence
de l’expression de ce groupe de gènes sur la probabilité d’être un bon répondeur est
contrastée par rapport à celle observée chez les femmes.
4 Modèles de mélange de distributions t asymétriques
à processus de Dirichlet pour la modélisation de données
de cytométrie en flux
La cytométrie en flux est une technologie à haut débit utilisée pour quantifier simulta-
nément différents marqueurs cellulaires de surface et intracellulaires, à l’échelle individuelle
de chaque cellule. Les développements et améliorations de cette technologie permettent
aujourd’hui de décrire des millions de cellules individuellement à partir d’un échantillon
sanguin, et ce sur plusieurs marqueurs. En conséquence, on obtient des jeux de données
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de taille plus d’un million de fois supérieure à celle d’il y a quelques années, dont le
traitement manuel se révèle très fastidieux et peu reproductible.
De nombreuses méthodes ont été développées afin de distinguer automatiquement les
différentes populations cellulaires à partir de telles données [Aghaeepour et al., 2013].
Cependant, la plupart d’entre elles s’intéressent au cas d’un seul échantillon (chez un
seul patient) utilisant très peu de couleurs (c’est-à-dire de marqueurs). D’autant que dans
le cadre d’essais cliniques, on dispose maintenant habituellement des mesures pour une
douzaine de marqueurs, mesures souvent répétées pour chaque patient à chaque temps de
mesure.
Nous proposons une approche bayésienne non paramétrique pour modéliser ce type de
données par des modèles de mélange à processus de Dirichlet [Ferguson, 1973; Antoniak,
1974; Lo, 1984; Escobar and West, 1995; Teh, 2010]. De tels modèles permettent d’estimer
le nombre de populations cellulaires différentes sans avoir recours à des outils de sélection
de modèle destinés à choisir le modèle comprenant le nombre de populations cellulaires le
plus adapté aux données. Notre modélisation étend le modèle de mélange gaussien à pro-
cessus de Dirichlet à la distribution skew t [Azzalini and Capitanio, 2003] (asymétrique et
à queue lourde), basée sur la paramétrisation de Frühwirth-Schnatter and Pyne [2010]. Si
C est le nombre de cellules observées, et yc désigne l’observation des différents marqueurs
cellulaires pour la cellule c, et k est l’indice de la population cellulaire, notre modèle peut
s’écrire :
↵|a, b ⇠ Gamma(a, b)
⇡
  ↵ ⇠ GEM(↵)
pour k = 1, 2, . . .
⇠k, k,⌃k, ⌫k ⇠ G0
pour c = 1, 2, . . . , C
`c
  
⇡ ⇠ Mult(⇡)
 c
   `c, (⌫k) ⇠ Gamma
⇣⌫`c
2
,
⌫`c
2
⌘
sc
    c ⇠ N[0,+1[
✓
0,
1
 c
◆
yc
   `c,  c, sc, (⇠k, k,⌃k) ⇠ N
✓
⇠`c + `csc,
1
 c
⌃`c
◆
Un tel modèle est particulièrement approprié pour la classification non supervisée de
données de cytométrie en flux grâce aux trois caractéristiques suivantes : i) il évite de fixer
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le nombre de populations à identifier en l’estimant directement à partir des données ; ii)
les données de cytométrie en flux sont particulièrement bien représentées par des distri-
butions asymétriques et à queue lourde telles que la skew t (dont la loi normale est un cas
particulier) ; iii) il produit une estimation de la probabilité a posteriori de co-classification
pour chaque paire d’observations, permettant ainsi une quantification de l’incertitude au-
tour de la partition des données. Nous avons développé un algorithme d’échantillonnage
de Gibbs partiellement replié (partially collapsed [van Dyk and Park, 2008; van Dyk and
Jiao, 2013]) basé sur l’échantillonnage par tranche (slice sampling [Neal, 2003; Walker,
2007; Kalli et al., 2011] pour estimer de tels modèles. Nous l’avons implémenté en sous
la forme d’un package, NPflow, qui est actuellement encore en développement.
Dans le cas où les mesures de cytométrie en flux sont répétées au cours de l’étude,
nous proposons une stratégie d’approximations séquentielles du posterior (sous l’hypo-
thèse que l’ensemble des données proviennent de la même distribution), en traitant les
échantillons répétés les uns à la suite des autres, lors de l’acquisition des données. Cela
permet d’utiliser l’information a priori obtenue sur les échantillons précédents pour pou-
voir traiter l’échantillon courant, sans avoir à attendre la fin de l’étude et de devoir traiter
l’ensemble des données simultanément, à l’inverse d’approches hiérarchiques telles que
celles proposées par Cron et al. [2013] ou Dundar et al. [2014].
En comparant nos résultats sur des jeux de données réelles utilisés dans une com-
pétition visant à comparer un grand nombre d’approches de traitement automatique de
données de cytométrie en flux, nous avons obtenu des résultats dans la moyenne des dif-
férents algorithmes proposés. Sur les simulations, la stratégie d’estimation séquentielle du
posterior offre des résultats prometteurs. Néanmoins, il faut reconnaître que l’évaluation
rigoureuse des algorithmes de traitement automatiques des données de cytométrie en flux
est rendue difficile en l’absence d’une véritable référence (gold-standard) pour les don-
nées réelles. En effet, à l’heure actuelle on utilise le traitement manuel comme référence
malgré le fait avéré qu’il soit relativement variable d’un opérateur à l’autre, peu reproduc-
tible et bien souvent ne couvre pas tout l’espace des observations [Ge and Sealfon, 2012;
Aghaeepour et al., 2013]. Une solution pourrait être d’utiliser un consensus entre diffé-
rents traitements, manuels ou automatiques, des données à la place d’un seul traitement
manuel [Aghaeepour et al., 2013].
5 Discussion générale
Grâce à de nombreuses améliorations technologiques, les données aujourd’hui générées
dans la recherche vaccinale permettent d’étudier de manière très précise les cellules pré-
levées, de l’expression de leurs gènes à leur production de cytokines, en passant par leurs
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marqueurs de surface. Ces données sont intrinsèquement de grande dimension, même au
niveau des populations cellulaires. Au cours de ce travail, nous nous sommes efforcés de
proposer de nouveaux outils statistiques afin d’améliorer l’analyse de telles données et
d’intégrer différents niveaux biologiques au sein d’une même analyse. Une idée prépondé-
rante qui sous-tend l’ensemble de ce travail est la recherche de l’utilisation au maximum
de l’ensemble de l’information disponible. Elle se fait d’une part en incorporant de l’in-
formation a priori dans la modélisation statistique, et d’autre part en intégrant toutes
les données mesurées, dans l’espoir d’améliorer les résultats d’inférence et leur interpréta-
tion. Cette ambition est motivée par le renforcement des mesures longitudinales dans la
recherche biologique et clinique, y compris pour les données de grande dimension. Ainsi,
à la fois pour les données d’expression génique, et pour les données de cytométrie en flux,
nous avons développé de nouvelles approches statistiques afin d’essayer de tirer partie de
telles mesures répétées.
Nous avons proposé une approche d’analyse par groupe de gènes spécialement centrée
sur les mesures longitudinales, qui permet de répondre avec une puissance statistique op-
timale à la question « Quels sont les groupes de gènes dont la dynamique d’expression
évolue au cours de l’étude ? », comblant certaines lacunes par rapport aux approches si-
milaires de la littérature [Subramanian et al., 2005; Efron and Tibshirani, 2007; Hummel
et al., 2008; Shahbaba et al., 2011; Wu and Smyth, 2012]. Néanmoins, dans le cas d’ana-
lyses par groupes de gènes, une attention toute particulière doit être portée aux groupes
de gènes testés, car ceux-ci constituent en réalité le premier niveau d’hypothèse du mo-
dèle. Si dans ce travail, nous les avons considérés connus a priori, il existe en réalité un
veritable domaine de recherche pour l’inférence de voies biologiques à partir de données
temporelles d’expression génique [Wu et al., 2014; Ratmann et al., 2009]. Par ailleurs,
nous nous sommes focalisés sur les données de puce à ADN dans ce travail, mais il existe
d’autres façons de mesurer l’expression génique. Par exemple les méthodes de séquençage
direct de l’ARN, bien plus précises que les puces à ADN. Si leur traitement fait encore
l’objet de développements actifs à la recherche de méthodes appropriées, il semble néan-
moins que notre méthode TcGSA soit facilement transposable à ce type de données en se
basant sur l’approche de Law et al. [2014]. Il s’agit simplement de modéliser directement le
logarithme de la proportion d’ARN mesuré tout en tenant compte de l’hétéroscédasticité
à l’aide de pondérations de la précision.
Concernant notre modélisation des données de cytométrie en flux par des modèles de
mélange de distributions skew t à processus de Dirichlet, plutôt que de nous tourner vers
une approche hiérarchique telle que celles proposées par Cron et al. [2013] ou [Dundar
et al., 2014], nous avons choisi une stratégie d’estimation séquentielle qui ne requiert pas
de traiter l’ensemble des données en une seule estimation. Face à l’augmentation des tailles
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d’échantillons, notamment due à des mesures longitudinales, nous pensons que c’est un
avantage en faveur de notre approche. Les perspectives de développement et d’application
de ce travail sont importantes notamment par l’utilisation à la fois sur des données de
moins grande dimension recueillie au cours du suivi des patients hospitalisés et sur des
données de plus grandes dimensions avec les nouvelles techniques de spectrométrie de
masse (CytoF).
Enfin, si nous avons développé deux exemples d’analyses intégratives dans cette thèse,
qui ont chacune conduit à formuler de nouvelles hypothèses sur les processus biologiques
sous-jacents, une étape supplémentaire serait d’utiliser les données de cytométrie en flux
afin de déconvoluer l’expression génique (plus correctement l’abondance génique) avec les
variations de population cellulaire, à la manière de Shen-Orr et al. [2010] mais au cours du
temps. Cela permettrait de faire la distinction entre une variation d’abondance due à la
circulation de certaines populations cellulaires spécifiques, et une variation d’abondance
due à un réel changement d’expression au niveau des cellules.
L’analyse du déluge de données qu’est en train de connaître la recherche biologique et
clinique nécessite de nouvelles méthodes statistiques, qui sont en train d’être développées.
De telles méthodes sont souvent spécifiquement adaptées à chaque question d’analyse,
et donc aux données disponibles. Ces données, qui sont les observations complexes d’un
système encore plus complexe, nécessitent des modélisations sophistiquées, interdisant le
plus souvent l’utilisation de statistiques éprouvées qui se révèlent trop simplistes et ne per-
mettent pas de répondre à la question posée. Ce phénomène offre aux biostatisticiens des
perspectives de recherche ambitieuses, à une époque où les collaborations translationnelles
sont devenues indispensables.
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1 Introduction
1.1 The analysis of high dimensional data in clinical
research
Statistics for high-dimensional data has been a field of growing interest for a few
decades, including biostatistics for high-dimensional data (Figure 1.1). More recently, the
term "Big Data" has been coined to designate the flow of high dimensional data generated
in various contexts. We have definitely entered the "Big Data" era, as one can see from a
search on Google Trends (Figure 1.2). Apart from the current hype that surrounds this key
words, the real underlying phenomenon at play is the massive production of data, at a rate
that keeps increasing. The main data providers are the usuals suspects: particle physics
(data from particle colliders), astronomy (data from high definition telescopes such as
Planck), Facebook, YouTube, emails. . . But medicine and biology are also involved in the
increasing amount of data generated [Marx, 2013]. At the end of the twentieth century,
the first human genome took more than 10 years to be sequenced, with an associated
cost exceeding 3 billion dollars. Today, 10 years later, a whole genome can be sequenced
within the day at a cost not exceeding 1,000 dollars. Technological headways have made
data much cheaper and much easier to get. In addition to sequencing and other genomics
data, every biomedical data type is concerned: from peptides (proteomics), to imaging
(fMRI data), to cellular markers (high-throughput flow-cytometry). All these biomedical
big – or high-dimensional – data have lead to the publication of an always increasing
number of related articles indexed on Pubmed (Figure 1.1). Moreover, because of the
need for tackling the issues that arise from such data, the development of methods for
high-dimensional data is soaring (even though "high-dimensional" data is not brand new
in biostatistics, the first occurrences of this term in the literature dating back to the mid-
seventies). But the challenge does not only concern the volume of data. The increase in
the amount of information is coupled with an increase in complexity of the data, generated
from different sources. The resulting requirement of integrating such a high variety of data
constitutes a key challenge in the analysis of big data.
The increase of collected data also affects clinical trials [Thiébaut et al., 2014]. The
measurement of whole genome expression has become more and more common in human
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clinical trials, sometimes at repeated time points. In addition to genomics measures,
imaging, flow cytometry and other high-throughput technology measures can often be
part of clinical measurements, leading to the idea of deep phenotyping of individuals
[Tracy, 2008; Robinson, 2012]. All these add up to create real big clinical trial data. The
particularity of this context is that the high-dimension of the data concerns each patients.
This is somewhat different from the context of the big data observed in the web or in other
industries for instance. The question however remains how to deal with such amounts
of data. In exploratory analyses, the number of potential associations to be investigated
rapidly increases as with data dimensionality, raising multiplicity issues. If analysis is
not done carefully, the number of false positive grows very rapidly. Moreover, those high
dimensional data are often generated from different sources, different tissues, and measure
various aspects of a biological reality. Indeed, gene expression, intracellular cytokine
production, cell surface markers, etc. can be measured for the same patient. Analyzing
all those different kinds of data simultaneously for the same individual is very complex.
The data generated through this deep phenotyping of individuals needs to be integrated
to answer a given research question. On the one hand, the information carried by all the
data altogether is often largely superior to the noise of the numerous measurements. On
the other hand, a thorough analysis of all these data requires sophisticated statistical tools
and thoughtful analysis strategy. Furthermore, the high dimensionality implies substantial
computation times.
Most of the works presented in this thesis emanate from a specific therapeutic HIV
vaccine trial: the DALIA-1 trial. It is a therapeutic HIV vaccine clinical trial in which 19
patients were vaccinated. This trial evaluated the administration of a dendritic cell based
vaccine to HIV infected patients as a way to boost their immune response against HIV
infection. In order to better understand the underlying biological mechanisms activated
by this vaccine, a huge number of data were collected during this trial: longitudinal gene
expression in the blood was repeatedly measured with microarrays over the course of the
trial, as well as blood cell markers that were measured with flow cytometry and multiplex
technologies.
1.2 The search for an effective HIV vaccine
Since the beginning of the pandemic, HIV/AIDS has caused more than 35 (95% CI:
35-43) million deaths. Today, 35.3 (95% CI: 32.2-38.8) million people are living with HIV
and 2.3 (1.9-2.7) million new cases of HIV infection occur per year [The Joint United
Nations Programme on HIV/AIDS (UNAIDS), 2013, 2014]. The development of highly
active antiretroviral therapies has improved the prognostic of infected individuals [Lewden
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et al., 2007]. It may also impact the pandemic by reducing the transmission of the virus
[Granich et al., 2009]. Several approaches have already demonstrated their efficacy such
as male circumcision [Auvert et al., 2005] or antiretroviral prophylaxis [Abdool Karim
et al., 2010; Grant et al., 2010]. Vaccination is usually the most effective intervention
to prevent and control infectious diseases but the development of HIV vaccine remains
challenging in particular because of the high variability of its genomic sequence [Rappuoli
and Aderem, 2011].
Promising advances in HIV vaccine development include novel approaches in immu-
nization strategies, including prime-boost immunization with heterologous vectors (e.g.
attenuated viral vectors, protein-based vaccines) and new methods for antigen presenta-
tion. The first positive results from a phase 3 trial (the RV144 Trial) showing a vaccine
efficacy of 31% has underlined the relevance of prime-boost strategies [Rerks-Ngarm et al.,
2009]. Researchers are now developing and comparing several prime boost strategies using
different combinations of candidates to ultimately increase the vaccine efficacy. New ways
of antigen presentation are also emerging. Immunologists are now able to load HIV-1
antigens in the best antigen presenting cells, i.e. dendritic cells [Cobb et al., 2011]. Such
a monocyte-derived dendritic cell vaccine is currently evaluated in phase 1 trials such as
the DALIA-1 trial. One approach to improve delivery of protein vaccines to dendritic
cells is to introduce the protein into monoclonal antibodies that efficiently target den-
dritic cell receptors. In macaques, the immunological response has been then showed to
improve [Flynn et al., 2011], and it could be oriented according to the targeted dendritic
cell receptor[Cobb et al., 2011; Flamar et al., 2013].
Vaccines are a corner stone of modern medicine. It is by no comparison the single most
effective intervention against an infectious disease [Pulendran and Ahmed, 2011]. One of
the main challenge in developing an effective HIV vaccine is the identification of predictive
correlates of immunity [Roederer et al., 2014]. Indeed, if the first vaccines date back to
more than 200 years, the details of the immunological pathways triggered by vaccines still
remains partly unknown [Pulendran and Ahmed, 2011]. Hopefully, the late downpour of
data faced in clinical trials will help to improve this knowledge. Nevertheless analyzing
this stream of complex data requires new approaches suited for this high-dimensional,
versatile context. Recently, systems biology approaches have been developed in order
to integrate global sets of biological data from many hierarchical levels. Their goal is to
identify emergent properties that are not demonstrated and cannot be predicted from their
individual parts alone [Zak and Aderem, 2009]. The system analysis of vaccine usually
aims at finding signatures that are predictive of protection, but they can also provide
insights into the mechanisms underlying protection. A good example is the yellow fever
vaccine. A recent microarray analysis gave signatures taken 3 and 7 days after yellow
32
INTRODUCTION
fever vaccination that are able to predict B- and T-cell responses measured at a later
time [Querec et al., 2008]. Gene expression analysis also highlighted the activation of
some components of the immune system that were not expected, and are not usually
explored phenotypically, such as the innate immune system.
1.3 Methodological challenges
In high-dimensional settings, standard modeling tools, such as multivariate linear mod-
els for instance, are usually not identifiable. Solutions to methodological challenges faced
with high-dimensional data include resorting to (over-) simplistic univariate modeling
strategies, correcting for the multiplicity downstream of the analysis, performing vari-
able selection, or adding prior biological knowledge to reduce the model complexity. In
multivariate linear models, high-dimensionality generally prevents the use of Ordinary
Least Squares (OLS) estimators (more details are presented in Appendix C page 131).
Indeed co-linearities between covariates quickly arises as their number increase. In the
extreme but common case where the number of individuals is lower than the number of
covariates considered, the OLS. One can still perform a regression analysis by penalizing
the likelihood to optimize. Different penalties are available, relying on different norms of
the regression coefficient vector: for instance the LASSO penalty (L1 norm) [Tibshirani,
1996], the ridge penalty (L2 norm) [Hoerl and Kennard, 1970] or the elastic net (balance
between L1 and L2 norms) [Zou and Hastie, 2005].
One might therefore consider high dimensionality only as an obstacle to overcome in
an analysis process. However, high dimensionality can revealed itself as a major asset in
separating noise from signal. As an example, VSURF [Genuer et al., 2010] leverages the
high dimensionality of the data to estimate the level of variability of a noise variable. Be-
sides, many multiple testing correction methods require to estimate the proportion of true
positive as precisely as possible [Guedj et al., 2009]. In both cases the high-dimensionality
of the data becomes a strength for the estimation procedure. High dimensionality of the
data can in fact be both a complication and a helper regarding the analysis.
High-dimensional data are often structured data. For example the fact that gene
expression likely precedes cellular cytokines production induces a structure between the
gene expression variables and cytokines production variables. In addition an important
amount of prior knowledge can be available; this prior knowledge can sometimes help to
identify even deeper structures, such as in the case of gene expression data with prior
information taking the form of pathway databases like Gene Ontology [Ashburner et al.,
2000] or KEGG [Kanehisa and Goto, 2000]. Taking into account the structure and the
prior knowledge can lead to significant improvement in the modeling strategy, for example
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by influencing a variable selection procedure, or by decreasing the loss of statistical power
due to multiplicity correction, etc.
Another recent challenge appeared through the repetition of the measurements by
high throughput assays. This constitutes a great opportunity to better disentangle the
relationship between markers, but requires specific approaches that take into account
the hierarchical structure of the data. However, being able to separate the within and
between individual variability might be very informative. For instance, it can help in
identifying groups of patients for which the response to the intervention differs, leading to
the potential of personalized medicine. As a practical example, sex can be an important
factor influencing the immune response to vaccine [Klein et al., 2010; Klein and Pekosz,
2014].
An integrative analysis of high dimensional data is all the more powerful than prior
knowledge and natural structure of the data are used, while as much heterogeneity as
possible is taken into account. However, depending on which modeling strategy is chosen,
some of these goals can be relatively difficult to achieve.
1.4 Thesis objective and outline
The work described in this document is primarily motivated by this new surge of
data, especially in the context of clinical trials. Data that cannot be ignored, but whose
high-dimensionality requires more complex analyses. The level of gene expression is well
recognized as a high dimensional level that needs specific statistical tools for its sound
analysis. However, phenotypic measures in vaccine trials are also high dimensional. Im-
mune cell populations are measured by 8 to 16-color cytometers making it theoretically
possibile to distinguish up to 216 types of cells. Moreover such measurements are often
repeated over time, during the follow-up of patients. Hence, an integrative analysis should
relate these noisy high dimensional data, that is transcriptomics with phenotypic data.
First, this thesis presents an original methodological development for the analysis of
longitudinal gene expression data, taking into account prior biological knowledge in the
form of predefined gene sets. Then, the thesis focuses on two integrative analyses per-
formed on two different vaccine trials, against HIV and against flu, respectively. Finally,
the thesis introduces a new model-based clustering approach for the automated treatment
of cell populations from flow-cytometry data, namely a Dirichlet process mixture of skew
t-distributions.
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2 Time course gene set analysis
Abstract: Gene expression measurements have revolutionized the way to monitor bio-
logical activity among living organisms. Thanks to microarray technology, whole genome
gene expression can be measured from a simple blood sample.
After specific preprocessing of gene expression data, standard univariate gene-by-gene
analysis often suffer from a lack of power due to multiplicity correction. In order to gain
in statistical power, gene set analysis methods use prior biological knowledge to analyze
such gene expression data. This prior knowledge takes the form of predefined groups of
genes, linked through their biological function. Gene set analysis methods results are
more sensitive and interpretable than those of methods investigating genomic data one
gene at a time, and they have been successfully applied in cross-sectional studies.
The time-course gene set analysis (TcGSA) introduced here is an extension of such
gene set analysis to longitudinal data. This method identifies a priori defined groups of
genes whose expression is not stable over time, taking into account the potential hetero-
geneity between patients and between genes. When biological conditions are compared,
it identifies the gene sets that have different expression dynamics according to these con-
ditions. Data from two studies are analyzed: data from an HIV therapeutic vaccine trial,
and data from a recent study on influenza and pneumococcal vaccines. In both cases,
TcGSA provided new insights thanks to an increased sensitivity compared to standard
approaches. Those results highlight the benefits of the TcGSA method for analyzing gene
expression dynamics.
Key Words: Gene expression; Gene set analysis; Likelihood, ratio test; Linear mixed
effects model; Longitudinal data;
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2.1 Gene expression data
Genes are the vector of heredity. From one cell to another, from one organism to
its descendants, they constitute the information that is passed across generations. It is
encoded through Deoxyribonucleic Acid (DNA). In the human body, each cell contains
the whole DNA of a person, encapsulated inside its nucleus. Yet, differentiation processes
results in many different types of cell inside the body, with very different functions. In
spite of having the same genome, those cells are different because they express different
genes.
Gene expression is a dynamic process at the root of any metabolic reaction. The
expression of the information encoded in the genes occurs in two steps: i) transcription,
during which DNA is transcribed into messenger ribonucleic acid (mRNA); ii) translation,
during which mRNA is translated to produce a protein (Figure 2.1). DNA is a double
stranded polymer with a double helix shape, made of four basic nucleotides (adenine,
cytosine, guanine and thymine, respectively denoted A, C, G and T ). mRNA is a single
stranded molecule. It is complementary to the nucleotid sequence of the DNA molecule
(where the uracile nucleotide, denoted U , replaces the thymine). Finally, proteins are
made of 20 different amino acids, each being coded by a specific triplet of 3 consecutive
nucleotides from mRNA [Dudoit et al., 2002]. 
DNA mRNA Protein 
Figure 2.1 – Representation of the metabolic production chain
Gene expression can therefore be studied at many different levels. Microarrays are
a convenient way to measure mRNA across the whole genome. Microarrays are made
of microscopic spots attached on a solid surface (often glass or silicon). Each spot is
filled with a specific nucleic acid (DNA or RNA) sequence. Those specific sequences
are carefully engineered, in order to hybridize to characterized gene or candidate gene
transcripts. Hybridization between two DNA (or two RNA) strands is the property of
a nucleic acid sequence to specifically match only with its complementary sequence (by
forming hydrogen bonds between them). Their size allows genome-wide transcriptional
coverage, as tens of thousands of transcripts are profiled on a single microarray.
Numerous industrial companies market gene expression microarrays that measures
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mRNA levels in a biological sample (Illuminar, Affymetrixr, Agilent. . . ). Although mi-
croarrays may involve slightly different technologies, all rely on hybridization of labeled
nucleic acid (either RNA or DNA) from the biological samples to predefined comple-
mentary probes fixed on the microarray [Schulze and Downward, 2001; Patel, 2008]. As
an example, the Illuminar technology is based on the following steps: i) mRNA is ex-
tracted from the biological samples through purification; ii) this mRNA is then converted
to double stranded DNA through reverse transcription; iii) this DNA is then amplified
into complementary RNA (cRNA) through in vitro transcription using biotin labeled nu-
cleotides; iv) this cRNA is then hybridized with the probes present on the array (Figure
2.2); vi) the excess of cRNA that has not hybridized with any probes is washed away; vii)
biotin is bound to a fluorescent molecule (Cy3 fluorescent dye via streptavidin bound)
viii) Fluorescence emission is measured with a laser scanner [Strachan and Read, 1999;
Illumina, 2010].
A: Picture of a BeadChip from
Illuminar with 12 microarrays
Address Probe
Biotin 
Labeled 
cRNA
B: Schematic representation of the direct hybridization
process
Source: Illumina, Inc.
Figure 2.2 – Illuminar HumanHT-12 v4.0 Expression BeadChip
The gene expression could be measured on whole blood as on specific cells after selec-
tion, this latter process being much more expensive and complex. The gene expression
in whole blood or peripheral blood mononuclear cells (PBMC) would be more appro-
priately called gene abundance, as the variation of the measures could be due to either
a variation of gene expression by cells, or a variation of the number of cells expressing
a given gene. Gene expression data are usually high-dimensional data. Indeed, a gene
expression microarray generally measures a few tens of thousands of probes (for instance,
Illuminar HumanHT-12 v4.0 Expression BeadChip arrays target a little bit more than
47,000 transcripts). As of today, a gene expression microarray costs a little less than
US$100 per sample (depending on the manufacturer), so most of the time there are more
probes measured than individuals ("p >> n" kind of problem).
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2.2 Gene expression analysis of microarray data
2.2.1 Gene expression data pre-processing
Gene expression is especially prone to technical variability [Hartemink et al., 2001]. It
is therefore mandatory to preprocess such data, in order to ensure the comparability of
the different samples measured.
The very first step when dealing with gene expression data is the quality control of the
data. First and foremost, one generally has to make sure that enough RNA was available
from each biological sample, and that its integrity was not low [Schroeder et al., 2006].
Then, various graphics tools can be useful for identifying outlier samples, whose signal
intensity distribution across all the probes is significantly different compared to the other
samples [Irizarry et al., 2003].
Background correction Gene expression microarrays are systematically subject to
some background noise signal. There are various methods to correct the data for this
background noise, but those are highly dependent on the microarray technology used [Wu
et al., 2004; Shi et al., 2010]. For the Illumina plateform, numerous negative control
probes (that do not bind to any known cRNA) are used to measure the background level.
Then a normal-exponential convolution model can be fitted to estimate which part of the
observed signal is attributable to background noise and which part constitutes the actual
biological signal [Xie et al., 2009].
Normalization In order to stabilize the variance of the signal in regards of the in-
tensity, it is desirable to reduce the scale of the data [Shi et al., 2010], for instance by
applying a log2 transformation (a small offset can be added to all the data prior to this
transformation). At this point there is usually still a lot of unwanted variability between
the different samples of a study. Under the hypothesis that only a few probes are highly
expressed, regardless of the sample, a quantile normalization [Bolstad et al., 2003] can
be applied to reduce the between-sample variability. Such a normalization makes the as-
sumption that the gene expression signal overall distribution should be the same from one
sample to another. If the quantile normalization assumption is too strong or not suitable
for a specific context (for instance with different tissues or in case of acute infection), loess
normalization [Yang et al., 2002] (based on robust local regression) can be used instead.
Both Bolstad et al. [2003] and Shi et al. [2010] perfom comparison of various normalization
strategies.
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Batch effect removal Finally, potential batch effects must be investigated (and cor-
rected when possible). Microarrays are very sensitive to batch effects as their measure-
ments are easily affected by experimental conditions. Such batch effects can have a sub-
stantial impact on the final results Leek et al. [2010]; Parker and Leek [2012].
Several methods exist for the quantification and identification of batch effect, such as
the PVCA [Boedigheimer et al., 2008; Li et al., 2009] or the more recent PC-PR2 [Fages
et al., 2014]. Both of above mentioned methods rely on a two step procedure: i) a principal
component analysis of the expression data; ii) either a variance component analysis via
multivariate linear mixed effect modeling of each component, or partial R2 computation
via a multivariate linear regression. PC-PR2 determines the variability imputable to
non categorical variables or technical variables with only a few batches to be correctly
estimated compared to the PVCA, and takes into account some correlation between the
explanatory variables.
Once batch effects are identified, it is desirable to correct the signal for those unwanted
batch effects. Several methods are available to remove batch effects [Chen et al., 2011].
Two approaches seems particularly efficient: on the one hand the ComBat algorithm,
which is based on empirical Bayesian estimation of a location/scale model [Johnson et al.,
2007]; and on the other hand, the Surrogate Variable Analysis (SVA), which is based on
surrogate variables identification and construction from the estimated residual data once
the primary effect of interest is removed [Leek and Storey, 2007]. The two methods takes
two rather different approaches to the problem of batch effect: the ComBat algorithm aims
at "correcting" the data for batch effects; whereas SVA constructs surrogate variables for
inferred batch effects and any downstream analyzes must be adjusted on those surrogate
variables to take into account batch effects. The ComBat algorithm has the advantage
of taking into account potential batch effects on the variance of the signal. It can use
either parametric Normal and inverse-Gamma prior distributions for the batch effects
respectively on mean and variance, or non-parametric prior distributions. In both case
prior distributions are estimated from the data in an empirical Bayes manner. The SVA
algorithm is supposed to be able to identify batch effect even when the batch variable
is unknown. Both methods face difficulties when batches are collinear with variables of
biological interest.
2.2.2 Standard differential expression analysis
The most common approach to deal with the high dimensionality of gene expression
data (e.g. 47,000 transcripts by sample) is to perform a univariate analysis for each probe
on pre-processed data. If the results of these analyses are summarized as p-values (for
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instance an association test is performed for each probes with a biological variable of
interest), then those p-values can be corrected for the multiple testing issue (Appendix A
page 121).
A popular and efficient method to derive such probe wise p-values is to use empir-
ical Bayes estimation of linear models [Smyth, 2004]. An empirical Bayes model refers
to Bayesian model in which the prior parameters are estimated from the data instead
of reflecting expert prior knowledge (which in practice, often results in non-informative
conjugate priors) [Casella, 1985; Efron, 2014].
The results of such differential expression analyses typically take the form of lists
of differentially expressed genes between different biological conditions. This can have
two shortcomings: first such lists can be hard to interpret (especially if a lot of genes are
significantly differentially expressed), as genes; second, only strong individual gene signals
can be picked up, due to the (much needed, but conservative) multiplicity correction.
2.2.3 Gene set analysis
Gene set analyses focus on predefined sets of genes, that are linked a priori by their
biological function or their co-expression in given biological settings. Gene set analyses are
more powerful than gene-by-gene univariate analyses [Subramanian et al., 2005] as they
use more information. Furthermore, it is biologically more relevant to detect the small
but concomitant variation of the expression of several genes from a given pathway than
an intense variation of a couple of genes. Results from gene set analyses are also easier to
interpret as they are usually directly annotated with relevant biological functions.
Several methods available to perform gene set analysis, that can be separated into two
groups:
i) enrichment analyses are two steps procedures, first requiring univariate analysis of
the data, and then using each probe to determine if a given set of genes is over
represented among differentially expressed genes; [Subramanian et al., 2005; Barry
et al., 2005; Efron and Tibshirani, 2007]
ii) direct gene set analyses assess the significance of a given gene set in a single step;
[Kim and Volsky, 2005; Hummel et al., 2008; Wang et al., 2009; Shahbaba et al.,
2011]
The enrichment procedures, despite their "top-down" approach of the problem [Liu et al.,
2007], are the most popular, notably due to the commercial software Ingenuityr Pathway
Analysis, and other "point & click" software that implements enrichment approaches.
Another classification of the methods can be made on the type of hypothesis that is
tested to identify significant gene sets (subsection 2.3.1).
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One of the key step in a gene set analysis is the gene set definition. Several gene
set databases exist: on the one hand Gene Ontology [Ashburner et al., 2000] or KEGG
[Kanehisa and Goto, 2000] are widely used system-wide gene sets definitions, driven by
biological knowledge ; on the other hand data driven immunological gene sets have been
derived by Chaussabel et al. [2008] (Modules) and Li et al. [2013] (BTM) based on co-
expression across multiple biological conditions. According to Li et al. [2013] data driven
gene sets such as the BTM are more sensitive than knowledge driven gene sets such as
KEGG or GO. The Modules and the BTM are similar in their principle, their main dif-
ference being that Modules were derived from data concerning 9 immune related patholo-
gies produced with the Illuminar technology, whereas BTM were obtained from public
datasets produced on different platforms. Numerous other knowledge based database
exist: PANTHER is focused on proteins and their related genes, based on phylogenetic
trees extrapolations [Mi et al., 2013] it takes advantage of experiments across different
organisms to increase biological knowledge; the Reactome Knowledgebase also focuses
on protein molecular functions and reactions [Croft et al., 2014], etc. Finally gene set
analyses can also be performed with data-driven gene set defined directly on the same
observed expression through co-expression.
2.3 Time course gene set expression analysis
This section is mainly part of an article that was submitted for publication in Plos
Computational Biology and that is currently under revision.
Gene set analysis methods, which consider predefined groups of genes in the analysis
of genomic data, have been successfully applied for analyzing gene expression data in
cross-sectional studies. The time-course gene set analysis (TcGSA) introduced here is an
extension of gene set analysis to longitudinal data. The proposed method relies on random
effects modeling with maximum likelihood estimates. It allows to use all available repeated
measurements while dealing with unbalanced data due to missing at random (MAR)
measurements. TcGSA is a hypothesis driven method that identifies a priori defined gene
sets with significant expression variations over time, taking into account the potential
heterogeneity of expression within gene sets. When biological conditions are compared,
the method indicates if the time patterns of gene sets significantly differ according to these
conditions. The interest of the method is illustrated by its application to two real life
datasets: an HIV therapeutic vaccine trial (DALIA-1 trial) where microarray data were
measured every 4 weeks, and data from a recent study on influenza and pneumococcal
vaccines where microarray data where available at day 1, 3, 7 and 21. In the DALIA-1
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trial TcGSA revealed a significant change in gene expression over time within 69 gene
sets during vaccination, while a standard univariate individual gene analysis corrected for
multiple testing as well as a standard a Gene Set Enrichment Analysis (GSEA) for time
series both failed to detect any significant pattern change over time. When applied to the
second illustrative data set, TcGSA allowed the identification of 4 gene sets initially linked
only with the pneumococcal vaccine, as also highly significant with the influenza vaccine.
In our simulation study TcGSA exhibits good statistical properties, and an increased
power compared to other approaches for analyzing time-course expression patterns of
gene sets.
2.3.1 Introduction to time-course gene set analysis
Microarray experiments are increasingly used for evaluating changes in gene expres-
sion over time. The analysis of the temporal change of gene expression should help in
understanding the complex mechanisms of gene regulation. For instance, transcriptional
profiles have been repeatedly measured to study the change in gene expression during the
natural history of SIV/HIV infection [Bécavin et al., 2011; Bosinger et al., 2012] or to
evaluate the effect of vaccines [Querec et al., 2008; Palermo et al., 2011]. In the applica-
tions considered here in section 2.3.3 page 52, the investigators wanted to detect the genes
for which the abundance changed over time after a vaccination (against HIV, influenza or
pneumococcus)[Lévy et al., 2014; Obermoser et al., 2013].
In order to analyze such longitudinal high-dimensional data, several approaches have
been suggested including a gene-by-gene statistical analysis [Storey et al., 2005; Berk et al.,
2012], dimension reduction methods [Liquet et al., 2012] or gene set analysis [Wang et al.,
2009]. A gene set is a group of genes that are a priori co-regulated or functionally linked.
Examples of such gene set relating to biological processes or pathways are those defined by
KEGG [Kanehisa and Goto, 2000], Gene Ontology [Ashburner et al., 2000] or Chaussabel’s
functional modules [Chaussabel et al., 2008]. The gene set analysis [Subramanian et al.,
2005; Efron and Tibshirani, 2007; Maciejewski, 2014] is supposed to be more powerful than
a gene-by-gene analysis because it can detect a change of expression of a group of genes
although none of them show a very high absolute fold change. Furthermore, a change of
all genes in a given pathway may be biologically more meaningful than a large increase
of a single gene. Also, provided that the gene sets are well defined, the result should be
more sound and comparable across studies than a gene-by-gene analysis [Subramanian
et al., 2005]. Finally, gene set analysis avoids a second step for a global interpretation as
described in the "bottom up" approach [Liu et al., 2007; Wang et al., 2009].
The analysis of longitudinal microarray experiments through a gene set approach is
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not trivial because the dynamics of gene expressions inside a gene set can be complex and
heterogeneous. This has already been underlined in some of the approaches developed
to analyze gene sets [Efron and Tibshirani, 2007; Nueda et al., 2009; Shahbaba et al.,
2011; Ackermann and Strimmer, 2009]. Figure 2.3 shows an example of a homogeneous
gene set, whereas Figure 2.4 shows an example of a heterogeneous one. Actually, such
a heterogeneity is frequently observed [Ackermann and Strimmer, 2009], and cannot be
ignored, as genes inside a functional gene set are not expected to change their expression
synchronously (Figure 2.5). Moreover this heterogeneity can be biologically meaningful by
itself. Prieto et al. [2006] provide an example from a cancer application, where deregulated
pathways are of primary biological interest. They identified heterogeneous gene sets linked
to acute promyelocytic leukemia. Another example is given by Hu et al.: pathways affected
by the HER2, such as the KEGG pathways of ’Ubiquitin mediated proteolysis’, ’Glioma’,
and ’Prostate cancer’ were identified by studying heterogeneity [Hu et al., 2013]. The
main advantage of detecting the heterogeneity inside a gene set is to detect any change
over time whatever the specification of the model for the trends. In other words, the
dynamics of gene expression inside a stable gene set will be summarize by a flat slope and
no heterogeneity. Hence, in the spirit of [Shahbaba et al., 2011], to find any significant
change of the overall expression of genes inside a gene set over time, we suggest to look
for any significant trend over time or any heterogeneity between gene trends inside the
gene set.
Several approaches have already been proposed to analyze longitudinal measurements
of gene expression [Storey et al., 2005; Conesa et al., 2006; Guo et al., 2003; Rajicic et al.,
2010; Park et al., 2003; Wolfinger et al., 2001; Luan and Li, 2004], but only a few include
gene set analysis [Hummel et al., 2008; Nueda et al., 2009; Wang et al., 2009; Zhang
et al., 2011]. Among the latter, all but Nueda et al. [2009] fail to account for possible
heterogeneity inside a gene set. An extension of the popular Gene Set Enrichment Analysis
(GSEA) method [Subramanian et al., 2005] is available for the analysis of time series
data. Unfortunately, it does not account for the structure of longitudinal data, simply
treating all observations as independent. The globalANCOVA procedure developed by
Hummel et al. [2008] focuses on the comparison of groups, testing whether there is a
group influence on change over time of any gene expression inside a gene set. In practice,
the global null hypothesis tested is quite flexible relying on the ANOVA framework, but
cannot accommodate missing values. Wang et al. [2009] proposed to use a linear mixed
effects model to explain gene expression inside a gene set. They considered a random
effect for the array level rather than for the patient or the gene level. Zhang et al.
[2011] proposed a robust non-parametric approach to compare gene expression dynamics
between different treatment-groups. Of note, it is not possible to look at the change
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Note: Each line is the median expression of a gene inside this particular gene set across all the patients.
The expression of the genes inside this gene set is quite homogeneous and it is easy to identify a global time
trend, displayed by the dashed black line (smoothed median). For more information see the presentation
of the DALIA-1 trial in section 2.3.3 page 52.
Figure 2.3 – Example of a homogeneous gene set (M1.2: interferon – from the DALIA-1
trial, after treatment interruption)
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Note: Each line is the median expression of a gene inside this particular gene set across all the patients.
The expression of the genes inside this gene set is rather heterogeneous. This makes it difficult to
identify any time trend, as the mean expression inside this gene set stays close to zero. However a closer
look reveals two distinct time trends, displayed by the two respectively dashed and dotted black lines
(smoothed medians). For more information see the presentation of the DALIA-1 trial in section 2.3.3
page 52.
Figure 2.4 – Example of a heterogeneous gene set (M4.16: cell cycle – from the DALIA-1
trial, after treatment interruption)
45
TIME COURSE GENE SET ANALYSIS
G1#
G2#
G3#
G4#
G1#
G2#
G3#
G4#
Biological 
Pathway 
G1 & G2 (regulators) 
G3 & G4 (targets) 
expression 
time 
up-regulated 
down-regulated 
mean 
Time 
Figure 2.5 – Simplistic representation of heterogeneous gene expression dynamics inside
a biological pathway
of gene expression in only one group using either Hummel et al. [2008] or Zhang et al.
[2011] approaches. In contrast, the PCA-maSigFun procedure developed by Nueda et al.
[2009, 2010] can account for possible heterogeneity inside a gene set. It is based on a
Principal Component Analysis (PCA) of each gene set followed by a linear regression of
the significant principal components (i.e. components that have a variation above the
mean gene variance) over time. However, they did not consider time-course experiments
where repeated measures are available for multiple patient. Gene set analysis methods
can also be distinguished by their choice of the null hypothesis. Those can be classified
into two main types of hypothesis: i) the competitive null hypothesis, that tests the genes
inside a given gene set against all the other genes outside the gene set; ii) the self-contained
null hypothesis, that only uses the genes inside the gene set of interest [Tian et al., 2005;
Goeman and Bühlmann, 2007; Ackermann and Strimmer, 2009]. In the present paper,
interest is focused on self-contained null hypotheses because the question was "Which
gene sets have a change of gene abundance over time?".
We propose the implementation of a hypothesis driven method that directly tests
the time-course significance of predefined gene sets: the Time-course Gene Set Analy-
sis (TcGSA). It relies on the use of linear mixed effect models, a very useful and well
established statistical tool [Laird and Ware, 1982; Diggle et al., 2002] especially suited
for longitudinal settings. By using all available repeated measures, it provides increased
statistical power. TcGSA can accommodate for heterogeneity of gene expression within
the gene sets through random effects, and is robust to unbalanced designed due to missing
(at random) values thanks to the maximum likelihood estimates. No previously proposed
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approach combines all of TcGSA features. A simulation study demonstrated the good
statistical performance of the proposed method. It has been applied to two studies: one
HIV vaccine trial, and one influenza and pneumoccocal vaccine study [Obermoser et al.,
2013], using the same definition of gene sets [Chaussabel et al., 2008] that is increasingly
used in systems immunology research [Berry et al., 2010; Zak et al., 2012; Doering et al.,
2012; Simonini et al., 2013; Cliff et al., 2013]. Compared to gene-by-gene analyses, TcGSA
disclosed changes of additional gene sets that endorse previous conclusions [Obermoser
et al., 2013], but also revealed common pathways across the three vaccines.
2.3.2 Time-course Gene Set Analysis method
Time-course Gene Set Analysis
The TcGSA method includes three steps: 1) modeling gene expression in a gene set
with mixed models, 2) testing the significance of a gene set, and 3) estimating individual
gene profiles.
1. Modeling gene expression in a gene set with mixed models Let S be a gene
set of interest. We start by the case of a one group experiment, where each patient act
as her/his own respective control, her/his condition changing over time. The expression
of genes inside S is modeled over time according to a function f as:
for all the genes g 2 S,
ygpi = µ+  g + cgp + fg(ti) + "gpi (1)
where ygpi is expression of the gth gene for the pth patient at the ith time, µ is the intercept
in the gene set S,  g is the fixed effect of the gth gene, cgp ⇠ N (0,  c) is a random effect
grouped by the gth gene of the pth patient, ti is the ith measurement time, "gpi ⇠ N (0,  )
is an error term. Finally fg(ti) is a function of time, that can be linear, polynomials,
etc. Every time coefficient of the trend fg(ti) is actually divided into a fixed effect ⌘·
(representing the average trend in the gene set S) and a random effect hg,· ⇠ N (0,  h·)
grouped on the gene g, accounting for the possible heterogeneity between the genes in
the gene set S. In this paper we focus on three forms for fg (but other forms, such as
exponential, etc. could easily be envisaged):
— linear polynomials:
fg(t) = (⌘1 + hg,1) t
— cubic polynomials:
fg(t) = (⌘1 + hg,1) t+ (⌘2 + hg,2) t
2
+ (⌘
3
+ hg,3) t
3
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— natural cubic splines:
fg(t) =
K+1X
k=1
(⌘k + hg,k)Nk(t)
where the Nk(t) form the natural cubic splines basis [Hastie, 1992] of the time t (with
K internal knots), ⌘· are the fixed effects of time shared across the gene set S, and
hg,· are the random effects of time accounting for possible heterogeneity between genes.
(hg,1, . . . , hg,d) ⇠ N (0,⌃h) with d being the degree of the time function, and for k =
1, . . . , d hg,k ⇠ N (0,  hk). Alternatively, one can make the assumption that the patient
effect is the same for all the genes. In that case, the random effect c is no longer grouped
on the gene level, and the model can be written as:
for all the genes g 2 S,
ygpi = µ+  
0
g + c
0
p + fg(ti) + "gpi (1bis)
with c0p ⇠ N (0,  c0 ) the random effect of the patient p, and   0g ⇠ N (0,   0 ) the random
effect of the gene g . This alternative modeling has the advantage to be more parsimonious
than the model (1), with less parameters to be estimated.
Let’s now consider the case of a multiple group experiment (such as treatment/vaccine
groups for instance). The expression of genes inside S is modeled over time according to
a function fg,m that is now stratified on the groups:
for all the genes g 2 S,
ymgpi = µ+  g +  m + cgp + fg,m(ti) + "gpi (2)
where m indicates which group is concerned and  m is the fixed intercept of the mth group,
everything else being the same as in the model (1).
2. Testing the significance of a gene set In TcGSA, a "significant" gene set is a
gene set whose expression is not stable either over time (in one group experiments) or
over groups (in several groups experiments), once between genes and patients variability
is taken into account. In other words, we want to test the significance of the time trend
while being sensitive to both homogeneous and heterogeneous changes of gene expression
over time inside a gene set. Testing the significance of a given gene set S therefore means
testing both fixed and random effects at once, in a single test. A likelihood ratio test is the
natural way to do so, fitting models under both the null hypothesis and the alternative.
In the case of one group experiment (models (1) and (1bis)) the null hypothesis (H0)
is that the genes inside S are stable over time, i.e. that their expressions are constant
and homogeneous over time (all coefficients of the function of time f are not significantly
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different from zero). The alternative hypothesis (H1) is that the genes inside S vary
significantly over time:
(H0): 8 k, ⌘k = 0 and  hk = 0 (1.0)
(H1): 9 k, ⌘k 6= 0 or  hk 6= 0 (1.1)
In the case of a multiple group experiment (model (2)), the null hypothesis is that
inside the gene set S, the evolution of gene expressions over time is the same regardless
of the group. The alternative hypothesis is that time trends f are different depending on
the group m:
(H0): 8m, fg,m(·) = fg(·) (2.0)
(H1): 9m, m0 such that fg,m(·) 6= fg,m0(·) (2.1)
In both case, one model is fitted under the null hypothesis, and one is fitted under the
alternative. The likelihood ratio is then computed.
However, since both fixed and random effects are tested simultaneously in this like-
lihood ratio, its null distribution is not the standard chi-square distribution (because of
boundary constraints due to the variance of random effects). According to Self and Liang
[1987], it can be approximated by a mixture distribution of chi-squares with the following
formula:
LRH0 ⇠
q+rX
k=q
✓
r
k   q
◆
2
 r 2
(k)
where q is the number of fixed effects and r the number of random effects to be tested si-
multaneously. This approximation implies that the tested random effects are independent
of one another [Stram and Lee, 1994, 1995; Molenberghs and Verbeke, 2007]. This seems
an acceptable assumption according to our simulations under the null hypothesis. See
Figures 2.6 and 2.7 which compare 100,000 LRTs computed on simulated gene sets (with
similar settings as those of the DALIA-1 trial presented in section 2.3.3 page 52) under
the null hypothesis (no effect of time, either as a fixed effect or a random effect, using a
cubic polynomial function of time): even though the random effects (three functions of
time) are not independent, the approximation seems quite valid. This allows to compute
a p-value for the significance of the variation of a given gene set over time.
When several gene sets are investigated at a time, it is necessary to take into account
multiple testing. A number of procedures are available to do so [Dudoit and Van der Laan,
2008]. As the TcGSA is mostly an exploratory analysis (even though hypothesis driven in
the sense that gene set are defined a priori), we recommend using the Benjamini-Yekutieli
procedure for controlling the False Discovery Rate [Yekutieli and Benjamini, 2001], as gene
sets are necessarily correlated between each others and this procedure is robust to some
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Figure 2.6 – Density plot for both the 100,000 simulations under the null and
a 100,000 sample of the corresponding  2 mixture approximation.
Figure 2.7 – Quantile-Quantile plot comparing the 100,000 simulations under
the null to a 100,000 sample of the corresponding  2 mixture ap-
proximation.
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of these dependances. Other mutliple testing correction procedures are available in the
TcGSA package.
3. Estimation of individual gene profiles In the estimation of linear mixed model,
it is common to use the Restricted Maximum Likelihood (REML) instead of the classic
Maximum Likelihood (ML) in order to avoid biased estimates of the variance components
[Harville, 1977]. But note that REML cannot be used to estimate the likelihood ratios
presented here. Indeed, REML estimation of the likelihood ratio between two models
can only be used when both models have the same fixed part [Snijders and Bosker, 2012].
Since here the compared models (under H0 and under H1) have different fixed components
(due to the ⌘· coefficients under H1), the use of ML estimation is needed.
For the inference of the random effects, Best Linear Unbiased Predictor (BLUP) are
used [Verbeke and Molenberghs, 2000], giving access to estimations of a single profile for
each gene among a gene set, in each patient (Figures 2.9 and 2.10 where the medians of
those profiles over the patients are represented in our motivating example). As a result, the
estimations from the mixed model are shrunken towards the average expression inside the
gene set. This shrinkage occurs when the residuals variability is relatively large compared
to the the random effects estimated variances [Verbeke and Molenberghs, 2000]. The
mixed model uses the repeated pattern of the longitudinal measurements to structure
the variation. Its estimations give smoother trajectories for the genes than the raw data,
which makes the general evolution of the set clearer [Hitchcock et al., 2007], as it can be
seen in Figures 2.9 and 2.10.
Characterization and visualization of Dynamics
Dynamic of a significant gene set Once a gene set S has been identified as sig-
nificant, a summary of its dynamic over time is needed. However, due to the possible
heterogeneity of S, giving a summary representation of S dynamic is not obvious. We
propose to automatically identify the number of trends in a significant gene set. Pre-
dicted gene expressions are clustered, and the optimal number of trends is selected with
the gap statistic [Tibshirani et al., 2001]. It is a formalization of the elbow criterion for
the within-cluster variance. In order to determine the optimal partition of each gene set
here, the gap statistics is applied onto a hierarchical clustering of gene expressions inside
each gene set. Then the median within each of the identified clusters can summarize each
trend. Therefore, gene sets are actually split when heterogeneous, before being summa-
rized. The predicted gene expression is used (and not the observed expression) because
smoothness of trajectories facilitates classification [Hitchcock et al., 2007]. Examples of
such representations are given in Figures 2.9 and 2.10.
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Global dynamics Most often, TcGSA will be used to investigate a large number of gene
sets (from a few hundreds to a few thousands). This multiplicity can make visualization of
the results more challenging, in addition of requiring a multiple testing correction. TcGSA
is designed to identify gene sets that shows a simultaneous evolution of gene expression,
but possibly of a small intensity. The method can therefore be quite sensitive, and it can
be of interest to rank the significant gene sets to identify the most acute signals. The
likelihood ratio provides insight on the magnitude of the variation of each gene set. The
percentile of their corresponding likelihood ratio gives an idea of the importance of the
variation for a significant gene set. Examples of such representations are given in Figure
2.11.
2.3.3 Applications of Time-course Gene Set Analysis
Motivating example: the DALIA-1 trial
The DALIA-1 trial is a phase 1 therapeutic HIV vaccine trial whose details are de-
scribed on http://clinicaltrials.gov (ClinicalTrial.gov identifier: NCT00796770) and in
Lévy et al. [2014]. The vaccine candidate was based on ex-vivo generated interferon-
↵ dendritic cells loaded with HIV-1 lipopeptides and activated with lipopolysaccharide.
The objectives of the trial was to evaluate the safety of the strategy and to evaluate the
immune response to the vaccine. For the purpose of the present paper, we focus on the
gene expression component of this study. Gene abundance in whole blood was measured
through Illuminar HumanHT-12 v4 Expression BeadChips.
The DALIA-1 trial design All of the nineteen HIV infected patients received the
therapeutic vaccine while under antiretroviral treatment. The patients received four in-
jections at week 0, 4, 8 and 12. This vaccination period was followed by an antiretroviral
treatment interruption (ATI) at week 24. The patients were followed up to week 48.
Antiretroviral treatment was resumed from week 24 to week 48 at any time under the
following criteria: i) if the patients or their doctors wished so; ii) if CD4+ T-cell count
was <350 cells/µL and <25% of total lymphocytes. Fourteen time points (five in pre-ATI
from week 0 to week 22, and nine in post-ATI from week 24 to week 44) were used for this
analysis (Figure 2.8). One patient was removed from the analysis as his/her antiretroviral
treatment compliance was irregular during the vaccination phase.
In the following analysis, two distinct datasets were considered: pre-ATI and post-
ATI. The two datasets were normalized separately – via a normal-exponential convolution
model [Xie et al., 2009; Shi et al., 2010], followed by the application of the ComBat method
[Johnson et al., 2007] to correct for batch effects. Splitting the data allows us to study sep-
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Note: Gene expression was measured at each time point, represented by a week number above the time
axis. The trial was composed of two separated stages: (1) the treatment phase, during which the patients
were vaccinated but remained under antiretroviral treatment; and(2) the follow- up phase commencing
after the week 24 antiretroviral treatment interruption. Those two phases will be referred as pre-ATI
and post-ATI respectively. The three apheresis time points were removed from the analysis due to a
possible effect of the apheresis on the gene expression samples, and so was the first measurement (week
-8) occurring right at the inclusion in the study.
Figure 2.8 – DALIA-1 trial design
arately the vaccine effect and the treatment interruption, otherwise the ATI effect would
mask any noticeable vaccine effect, because of the huge modification of gene expression
related to viral replication [Bécavin et al., 2011; Bosinger et al., 2012]. We investigated the
gene sets defined by Chaussabel et al. [2008], which are oriented towards the immune sys-
tem. The definition and annotations of those 260 gene sets (called ’Modules’) are available
online (http://www.biir.net/public_wikis/module_annotation/V2_Trial_8_Modules).
Pre-ATI: the vaccination phase During the vaccination period, a standard gene-by-
gene mixed model analysis did not found any significant change of gene abundance at a
5% False Discovery Rate (Table 2.1). However, during this vaccination phase, cytokines
production analysis of the same blood samples (as measured by Luminex or intracellular
staining) have showed that a response was induced by the vaccine at week 16 [Lévy et al.,
2014]. Therefore, one expected to observe a signal at the gene expression level between
week 0 and week 16, the gene expression preceding molecular activation. Although the
measurements were not performed in the hours or days following vaccination, the changes
of gene abundance may reflect a change of the equilibrium of the overall expression in
some gene sets. This kind of results has already been reported in cross-sectional studies
[Murohashi et al., 2010]. Likewise, GSEA for time-series did not identify any significant
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gene set during vaccination. This can be explained by the lack of power of GSEA for
time-series, as this method does not take into account the repeated structure of the data
and is not suitable for longitudinal measurements.
We applied the Time Course Gene set Analysis (Methods) that allows to detect any
change over time of gene abundance inside a gene set by detecting either trends over
time or heterogeneity between gene dynamics. Fitting the model (1) with a cubic spline
function of time, 69 gene sets out of 260 turned out to vary significantly. Figure 2.9
displays the raw and estimated gene expressions of 3 of the significant gene sets identified
by TcGSA: T-cell, inflammation and B-cell gene sets. The identification of gene sets such
as M4.1: T-cell (that includes CD402, CCR7, BCl2) was expected with regards to the
CD4 T-cell response observed at Week 16 [Lévy et al., 2014]. Also, the gene sets M4.6:
inflammation and M6.7: B-cell are good examples of how smoothing from the estimations
can give a much clearer dynamic pattern compared to the raw expression (Methods).
Post-ATI: after antiretroviral treatment interruption Model (1) was then fitted
to the data after antiretroviral treatment interruption that occurred at week 24: 216 gene
sets out of 260 were found to be significant. Figure 2.10 displays the raw and estimated
expressions of nine of those significant gene sets. It features heterogeneous gene sets, such
as M4.16 and M7.1, which are both also good examples of the shrinkage that occurs with
the estimations (Methods).
The large number of significant gene sets post-ATI illustrates the tremendous impact
of the treatment interruption on the organism. Followed by a viral rebound, the treatment
interruption is indeed a major event that triggers the expression of thousand of genes.
Indeed, a gene-by-gene analysis revealed 7,534 significant probes (more than 20% of the
investigated probes – an unusually high number of differentially expressed genes). The
immune system is very much in demand during the viral rebound. Therefore most of the
gene sets from the Modules defined by Chaussabel et al. [2008] are activated, as they are
tightly linked with the immune system activity. Of particular interest are the three gene
sets M1.2, M3.4 and M5.12 which are all annotated as interferon-related. These three gene
sets exhibit similar dynamics (Figure 2.10). Such a timely upregulation was expected, as
it is linked to the viral rebound after treatment interruption and was previously reported
[Bécavin et al., 2011; Bosinger et al., 2012]. The gene set M3.4 is also linked with antiviral
response.
Another application: influenza and pneumococcal vaccines responses
In a recent paper, Obermoser et al. [2013] investigated the response to influenza and
pneumococcal vaccines in healthy individuals at the gene expression level.
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Pre-ATI Post-ATI Units
Gene-by-gene 0 7, 534 probes a
GSEA for time series 0 67 genes set b
TcGSA linear 23 203 gene sets b
TcGSA cubic 69 216 gene sets b
TcGSA splines 68 219 gene sets b
a 32,978 probes investigated after filtering
b 260 immune-related gene sets investigated (29 gene sets were automatically discarded because less
than 10 probes were observed)
Table 2.1 – Number of significant units in DALIA-1 at a FDR of 5%
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M4.1: T Cell 
M4.6: Inflammation 
M6.7: B Cell 
Note: Each line is the median over the patients of the expression of one gene. Each graph shows all the
genes in one particular gene set. The left graph displays the raw gene expression, the right one displays
the estimations from the mixed model for the same gene set. The expressions have been centered and
reduced for this representation. The percentile likelihood ratio associated with the displayed gene sets is
given as an indication of their rank of significance.
Figure 2.9 – Four significant gene sets during pre-ATI in DALIA-1
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M1.2: Interferon M5.12: Interferon 
M3.4: Interferon M3.6: Cytotoxic/NK Cell 
M4.4: Cell Proliferation M4.14: Monocytes 
M4.10: B Cell  M4.15: T cell 
M4.16: Cell Cycle  M7.1: Inflammation 
Note: Each line is the median over the patients of the expression of one gene. Each graph shows all the
genes in one particular gene set. The left graph displays the raw gene expression, the right one displays
the estimations from the mixed model for the same gene set. If several dynamics are identified by the
gap statistics among the estimated expressions inside one gene set, they are displayed in different colors
– such as for the gene sets M 4.16 and M 7.1 that each features three different dynamics. The expressions
have been centered and reduced for this representation. The percentile likelihood ratio associated with
the displayed gene sets gives an indication on the relative importance of their variation.
Figure 2.10 – Ten significant gene sets during post-ATI in DALIA-1
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Study design Healthy, young adults were randomly split in three groups of six volun-
teers each, receiving either a 2009-2010 seasonal influenza vaccine (Fluzone), a 23-valent
pneumococcal vaccine (Pneumovax23), or a placebo (saline injections). Blood samples
were collected at days -7, 0, 1, 3, 7, 10, 14, 21, and 28 to measure gene expression in
whole blood. A more detailed description of the study can be found in Obermoser et al.
[2013].
Original analysis In their modular analysis, Obermoser et al. [2013] focused on 62 of
the 260 available gene sets defined in Chaussabel et al. [2008]. They investigated the
changes of gene expression in those 62 gene sets for each of the seven time points from
day 1 to day 28 in regards of the baseline, that was considered as the average of the two
measurements at days -7 and 0. So hierarchical structure of the data was not taken into
account. The three arms (saline, flu and pneumococcal) were analyzed separately, and
only significant gene sets at day 1 and day 7 (not further on) are presented in their paper.
Changes in eight gene sets were common to both vaccines: M4.6 (inflammation), M6.6
and M6.13 (apoptosis/cell death) and modules M4.1 and M4.15 (T cells), M4.3 (protein
synthesis), M5.11, and M6.9 (no functional annotation). Nine gene sets were uniquely
changing after the influenza vaccine, three were associated with antiviral responses (M1.2,
M3.4, M5.12) and included genes coding for interferon (IFN)-inducible molecules. Six gene
sets were uniquely responsive to the pneumococcal vaccine. Of these, five were modules
including genes associated with inflammation: M3.2, M4.2, M4.13, M5.1 and M5.7.
TcGSA results To compare the gene expression at the gene set level between the
vaccine arm (flu or pneumococcal) and the placebo (saline) arm, we applied TcGSA on
these data using model (2) (for each vaccine separately). In both vaccines, a large response
is observed at Day 1. To avoid smoothing down the expression at ti = 1, we used the
following function of time to model the dynamic evolution of gene expression:
fm(ti) = (⌘m + hg)1{ti=1} + (⌘
0
m + h
0
g)1{ti 6=1}
with (hg, h0g) ⇠ N (0,  h), and m the group (either vaccine or placebo).
Most of the 62 investigated gene sets presented a significantly different evolution in
vaccine arms compared to the placebo arm. Globally, the intensity of the response was
stronger with the pneumoccocal vaccine than with the flu vaccine (Figure 2.11). The early
response induced by the pneumococcal vaccine was dominated by inflammation whereas
the top signal triggered by the flu vaccine involved an interferon signature (Figure 2.11B
and 2.11D). In both vaccine, a T-cell response was also visible. In the pneumoccocal
vaccine, a plasma cell signal, in association with cell cycle gene sets (Figure 2.11A and
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2.11C), started at Day 7 until Day 14. This plasma blast signal was much less clear in the
flu vaccine (Figure 2.11B and 2.11D). This is in agreement with the results of Obermoser
et al. modular analysis.
TcGSA offers an extended and appropriate hierarchical analysis of these data. It
provides a truly longitudinal insight into the vaccine responses, that are intrinsically
compared to the placebo response. One of the main difference from the results presented
in Obermoser et al. [2013] is that, according to our analysis, the inflammation gene sets
(M3.2, M4.13, M5.1 and M5.7) were also involved with the flu vaccine and were not
specific to the pneumoccocal vaccine. This result is important as it means that both
vaccine involved these inflammatory pathways. This result was not obvious from the
original analysis because their approach was less powerful compared to the TcGSA.
Assessment of statistical performances on simulated data
In order to assess the behavior of the proposed method, a simulation study of TcGSA
has been performed. The simulation scheme was chosen to be very close to the motivating
exemple: the DALIA-1 trial. In each simulation run, gene expression data was simulated
for 20 patients at 8 time points. 5,000 genes were simulated, divided into 100 non overlap-
ping gene sets of 50 genes each. Each of the 100 gene sets was either simulated under (H0)
or (H1). The proportion of genes under (H1) varied between 0%, 27% (which corresponds
to results found in pre-ATI) and 85% (which corresponds to results found in post-ATI).
When there are gene sets simulated under (H1), 75% of those were homogeneous (simu-
lated with parameters close to those estimated for gene set M1.2 in DALIA post-ATI –
see Figure 2.10) while the remaining 25% were heterogeneous (simulated with parameters
close to those estimated for gene set M7.1 in DALIA post-ATI – see Figure 2.10).
Statistical performances of the proposed method are presented in Table 2.2. Without
correcting for the fact that 100 gene set were investigated by TcGSA at each simulation
runs, the average Type I error (the probability of rejecting H0 given that H0 is actually
true) over a hundred runs was between 0.03 and 0.07 depending on the situation. But
as soon as a control of the FDR was used, the Type-I error rate dropped well below 1%,
regardless of the flexibility of the time function estimated (linear or cubic polynomials).
The average statistical power (the probability of rejecting H0 given that H0 is actually
false) is very good, always above 0.8 (dropping a little bit after multiple testing correction
as expected).
Two other methods were also evaluated on those simulations, namely globalANCOVA
[Hummel et al., 2008] (using either permutations or an approximation to compute p-
values) and GSEA for time series. Their statistical performances are also presented in
Table 2.2. Type I error is always well controlled for both those methods. However,
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M6.18[8th pctile]: Erythrocytes 1/1
M6.16[9th pctile]: Cell Cycle 2/2
M6.16[9th pctile]: Cell Cycle 1/2
M6.10[11th pctile] 1/1
M6.11[13th pctile]: Cell Cycle 1/1
M6.5[14th pctile] 1/1
M4.4[16th pctile] 1/1
M6.12[18th pctile]: Mitochondrial Stress 1/1
M6.7[19th pctile] 1/1
M5.15[21th pctile]: Neutrophils 1/1
M4.5[22th pctile]: Protein Synthesis 1/1
M4.16[24th pctile] 1/1
M6.2[26th pctile]: Mitochondrial Respiration 1/1
M4.11[27th pctile]: Plasma Cells 1/1
M6.20[29th pctile] 1/1
M6.3[31th pctile] 1/1
M6.19[32th pctile] 1/1
M2.3[34th pctile]: Erythrocytes 1/1
M6.14[36th pctile] 1/1
M6.4[37th pctile] 1/1
M5.13[39th pctile] 1/1
M6.6[40th pctile]: Apoptosis / Survival 1/1
M5.4[42th pctile] 1/1
M5.10[44th pctile]: Mitochondrial Respiration 1/1
M5.6[45th pctile]: Mitochondrial Stress / Proteasome 1/1
M3.1[47th pctile]: Erythrocytes 1/1
M5.3[49th pctile] 1/1
M5.14[50th pctile] 1/1
M5.9[52th pctile]: Protein Synthesis 1/1
M4.10[54th pctile]: B cell 1/1
M6.15[55th pctile] 1/1
M4.7[57th pctile]: Cell Cycle 1/1
M4.12[59th pctile] 1/1
M6.13[60th pctile]: Cell Death 1/1
M6.9[62th pctile] 1/1
M4.8[63th pctile] 1/1
M4.3[65th pctile]: Protein Synthesis 1/1
M1.1[67th pctile]: Platelets 1/1
M3.6[68th pctile]: Cytotoxic/NK Cell 1/1
M3.5[70th pctile]: Cell Cycle 1/1
M4.2[72th pctile]: Inflammation 1/1
M4.9[73th pctile] 1/1
M4.15[75th pctile]: T cells 1/1
M5.11[77th pctile] 1/1
M5.8[78th pctile] 1/1
M5.2[80th pctile] 1/1
M5.7[81th pctile]: Inflammation 1/1
M4.1[83th pctile]: T cell 1/1
M5.5[85th pctile] 1/1
M5.1[86th pctile]: Inflammation 1/1
M4.14[88th pctile]: Monocytes 1/1
M4.13[90th pctile]: Inflammation 1/1
M4.6[91th pctile]: Inflammation 1/1
M2.1[93th pctile] 1/1
M5.12[95th pctile]: Interferon 1/1
M3.2[96th pctile]: Inflammation 1/1
M1.2[98th pctile]: Interferon 1/1
M3.4[100th pctile]: Interferon 1/1
Median trends
Flu vs Saline
−2 −1 0 1 2
Value
Color Key
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D
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7
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14
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21
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28
M3.1: Erythrocytes 1/1
M4.4 1/1
M5.3 1/2
M2.3: Erythrocytes 1/1
M6.18: Erythrocytes 1/1
M2.2: Cell Cycle 1/1
M4.10: B cell 1/1
M6.14 1/1
M5.10: Mitochondrial Respiration 1/1
M3.5: Cell Cycle 1/1
M1.1: Platelets 1/1
M5.4 1/1
M5.6: Mitochondrial Stress / Proteasome 1/1
M5.3 2/2
M3.4: Interferon 1/1
M1.2: Interferon 1/1
M5.12: Interferon 1/1
M5.15: Neutrophils 1/1
M6.3 1/1
M5.13 1/1
M4.14: Monocytes 1/1
M4.16 1/1
M6.2: Mitochondrial Respiration 1/1
M6.10 1/1
M2.1 2/2
M4.7: Cell Cycle 1/1
M6.7 1/1
M4.8 1/1
M3.6: Cytotoxic/NK Cell 1/1
M6.15 1/1
M5.9: Protein Synthesis 1/1
M5.8 1/1
M4.12 1/1
M4.1: T cell 1/1
M5.5 1/1
M6.12: Mitochondrial Stress 1/1
M5.11 1/1
M4.15: T cells 1/1
M4.3: Protein Synthesis 1/1
M6.9 1/1
M4.11: Plasma Cells 1/1
M3.3: Cell Cycle 1/1
M5.2 1/1
M2.1 1/2
M4.5: Protein Synthesis 1/1
M4.2: Inflammation 1/1
M4.6: Inflammation 1/1
M4.13: Inflammation 1/1
M3.2: Inflammation 1/1
M5.7: Inflammation 1/1
M6.13: Cell Death 1/1
M5.1: Inflammation 1/1
M6.20 1/1
M5.14 1/1
M6.6: Apoptosis / Survival 1/1
M4.9 1/1
M6.1 1/1
Median trends
Pneumo vs Saline
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Color Key
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28
M5.15[11th pctile]: Neutrophils 1/1
M5.13[13th pctile] 1/1
M6.18[14th pctile]: Erythrocytes 1/1
M6.7[16th pctile] 1/1
M5.2[18th pctile] 1/1
M5.4[19th pctile] 1/1
M6.10[21th pctile] 1/1
M2.2[22th pctile]: Cell Cycle 1/1
M6.1[24th pctile] 1/1
M6.14[26th pctile] 1/1
M4.5[27th pctile]: Protein Synthesis 1/1
M3.3[29th pctile]: Cell Cycle 1/1
M6.2[31th pctile]: Mitochondrial Respiration 1/1
M6.12[32th pctile]: Mitochondrial Stress 1/1
M6.3[34th pctile] 1/1
M4.16[36th pctile] 1/1
M6.20[37th pctile] 1/1
M6.15[39th pctile] 1/1
M5.6[40th pctile]: Mitochondrial Stress / Proteasome 1/1
M1.2[42th pctile]: Interferon 1/1
M4.4[44th pctile] 1/1
M3.4[45th pctile]: Interferon 1/1
M5.3[47th pctile] 2/2
M5.3[47th pctile] 1/2
M4.10[49th pctile]: B cell 1/1
M4.8[50th pctile] 1/1
M6.9[52th pctile] 1/1
M3.6[54th pctile]: Cytotoxic/NK Cell 1/1
M5.12[55th pctile]: Interferon 1/1
M6.6[57th pctile]: Apoptosis / Survival 1/1
M5.10[59th pctile]: Mitochondrial Respiration 1/1
M2.3[60th pctile]: Erythrocytes 1/1
M2.1[62th pctile] 2/2
M2.1[62th pctile] 1/2
M4.9[63th pctile] 1/1
M4.7[65th pctile]: Cell Cycle 1/1
M4.14[67th pctile]: Monocytes 1/1
M5.11[68th pctile] 1/1
M5.9[70th pctile]: Protein Synthesis 1/1
M4.11[72th pctile]: Plasma Cells 1/1
M5.8[73th pctile] 1/1
M4.15[75th pctile]: T cells 1/1
M5.14[77th pctile] 1/1
M4.1[78th pctile]: T cell 1/1
M6.13[80th pctile]: Cell Death 1/1
M4.12[81th pctile] 1/1
M3.1[83th pctile]: Erythrocytes 1/1
M3.5[85th pctile]: Cell Cycle 1/1
M4.3[86th pctile]: Protein Synthesis 1/1
M5.5[88th pctile] 1/1
M1.1[90th pctile]: Platelets 1/1
M5.7[91th pctile]: Inflammation 1/1
M4.2[93th pctile]: Inflammation 1/1
M4.13[95th pctile]: Inflammation 1/1
M5.1[96th pctile]: Inflammation 1/1
M4.6[98th pctile]: Inflammation 1/1
M3.2[100th pctile]: Inflammation 1/1
Median trends
Pneumo vs Saline
−2 −1 0 1 2
Value
Color Key
D
0
D
1
D
3
D
7
D
10
D
14
D
21
D
28
M6.14 1/1
M1.1: Platelets 1/1
M6.11: Cell Cycle 1/1
M1.2: Interferon 1/1
M6.16: Cell Cycle 1/2
M4.11: Plasma Cells 1/1
M3.4: Interferon 1/1
M5.15: Neutrophils 1/1
M4.14: Monocytes 1/1
M6.6: Apoptosis / Survival 1/1
M5.12: Interferon 1/1
M6.13: Cell Death 1/1
M4.2: Inflammation 1/1
M3.2: Inflammation 1/1
M4.6: Inflammation 1/1
M4.13: Inflammation 1/1
M4.9 1/1
M6.18: Erythrocytes 1/1
M2.3: Erythrocytes 1/1
M5.3 1/1
M3.1: Erythrocytes 1/1
M4.4 1/1
M5.4 1/1
M6.5 1/1
M6.3 1/1
M5.6: Mitochondrial Stress / Proteasome 1/1
M6.20 1/1
M5.7: Inflammation 1/1
M5.13 1/1
M5.14 1/1
M5.1: Inflammation 1/1
M6.10 1/1
M6.4 1/1
M4.16 1/1
M6.2: Mitochondrial Respiration 1/1
M5.10: Mitochondrial Respiration 1/1
M3.6: Cytotoxic/NK Cell 1/1
M2.1 1/1
M4.8 1/1
M4.15: T cells 1/1
M4.10: B cell 1/1
M5.2 1/1
M4.5: Protein Synthesis 1/1
M6.16: Cell Cycle 2/2
M5.9: Protein Synthesis 1/1
M4.3: Protein Synthesis 1/1
M3.5: Cell Cycle 1/1
M6.12: Mitochondrial Stress 1/1
M4.12 1/1
M5.11 1/1
M5.8 1/1
M6.7 1/1
M5.5 1/1
M6.19 1/1
M4.7: Cell Cycle 1/1
M6.15 1/1
M4.1: T cell 1/1
M6.9 1/1
Median trends
Flu vs Saline
−2 −1 0 1 2
Value
Color Key
A B 
C D 
D
0
D
1
D
3
D
7
D
10
D
14
D
21
D
28
M5.15[11th pctile]: Neutrophils 1/1
M5.13[13th pctile] 1/1
M6.18[14th pctile]: Erythrocytes 1/1
M6.7[16th pctile] 1/1
M5.2[18th pctile] 1/1
M5.4[19th pctile] 1/1
M6.10[21th pctile] 1/1
M2.2[22th pctile]: Cell Cycle 1/1
M6.1[24th pctile] 1/1
M6.14[26th pctile] 1/1
M4.5[27th pctile]: Protein Synthesis 1/1
M3.3[29th pctile]: Cell Cycle 1/1
M6.2[31th pctile]: Mitochondrial Respiration 1/1
M6.12[32th pctile]: Mitochondrial Stress 1/1
M6.3[34th pctile] 1/1
M4.16[36th pctile] 1/1
M6.20[37th pctile] 1/1
M6.15[39th pctile] 1/1
M5.6[40th pctile]: Mitochondrial Stress / Proteasome 1/1
M1.2[42th pctile]: Interferon 1/1
M4.4[44th pctile] 1/1
M3.4[45th pctile]: Interferon 1/1
M5.3[47th pctile] 2/2
M5.3[47th pctile] 1/2
M4.10[49th pctile]: B cell 1/1
M4.8[50th pctile] 1/1
M6.9[52th pctile] 1/1
M3.6[54th pctile]: Cytotoxic/NK Cell 1/1
M5.12[55th pctile]: Interferon 1/1
M6.6[57th pctile]: Apoptosis / Survival 1/1
M5.10[59th pctile]: Mitochondrial Respiration 1/1
M2.3[60th pctile]: Erythrocytes 1/1
M2.1[62th pctile] 2/2
M2.1[62th pctile] 1/2
M4.9[63th pctile] 1/1
M4.7[65th pctile]: Cell Cycle 1/1
M4.14[67th pctile]: Monocytes 1/1
M5.11[68th pctile] 1/1
M5.9[70th pctile]: Protein Synthesis 1/1
M4.11[72th pctile]: Plasma Cells 1/1
M5.8[73th pctile] 1/1
M4.15[75th pctile]: T cells 1/1
M5.14[77th pctile] 1/1
M4.1[78th pctile]: T cell 1/1
M6.13[80th pctile]: Cell Death 1/1
M4.12[81th pctile] 1/1
M3.1[83th pctile]: Erythrocytes 1/1
M3.5[85th pctile]: Cell Cycle 1/1
M4.3[86th pctile]: Protein Synthesis 1/1
M5.5[88th pctile] 1/1
M1.1[90th pctile]: Platelets 1/1
M5.7[91th pctile]: Inflammation 1/1
M4.2[93th pctile]: Inflammation 1/1
M4.13[95th pctile]: Inflammation 1/1
M5.1[96th pctile]: Inflammation 1/1
M4.6[98th pctile]: Inflammation 1/1
M3.2[100th pctile]: Inflammation 1/1
Median trends
Pneumo vs Saline
−2 −1 0 1 2
Value
Color Key
Note: The median estimated gene expression over the patients is used for each trend. Each trend has
seen its values reduced (so that its variance is 1) in order to make the dynamics more comparable. Each
row is a group of gene having the same trend inside a gene set, and each column is a time point. The
color key represents the median of the standardized estimation of gene expression over the patients for
a given trend in a significant gene set. It is becomes red as median expression is up-regulated or blue
as it is down-regulated compared to the value in the placebo (saline) at the same time. A and C show
the hierarchically clustered trends for pneumoccocal and flu respectively. B and D show the same trends
but instead ranked by decreasing likelihood ratio percentiles of the associated gene set, for pneumoccocal
and flu respectively.
Figure 2.11 – Heatmap of estimated dynamics from the significant gene sets among the
62 investigated gene sets when comparing vaccines arms to placebo arm
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Percentage of Method Type I Type I Statistical Statistical
simulated gene error error after power power after
sets under H1 MTC⇤ MTC⇤
0% TcGSA (linear) 0.0394 0.0002 - -
0% TcGSA (cubic) 0.0649 0.0004 - -
0% globalANCOVA (perm) 0.0483 0.0001 - -
0% globalANCOVA (approx) 0.0006 0 - -
0% GSEA for time series 0 0 - -
27% TcGSA (linear) - - 0.883 0.829
27% TcGSA (cubic) - - 0.882 0.810
27% globalANCOVA (perm) - - 0.787 0.706
27% globalANCOVA (approx) - - 0.660 0.510
27% GSEA for time series - - 0.459 0.214
85% TcGSA (linear) - - 0.885 0.847
85% TcGSA (cubic) - - 0.882 0.833
85% globalANCOVA (perm) - - 0.785 0.728
85% globalANCOVA (approx) - - 0.660 0.549
85% GSEA for time series - - 0.289 0.074
* Multiple Testing Correction: performed via Benjamini-Yekutieli procedure with a 5% threshold.
Note: In each simulation, 100 gene sets are simulated and significance level ↵ = 5% is applied. This table
displays the Type I error and the statistical power means over a hundred simulation runs for 3 different
situations (0%, 27% and 85% of simulated gene sets are simulated under H1). Whenever the percentage
of gene sets simulated under H1 is not null, 25% of the gene sets simulated under H1 are heterogeneous,
the remaining 75% being homogeneous. Type I error is the probability of rejecting H0 given that H0 is
true, i.e. for declaring a gene set significant when it actually is not. Statistical power is the probability
of rejecting H0 given that H1 is true, i.e. for declaring a gene set significant when it actually is. Three
methods are evaluated: i) TcGSA, the proposed approach, fitted either with a linear or with a cubic
function of time ; ii) the GlobalANCOVA procedure [Hummel et al., 2008] in which p-values are either
computed by permutation (10, 000) or approximated; iii) the GSEA for time series [Subramanian et al.,
2005]. Default values are used for the various methods.
Table 2.2 – Assessment of statistical performances through a simulation study
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GSEA for time series has very low statistical power (as low as 10 times less than TcGSA
after multiple testing correction when there is a high proportion of significant gene sets).
globalANCOVA, whose global null hypothesis is not so different from the one tested in
TcGSA, performs quite well in terms of statistical power. Nonetheless it is still about
10% below TcGSA performances.
Those simulation results confirm that the higher number of selected gene sets by
TcGSA in the two real-life examples presented in this paper are mainly due to the increased
power of gene set analysis over gene-by-gene analysis (when repeated structure of the
measurement is properly accounted for), and not to a large number of false positives.
2.3.4 Discussion of Time-course Gene Set Analysis
In this paper, we present a method to analyze repeated measurements of gene expres-
sion using a gene set approach. Provided that the definition of the gene sets is relevant,
this method helps with detecting and interpreting subtle changes of gene expression over
time. In our applications where the same definition of gene sets has been applied, we were
able to compare the response to several vaccines (against HIV, Influenza and Pneumococ-
cus). Interestingly, we found common pathways that were triggered by all three vaccines,
mostly related to inflammation, as well as pathways specific to each vaccine.
The capacity of the proposed approach to detect subtle changes of gene expression is
due to two main factors: i) the use of a predefined gene sets that are functionally related
ii) the use of all available information, taking advantage of repeated measurements using
mixed models. Measurements of gene expression data in longitudinal studies may be
missing because of missed visits or poor quality of the samples, leading to unbalanced
data. Missing at random (MAR) processes (i.e. when the probability of missing data is
associated to the previously measured information) may lead to biased estimates when
using least squares or generalized estimating equations [Diggle et al., 2002]. TcGSA
can cope with such issues because of the use of Maximum Likelihood to estimate the
parameters of the mixed models. This is an advantage of the TcGSA approach over those
of Hummel et al. [2008] or Nueda et al. [2010].
An increasing number of gene sets databases are available: KEGG [Kanehisa and
Goto, 2000], Gene Ontology [Ashburner et al., 2000], Modules [Chaussabel et al., 2008].
An immune related subset of Gene Ontology as well as an immune related subset of KEGG
pathway have been used in additional analyses (Appendix B page 125). The choice of
the database used for the analysis impacts the interpretability but also the limitations of
TcGSA. The efficiency of TcGSA will vary according to the number of genes represented
in each gene set. The size of a given gene set has an impact on its significance, as the more
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genes it includes, the more likely a significant variation will be detected. The average size
of the Chaussabel’s V2 modules is 55 genes. 17% of the 260 modules include more than
100 genes, and 31% less than 20 genes. For small gene sets, the normality assumptions
of random effects of the models (1), (1bis) and (2) are questionable. Nevertheless, even
though we expect that the models could be miss-specified in many cases (if not all), the
objective of such an analysis is to detect any significant variation over time (in the spirit of
Shahbaba et al. [2011], a significant variability of the trajectories between the genes inside
a gene set indicates a change over time regardless of the fixed effects specification). The
use of flexible time functions may help to get a better fit of dynamics although beyond
cubic polynomials it did not have a substantial impact in our motivating example – see
Table 2.1. These results vary according to the dataset and the number of time points
available, and we recommend to try several models to check the robustness of the results.
Several extensions of the TcGSA are possible for its use in other contexts. One can also
model time trends with a random effect grouped on the patient level as of  p,·, instead of
on the gene level as in models (1), (1bis) and (2). This identifies gene sets whose dynamic
differs across the patients. This option is also implemented in the TcGSA package.
TcGSA could easily be adapted to mRNA counts data. In that case, generalized linear
mixed effects models should be used, with a Poisson distribution for instance, instead of
linear mixed effect models that rely on a Gaussian assumption.
In conclusion, the method presented gives a solution for the full exploitation of any
repeated measurements of gene expression data based on a gene set analysis where a great
sensibility to detect subtle change, while controlling false discovery, is needed.
Implementation
The TcGSA method has been implemented in as a package TcGSA, whose lat-
est release is available from the CRAN repository (http://cran.r-project.org/web/
packages/TcGSA/index.html).
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3 Integrative analyses of gene expres-
sion data in two vaccine trials
Abstract:
This chapter presents two integrative analyses applied to vaccine trials. The first ap-
plication concerned the HIV therapeutic trial DALIA-1 (presented in the previous chap-
ter). The second example was about the differential effect of a trivalent influenza vaccine
according to sex. Both analyses try to unravel some underlying biological mechanisms
triggered by the vaccine, in order to understand why some patients have a better immune
response following vaccination than others. In the DALIA-1 trial, the integration of gene
sets for which the expression changed over time and relevant immune variables revealed
that lower expression of inflammatory pathway during vaccination was associated with
a better immune response after antiretroviral treatment interruption. In the other ap-
plication on the flu vaccine, a high-dimensional analysis of interaction identified a group
of genes linked to lipid metabolism that could mediate the sex effect on the antibody
response following vaccination. In particular, further analysis showed that this mediation
was actually associated with circulating testosterone levels.
Key Words: Immuno-endocrine; Integrative analysis; Sexual dimorphism; Sparse Par-
tial Least Squares; Supervised analysis
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3.1 Integrative analysis of the DALIA-1 trial
The DALIA-1 trial, as described in subsection 2.3.3 page 52, is a phase-I therapeutic
HIV vaccine trial. Its primary goal was to evaluate the safety of the vaccine, and also
the immune response associated with it as a secondary endpoint. During the vaccination
phase, TcGSA identified 69 Modules whose expression varied significantly over time, en-
compassing a total of 5,399 probes. In a system biology perspective, it is now of interest
to relate these gene expression to other measurements of the immune response to the
vaccine.
3.1.1 Immune measurements in the DALIA-1 trial
During the DALIA-1 trial, in addition to the repeated measurements of gene expres-
sion, various immune markers were measured periodically in 16 patients from in vitro
T cell assays. Immune-related cytokines measured by the Multiplex technology and cell
polyfunctionality measured via intra-cellular staining summarized through Immunogenic-
ity scores [Lévy et al., 2014] were available before and after vaccination (at weeks 0 and
16, see Figure 2.8).
One fundamental hypothesis of the trial was the impact of the vaccine response on the
dynamics of viral load after treatment interruption. Figure 3.1 shows the multimodal non-
parametric density estimation of the observed peak viral load, suggesting that there might
be good responders (log(peak viral load)  5) and bad responders (log(peak viral load) >
5). According to Lévy et al. [2014] log(peak viral load) = 5 could be a good threshold
to distinguish between good and bad responders. The immune responses (measured at
week 16) most associated with this peak viral load are the following seven variables:
the cytokines luminex score, the T-helper 1 score, the CD4 cell polyfunctionnality, the
interleukins 2, 13 and 21 productions, and the interferon   production. We investigated
the potential associations between the vaccine elicited gene expression (at week 16) on
the one hand, and those immunological responses as well as the viral dynamics after
treatment interruption on the other hand. This may help to understand the mechanism
and the determinants of the vaccine effect.
3.1.2 Sparse Partial Least Squares method
Sparse Partial Least Squares (sPLS) is a penalized dimension reduction method that
explores two data sets at once, constructing a multivariate linear model. It is build on
the Partial Least Squares (PLS) approach, onto which a LASSO kind of penalization is
added. Appendix C page 131 gives an overview of this method. The sPLS relates two
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Note: The density of the logarithm transformation peak viral load appears multimodal. Median is 5.
Figure 3.1 – Distribution of patients peak viral load after antiretroviral treatment inter-
ruption in the DALIA-1 trial
data matrix X and Y by seeking to iteratively construct sparse linear combinations of
their respective columns, so that those respective combinations maximize the covariance
between themselves.
3.1.3 Supervised multivariate integrative analysis results
Let X be a 16⇥ 5 399 matrix and Y be a 16⇥ 8 matrix. Both matrix contains data
from the 16 patients that were sampled fro immunological measurements at week 16. X
contains the measured expression at week 16 for the 5 399 probes that were measured and
that participate in the 69 significant Modules according to TcGSA results (section 2.3.3).
Y contains the data for the following eight variables measured at 16 weeks:
— interferon-  production
— interleukin 2 production
— interleukin 13 production
— interleukin 21 production
— CD4 cells polyfunctionnality [Lévy et al., 2014]
— T-helper score [Lévy et al., 2014]
— Luminex score [Lévy et al., 2014]
and the maximum observed viral load after antiretroviral treatment interruption (ATI):
— log(peak VL) > 5 (post ATI)
Both X and Y components were chosen sparse. Four components were kept for the
analysis, mainly because this is the minimum number for all Y to be selected at least once.
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Yet this was sufficient for explaining a lot of the immune variability in Y (Figure 3.2A).
A sequential cross-validated (leave-one-out) optimization of the mean R2 between the Y
variables selected by a given component explained by the corresponding X component
gives the following optimum: for X 24, 13, 8 and 1 genes were respectively selected for
each component (Table 3.1) ; for Y 2, 2, 3 and 4 variables were respectively selected for
each component. Figure 3.2B shows the importance of each immune variable on each of
the four Y components. The maximum viral load (log(peak VL) >5) was selected only
by the third Y component. Therefore, the matching third X component separated very
well the patients depending on their peak viral load level (Figure 3.3).
Figure 3.4 displays the strength of the association between genes that are selected on
any of the four components and the immune variables. The log(peak viral load)>5 has an
opposite profile compared the other immune variables. This makes sense: the higher the
cytokines productions (i.e. the better the immune response), the lower the viral rebound.
In addition, a clear inflammatory response was positively correlated with a bad response
to the vaccine and lower cytokine productions. Each selected gene was annotated with
the module it belongs to and the component was selected in. One striking result was that
many selected Modules were not annotated.
Robustness analyses
A number of robustness analyses were performed: other approaches were tried out
(univariate response LASSO model, Variable Selection Using Random Forests – VSURF
[Genuer et al., 2010]), as well as other penalty parameters and robustness to outlier sam-
ples. The univariate LASSO models were hard to interpret because of frequent difficulties
in the tuning of the penalty parameters. The VSURF models have the advantage of
considering non linear relations between their univariate outcome and the explanatory
variables from X, but the disadvantage to be limited to a univariate response variable.
A 100 bootstrap (equiprobable sampling with replacement) samples of the individuals
were created. On each of these samples, the sPLS has been run with 4 components. The
keepX and keepY numbers (the numbers of genes and of response variables respectively
to be kept for each of the 4 components) were automatically determined, following the
same principle as the main analysis: the automatic procedure maximizes the mean cross-
validated (leave-one-out) R2 of the Y variables selected for each component sequentially
(above and Appendix C page 131). The resulting sPLS models are not comparable com-
ponent by component, as the selected Y variables on each component are different from
one model to another. Therefore, interest is focused on wether a module was selected in
one of the 4 components or not. Figure 3.5 and Table 3.2 display the results (only the
modules that were selected in at least in 1 of the 100 bootstraped models are featured).
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Illuminar probe ID Gene Module & Symbol 1st comp. 2nd comp. 3rd comp. 4th comp.
ILMN_1663422 M3.2:Inflammation RGL4 -0.02 0.00 0.00 0.00
ILMN_1707312 M3.2:Inflammation NFIL3 -0.19 0.00 0.00 0.00
ILMN_1714592 M3.2:Inflammation CDA -0.12 0.00 0.00 0.00
ILMN_1911677 M4.1:T cell 0.54 0.00 0.00 0.00
ILMN_1740864 M4.13:Inflammation TREML2 -0.17 0.00 0.00 0.00
ILMN_1661461 M4.13:Inflammation LOC283547 -0.02 0.00 0.00 0.00
ILMN_1714444 M4.15:T cells KLF12 0.30 0.00 0.00 0.00
ILMN_1794588 M4.15:T cells DYRK2 0.14 0.00 0.00 0.00
ILMN_1801216 M4.2:Inflammation S100P -0.00 0.00 0.00 0.00
ILMN_1795428 M5.11:Undetermined WDR59 0.02 0.00 0.00 0.00
ILMN_1724341 M5.11:Undetermined CXorf45 0.03 0.00 0.00 0.00
ILMN_1747052 M5.4:Undetermined ITGA4 0.12 0.00 0.00 0.00
ILMN_1736757 M5.5:Undetermined GNPTAB 0.02 0.00 0.00 0.00
ILMN_1749892 M5.7:Inflammation EGLN1 -0.04 0.00 0.00 0.00
ILMN_1752932 M5.7:Inflammation MPZL2 -0.03 0.00 0.00 0.00
ILMN_1653432 M5.8:Undetermined HNRPDL 0.38 0.00 0.00 0.00
ILMN_1792173 M5.8:Undetermined TUBGCP4 0.03 0.00 0.00 0.00
ILMN_1801043 M7.1:Inflammation GSN -0.23 0.00 0.00 0.00
ILMN_1667476 M7.1:Inflammation LTBR -0.39 0.00 0.00 0.00
ILMN_1746171 M7.1:Inflammation H2AFY -0.25 0.00 0.00 0.00
ILMN_1695763 M7.11:Undetermined PDIA5 -0.21 0.00 0.00 0.00
ILMN_1740486 M7.14:Undetermined POLR2J4 0.12 0.00 0.00 0.00
ILMN_1743570 M7.16:Undetermined CEACAM3 -0.04 0.00 0.00 0.00
ILMN_1654516 M7.27:Undetermined TMEM120A -0.15 0.00 0.00 0.00
ILMN_1815306 M3.1:Erythrocytes AP2A1 0.00 -0.08 0.00 0.00
ILMN_1670570 M3.1:Erythrocytes MXI1 0.00 -0.22 0.00 0.00
ILMN_1781001 M4.2:Inflammation SOCS3 0.00 0.01 0.00 0.00
ILMN_1815303 M5.13:Undetermined LOC642197 0.00 0.17 0.00 0.00
ILMN_1652787 M5.2:Undetermined PIK3AP1 0.00 0.06 0.00 0.00
ILMN_1653143 M5.4:Undetermined ECD 0.00 -0.42 0.00 0.00
ILMN_1741881 M5.7:Inflammation C9orf72 0.00 0.46 0.00 0.00
ILMN_1696065 M6.10:Undetermined SDF4 0.00 -0.13 0.00 0.00
ILMN_1785191 M6.9:Undetermined TMEM14A 0.00 0.59 0.00 0.00
ILMN_1807633 M7.11:Undetermined HRSP12 0.00 0.18 0.00 0.00
ILMN_1667171 M7.2:Undetermined LOC651881 0.00 -0.04 0.00 0.00
ILMN_1762883 M7.4:Undetermined ECE2 0.00 0.33 0.00 0.00
ILMN_1784785 M7.5:Undetermined COPS7B 0.00 -0.14 0.00 0.00
ILMN_1685005 M4.13:Inflammation TNFRSF1A 0.00 0.00 0.07 0.00
ILMN_1757730 M4.7:Cell Cycle TTC27 0.00 0.00 -0.47 0.00
ILMN_1708782 M5.1:Inflammation MFAP3 0.00 0.00 0.23 0.00
ILMN_1812688 M5.13:Undetermined C2orf18 0.00 0.00 -0.56 0.00
ILMN_1712423 M5.3:Undetermined SKIP 0.00 0.00 -0.62 0.00
ILMN_1765326 M6.10:Undetermined DGKD 0.00 0.00 0.00 0.00
ILMN_1733441 M7.14:Undetermined POGZ 0.00 0.00 -0.13 0.00
ILMN_1798612 M7.16:Undetermined SNX20 0.00 0.00 -0.03 0.00
ILMN_1717337 M5.7:Inflammation MARCH7 0.00 0.00 0.00 1.00
Table 3.1 – Loadings of the selected genes on any of the 4 X sPLS components
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Figure 3.5 – Modules selection Robustness on 100 bootstrap samples
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All in all it seems that the reproducibility of the variable selection at the gene level
is quite low. However, reproducibility at the Module level is relatively good, with the
stronger signal (Inflammation, T-cell activation, . . . ) being very consistent (Figure 3.5
and Table 3.2). Once again, many selected Modules are not annotated. In addition,
VSURF and bootstrap results were much in agreement.
Conclusions
Finally changes in gene expression in whole blood were consistently associated with
results from in vitro T cell assays. The integration of gene expression patterns and func-
tional assays identified signature inversely correlated with the peak of viral load following
ATI. Indeed patients with lower expression of inflammatory pathways during vaccination
developed a stronger vaccine elicited immune response. This analysis may help to better
define the endpoint of next vaccine trials and to identify patients who likely benefit from
the vaccination.
3.2 Systems analysis of sex differences in the response
to influenza vaccination
This section is mainly part of an article written in collaboration with David Furman
that was published in PNAS :
D. Furman⇤, B.P. Hejblum⇤, N. Simon, V. Jojic, C.L. Dekker , R. Thiébaut, R.J.
Tibshirani, M.M. Davis, A systems analysis of sex differences reveals an immunosup-
pressive role for testosterone in the response to influenza vaccination, Proceedings of the
National Academy of Sciences of the United States of America, 111(2):869-874, 2014.
DOI: 10.1073/pnas.1321060111
⇤ equal contribution
The original article is provided in Appendix E page 143.
3.2.1 Introduction to sex variability in immunity
The variability in the biology of human populations rises significant challenges in un-
derstanding various disease outcomes and developing successful therapeutics. The sources
of this variation are likely the consequence of genetics, epigenetics, and the history of anti-
genic exposure [Jirtle and Skinner, 2007; Knight, 2013]. As therapies targeting immune
function are developed to improve clinical outcomes in many situations such as cancer,
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Module Freq Annotation Module Freq Annotation
M7.1 92% Inflammation M7.28 56% Undetermined
M5.1 91% Inflammation M4.2 55% Inflammation
M5.13 91% Undetermined M5.14 55% Undetermined
M5.5 91% Undetermined M6.7 55% Undetermined
M5.4 84% Undetermined M5.15 53% Neutrophils
M3.5 83% Cell Cycle M6.4 52% Undetermined
M5.10 82% Mitochondrial Respiration M7.21 50% Undetermined
M5.6 81% Mitochondrial Stress / Proteasome M4.15 49% T cell
M5.7 80% Inflammation M4.4 49% Undetermined
M3.2 79% Inflammation M6.9 48% Undetermined
M7.11 79% Undetermined M7.24 48% Undetermined
M7.5 78% Undetermined M3.1 46% Erythrocytes
M4.13 76% Inflammation M5.2 46% Undetermined
M5.8 76% Undetermined M6.13 46% Cell Death
M7.12 76% Undetermined M6.20 46% Undetermined
M7.2 73% Undetermined M7.14 46% Undetermined
M4.1 72% T cell M7.26 46% Undetermined
M7.25 72% Undetermined M6.14 42% Undetermined
M4.6 70% Inflammation M4.3 40% Protein Synthesis
M4.7 70% Cell Cycle M7.27 40% Undetermined
M5.3 70% Undetermined M4.8 38% Undetermined
M6.2 70% Mitochondrial Respiration M7.33 38% Undetermined
M7.7 70% Undetermined M4.5 37% Protein Synthesis
M7.4 68% Undetermined M3.6 36% Cytotoxic/NK Cell
M5.9 65% Protein Synthesis M2.3 34% Erythrocytes
M4.12 64% Undetermined M2.1 33% Undetermined
M7.6 64% Undetermined M8.14 32% Undetermined
M1.1 61% Platelets M4.14 31% Monocytes
M7.8 61% Undetermined M6.6 31% Apoptosis / Survival
M6.10 60% Undetermined M7.35 26% Undetermined
M4.16 58% Undetermined M8.13 21% Undetermined
M4.9 58% Undetermined M8.59 21% Undetermined
M7.16 58% Undetermined M8.35 17% Undetermined
M5.11 56% Undetermined M4.11 11% Plasma Cells
M7.15 56% Undetermined
Table 3.2 – Modules selection consistency on 100 bootstrap samples
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infections, autoimmune diseases and transplantation, identifying the sources of immuno-
logical variation and finding biomarkers associated with immune health are crucial for
their success [Davis, 2008]. An important source of immunological variation is known to
be the sex of the individual. Males experience a greater severity and prevalence of bac-
terial, viral, fungal, and parasitic infections than females, who also exhibit a more robust
response to antigenic challenges such as infection and vaccination [Klein, 2000; Klein and
Poland, 2013]. This stronger immune response in females could also explain why they
more frequently develop immune-mediated pathologies during influenza infection [Robin-
son et al., 2011]. Furthermore, females are at a higher risk for developing autoimmune
diseases. In this later context, it is interesting to note that a recent study showed that
females had, on average, 1.7 times the frequency of self-specific T cells as males [Su et al.,
2013]. Despite the fact that initial observations relating the sex of the individual with
the immune response were made many years ago [Grossman, 1985], little is known about
the mechanisms underlying these differences. Some sex-specific variations in the immune
response can be directly attributed to sex hormones [Sakiani et al., 2013]. In humans, sex
steroids can bind to intracellular receptors located in immune cells such as monocytes, B
cells, and T cells and activate hormone-responsive genes, suggesting that they can directly
affect sex-related differences in both innate and adaptive immune responses [Pennell et al.,
2012]. Whereas estrogens are associated with inflammation and can stimulate prolifera-
tion and differentiation of lymphocytes and monocytes, androgens suppress the activity
of immune cells by increasing the synthesis of anti-inflammatory cytokines [Olsen and
Kovacs, 1996; Liva and Voskuhl, 2001]. To date, no clear associations have been found
between biological and clinical differences in the immune response between males and fe-
males in humans. In one study, results from public gene expression data [Gaucher et al.,
2008] showed that many of the genes induced by a yellow fever vaccine were preferentially
activated in females [Klein et al., 2010]. However, whether these differences correlate with
poor antibody outcomes remains to be determined.
3.2.2 Serological response to trivalent inactivated seasonal in-
fluenza vaccine
To study the differences in males’ versus females’ immune systems, we used data from
a vaccination and systems immunology study conducted on 91 individuals (37 males and
54 females) of different ages (20 to 30 and 60 to 89 years old) that was recently reported
[Furman et al., 2013]. We studied a variety of immune parameters from peripheral blood
before vaccination, including cytokines, chemokines, and growth factors in serum, fre-
quencies of diverse blood cell subsets, phosphorylation levels of signal transducer and
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activator of transcription (STAT) proteins in multiple cells stimulated with a variety of
cytokines or unstimulated (96 conditions in total), and whole-blood gene expression. The
gene expression data were reduced to 109 gene modules by cluster analysis and assignment
of a set of transcription factors (regulatory program) to each gene module as described
[Furman et al., 2013] (Appendix D.1 page 141). Four individuals were removed from the
analysis: two outliers and two with incomplete dataset.
In this study, we sought to determine whether we could identify biomarkers from pe-
ripheral blood that could explain the sex-related differences in the serological response
to the trivalent inactivated seasonal influenza vaccine (TIV) in both young (20 to 30
years old) and older cohorts (60 to 89 years old). To determine the magnitude of the
antibody response to TIV, virus microneutralization assays were performed for each of
the three strains contained in the TIV (H1N1, H3N2, B). The seroconversion rate (per-
cent of individuals with a fourfold or greater change in their post- versus pre-vaccination
antibody microneutralization titer) was computed for each strain and for each group of
individuals (Figure 3.6). Young and older females had higher neutralizing antibodies
than age-matched males (Figure 3.6), as previously reported [Cook, 2008]. The largest
differences between males and females were observed for the H3N2 strain (Figure 3.6 and
Table 3.3). Females also showed higher expression of inflammatory markers, however,
none of these specific sex-related differences correlated with the observed disparities in
the antibody response to TIV.
In the rest of the analysis, the focus was only on the antibody response to the H3N2
strain.
3.2.3 Interaction analysis and modeling of antibody response to
the H3N2 strain
The goal of this analysis was to identify potential gene module expressions that were
related to the sex effect on the antibody response to TIV for the H3N2 strain. The
response was modeled as a binary variable (fold increase of post- versus pre-vaccination
antibody microneutralization titer   4). A logistic regression [McCullagh and Nelder,
1989] was conducted for the estimation of the regression coefficients and odds ratios in
response to vaccination.
First and foremost, potential confounders of the sex effect on the response were con-
sidered. A variable was labelled as a confounder of the sex effect on the antibody response
if it modified the estimate of the sex effect on the response by more than 20%. A forward
strategy was performed starting with a basic model including the sex covariate only. Two
potential confounders were thus identified: the gene module 42 which is linked to the
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Figure 3.6 – Seroconversion rate after TIV in all three stains stratified on sex for young
and old individuals
Strain Variable Effect size p-value
H1N1 (intercept) -0.272 0.234
age -0.690 0.004?
male -0.011 0.962
H3N2 (intercept) -0.038 0.962
age -0.190 0.421
male -0.716 0.003?
B (intercept) -0.502 0.033?
age -0.583 0.018?
male -0.594 0.020?
?: significant at a 5% level for type I error
Note: The response was modeled as a binary variable (fold increase of post- versus pre-vaccination
antibody microneutralization titer   4) in a logistic regression model [McCullagh and Nelder, 1989]. For
the sex variable male, women are the reference.
Table 3.3 – Age and sex effects on antibody titer responses to TIV
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encoding of ribosomal proteins and the acute-phase inflammatory marker CRP (Figure
3.7). First gene module 42 modified the sex effect by more than 20% in the following
model:
logit (p(yi = 1)) = µ+  smalei +  vari (6)
where yi = 1{AntibodyT iter(prevac)/AntibodyT iter(postvac) 4}, µ is the intercept,  s is the effect of
being male (female are the reference) on the logit of the probability of responding to TIV
for the H3N2 strain, malei is 1 if individual i is male and 0 if individual i is female,  
the effect of the potential confounder variable, and vari the potential confounder variable
value for individual i. The model (6) was tried out for all immune variables in place of
var. Gene module 42 was the variable with the largest modification of the sex effect.
Then CRP modified the sex effect by more than 20% in the following model:
logit (p(yi = 1)) = µ+  smalei +  m42m42i +  vari (7)
Then no more variables modified the sex effect on the response once adjusting on both
CRP and gene module 42 using again the same strategy (Figure 3.7) and the final model
adjusted on potential confounders was:
logit (p(yi = 1)) = µ+  smalei +  cCRPi +  m42m42i (8)
Second, to identify possible gene module candidates that explain the differences ob-
served in responsiveness, significant marginal interactions between gene modules and the
sex effect on the response were tested. To do so, the Interact strategy from Simon and
Tibshirani [2012] was used in order to investigate all possible interactions in the binary
response while controlling the FDR using permutation methods. Testing for interactions
in high-dimensional settings is difficult and can lead to several issues. In particular, ap-
plying multiple testing correction to multiple fitted bivariate logistic regression models is
problematic [Bůžková et al., 2011]. Indeed, traditional FDR controlling procedures (Ap-
pendix A page 121) can fail to control the FDR in the logistic regression settings [Simon
and Tibshirani, 2012]. In addition, it is difficult to derive a permutation strategy that
would test only the interaction effect, and not both main and interaction effects at once
in logistic regression models under reasonable assumption on the independence of both
variables at play [Bůžková et al., 2011]. Simon and Tibshirani [2012] proposes a backward
strategy for testing, for each pair of variables, if their correlation is the same regardless of
the class output (in our case ). Their strategy allows to derive a permutation method that
controls the FDR correctly [Simon and Tibshirani, 2012] and thus identify any significant
marginal interactions. Setting the significance threshold at an FDR of < 10% identified
only one gene module interacting with the sex on the antibody response against the H3N2
strain: gene module 52.
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Figure 3.7 – Densities of size effects of the sex variable on the antibody response to H3N2
strain after TIV when ajusting on various potential confounders
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The following model was thus estimated (model (9)), which included the variables of
sex and gene module 052 and their interaction term, adjusted on the potential confounding
covariables gene module 42 and CRP:
logit (p(yi = 1)) = µ+  smalei +  cCRPi +  m42m42i (9)
+  m52i +  s:vmalei : m52i
The resulting odds ratio (OR) estimate for vaccine response based on the expression
of gene module 52 in model (9) was 0.39 [confidence interval (CI), 0.18-0.84] for males
and 2.25 (CI, 1.08-4.67) for females (Figure 3.8A). This indicates that the probability of
being a high responder to TIV for the H3N2 strain significantly decreases with an elevated
expression of module 052 in males and with decreased expression of module 52 in females.
To determine the extent to which module 052 and its interaction with sex contribute
to the classification model, we computed a cross-validated (leave-pair-out [Airola et al.,
2011]) area under the curve (AUCcv) for model (8) and model (9). The AUCcv was 0.712
for model (8), and 0.761 for model (9). Furthermore, direct comparison of the two models
by a likelihood ratio test showed that model (9) is significantly better (p-value of 0.0019)
than model (8). These results suggest that the observed sex differences in the neutralizing
antibody responses to vaccination could be mediated by the expression of genes involved
in lipid metabolism (as a significant part genes participating in the gene module 52 are
involved in lipid metabolism).
Our results showing that augmented expression of gene module 52 correlated with
weaker TIV responsiveness in males but not in females suggested that sex hormones
could be involved in expression of this gene module. Indeed, results from chemical-gene
interaction analysis (http://ctdbase.org) (24) show that expression of a significant fraction
of genes in module 052 can be modulated by testosterone (hypergeometric test p-value <
0.005). Free (unbound, bioactive form) testosterone was measured in the sera from the
individuals in our study with the hypothesis that, in males, the observed effect of module
52 on vaccine response was dependent on the circulating levels of testosterone. Male
subjects were stratified into testosterone high (Thi) or low (Tlo) if they were respectively
above or below the median for all of the male subjects (in our sample testosterone median
is 4.06 pg/mL and testosterone ranges from 0.58 pg/mL to 24.78 pg/mL). A final logistic
regression model (model 10) for antibody response to H3N2 strain was estimated, in which
the sex variable was replaced by a three category variable: individuals were either female
(the reference), Thi male (n = 17) or Tlo male (n = 17). The median testosterone level
in Thi subjects was 9.55 pg/mL (ranging from 4.25 pg/mL to 24.78 pg/mL), and 2.34
pg/mL (ranging from 0.58 pg/mL to 3.89 pg/mL) in Tlo subjects. The median age for Tlo
and Thi males was 77 and 24 years, respectively. Thus, model 3 included the interaction
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was found between the variables sex and gene module 052. (A) Odds ratio for vaccine response given
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Figure 3.8 – Odds ratios of gene module 52 for antibody responses to H3N2 strain after
TIV based on gender and Testosterone level
terms gene module 52 times Thi and gene module 52 ⇥ Tlo, and was also adjusted for
age, because of the effect of aging on testosterone levels:
logit (p(yi = 1)) = µ+  ccrpi +  m42m42i +  m52m52i +  aagei (10)
+  T lomaleT loi +  T lo:m52maleT loi : m52i
+  ThimaleThii +  Thi:m52maleThii : m52i
Strikingly, the interaction between testosterone levels and gene module 52 was signif-
icant only for the Thi group (Wald test p-value < 0.005 – see Figure 3.8B), and not for
Tlo males (Wald test p-value = 0.18), and the corresponding OR estimates for vaccine
response, according to module 052, were 0.87 (CI, 0.28-2.69) for Tlo and 0.19 (CI, 0.04-
-0.80) for Thi males. We also tested testosterone levels as a continuous measure in the
following model (also adjusted by sex and age):
logit (p(yi = 1)) = µ+  ccrpi +  m42m42i +  m52m52i +  aagei (11)
+  smale+  T testoi +  T :m52testoi : m52i
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Consistent with model 10, the interaction of gene module 52 and continuous testos-
terone levels was significant (Wald test p-value = 0.012 – see the significantly decreasing
trend of the OR of gene module 52 as testosterone level increase in Figure 3.9). This
indicates that gene module 52 has a significant effect on antibody response after TIV in
males with high levels of testosterone but not in those with lower levels. Models 10 and 11
were not nested therefore likelihood ratio test is not available to compare them. Both AIC
and BIC criteria favor model 11 (respectively 102.9 and 120.0) over model 10 (respectively
106.3 and 128.5). However, model 10 is more interpretable as including testosterone level
of women in the estimation is debatable.
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Note: Odds ratio for vaccine response based on expression of module 052 and testosterone levels. Logistic
regression analysis was conducted on the antibody-neutralizing activity based on expression of genes in
module 052 and the testosterone levels as a continuous measurement. The estimated odds ratio (OR)
for the antibody-neutralizing response is shown (black continuous line). Red, light blue, blue, and dark
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of testosterone levels for males. CI, confidence interval.
Figure 3.9 – Odds ratios of gene module 52 for vaccine responses based on expression of
module 52
Together, these results show that in males with higher levels of testosterone and ele-
vated expression of gene module 52 that participates in lipid metabolism, the antibody
response to vaccination is severely down-regulated, whereas in those with low levels of
testosterone, or in females, the contribution of gene module 52 is not detrimental and the
responses to the vaccine remain intact.
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Conclusions
There are marked differences between the sexes in their immune response to infections
and vaccination, with females often having significantly higher responses. However, the
mechanisms underlying these differences are largely not understood. Using a systems
immunology approach, we have identified a cluster of genes involved in lipid metabolism
and likely modulated by testosterone that correlates with the higher antibody-neutralizing
response to influenza vaccination observed in females. Moreover, males with the highest
testosterone levels and expression of related gene signatures exhibited the lowest anti-
body responses to influenza vaccination. This study generates a number of hypotheses
on the sex differences observed in the human immune system and their relationship to
mechanisms involved in the antibody response to vaccination.
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82
4 Dirichlet process mixture of skew t-
distributions for modeling flow cytom-
etry data
Abstract:
Flow cytometry is a high-throughput technology used to quantify multiple surface
and intracellular markers at the level of a single cell. Improvements of this technology
lead today to the ability of describing millions of individual cells from a blood sample
using multiple markers. This allows to identify cell sub-types, and to count the number
of cells of each sub-type. But it also results in high-dimensional datasets, whose manual
analysis is highly time-consuming and poorly reproducible. Several methods have been
developed to perform automated recognition of cell populations from flow cytometry data.
Most of them are suited for the analysis of a single sample from one patient. In clinical
trials, repeated measurements with several samples by patient and by time points are
actually available. We propose to use a Bayesian nonparametric approach with Dirichlet
process mixture (DPM) of skew t-distributions to perform model based clustering of such
data. DPM models enable the number of cell populations to be estimated from the
data avoiding any model selection. The use of skew t-ditributions provides robustness to
outliers and suits best the usually non elliptical shape of cell population distributions.
In the case of repeated measurements, we propose a sequential strategy relying on a
parametric approximation of the posterior. We apply this methodology to simulated data
and to two experimental benchmark datasets.
Key Words: Automated gating; Bayesian; Dirichlet process; Flow cytometry; Mixture
model; Nonparametrics Bayesian; Skew t-distribution.
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4.1 Introduction to flow cytometry data
Flow cytometry is a high-throughput technology used to quantify multiple surface and
intracellular markers at the level of single cell. More specifically, cells are stained with
multiple fluorescently-conjugated monoclonal antibodies directed to cell surface receptors
(such as CD4) or intracellular markers (such as the interleukine-2 cytokine) to determine
the type of cell, their differentiation and their functionality. Figure 4.1 shows a simplistic
representation of this idea. A flow cytometer (Figure 4.2) is then used to measured
the fluorescent intensity of the stained cells one by one. With the improvement of this
technology, leading currently to the use of up to 18 markers at the same time (using 18
colors), multi-parametric description of millions of individual cells can be generated.
4.2 A brief introduction to the Bayesian framework
The Bayesian approach to probability theory dates back to the 18th century and the
posthumous publication of Bayes article in 1764 (even though the discovery of Bayes’s
rule is subject to historical controversies [Stigler, 1983]). The Bayesian approach is often
opposed to the frequentist one. The frequentist approach assumes that model parameters
are deterministic, having a fixed (unknown) value, whereas in the Bayesian framework,
parameters themselves are considered as random variables, with associated probabilities.
Let’s consider the following model where the observations y and the parameters ✓ have
a joint probability density function p(✓,y). This joint density can be decomposed as the
product of the prior density function (i.e. the probability distribution representing the
prior belief or knowledge on the parameters) p(✓) and the likelihood of the data p(y|✓):
p(✓,y) = p(✓)p(y|✓)
Using the same decomposition but with the marginal distribution of the observations
p(y), one gets:
p(✓,y) = p(y)p(✓|y)
Then Bayes’ Theorem can be easily derived, giving the posterior density of ✓:
p(✓|y) = p(✓)p(y|✓)
p(y)
=
p(✓)p(y|✓)R
p(✓)p(y|✓))
The purpose of Bayesian inference is to estimate this posterior density of the param-
eters, usually focusing only on the part dependent of ✓:
p(✓|y) / p(✓)p(y|✓)
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Figure 4.1 – Simplistic representation of the idea of cellular markers staining
Figure 4.2 – Simplistic representation of a flow cytometer
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Various techniques can be used to estimate the posterior distribution of the parameters
[Gelman et al., 2013]. Posterior simulations through Markov Chain Monte Carlo (MCMC)
methods [Geman and Geman, 1984; Gilks et al., 1996] have become extremely useful
thanks to the increased computing capabilities of modern computers.
4.3 Dirichlet process mixture models
4.3.1 Mixture Models
Let’s consider C observations in d dimensions: yc 2 Rd, c = 1, . . . , C (typically
corresponding to the vector of fluorescence intensities measured for the cell c in the case
of flow cytometry data). We assume that those data are independent and identically
distributed (i.i.d.) from some unknown distribution F :
yc|G iid⇠ F for c = 1 . . . , C (12)
where F is a mixture of distributions:
F (y) =
Z
⇥
f✓(y)G(d✓) (13)
where f✓(y) is a known probability density function, parameterized by ✓ 2 ⇥, a set of
parameters, and defining the shape of a cluster. G is the unknown mixing distribution,
which carries the weights and locations of the mixture components. In a parametric
approach, G =
PK
k=1 ⇡k ✓k where ⇡k is the weight of the keth mixture component and ✓k
its respective parameters. Maximum likelihood or Bayesian estimates of F can be derived
for such models [Biernacki et al., 2000].
4.3.2 Dirichlet process mixture models
Dirichlet Process definition and basic properties
In a nonparametric perspective (where the number of clusters is unknown) G is written
as a infinite sum of atoms: G =
P
+1
k=1 ⇡k ✓k . Let’s assume that the random mixing
distribution G is drawn from a Dirichlet process [Ferguson, 1973]:
G ⇠ DP(↵, G
0
) (14)
where DP(↵, G
0
) denotes the Dirichlet process of scale parameter ↵ > 0 and base proba-
bility distribution G
0
.
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Definition. A Dirichlet Process (DP) is a probability distribution over the space of
probability measures whose marginal distributions are Dirichlet distributed:
If G ⇠ DP(↵, G
0
), 8 partition A
1
, . . . , Ak of a measurable space T ,
(G(A
1
), . . . , G(Ak)) ⇠ Dir (↵G0(A1), . . . ,↵G0(Ak))
The DP constitutes a very appealing prior for unsupervised clustering models, as it
generates infinitely large atomic discrete distributions. Indeed, a draw G ⇠ DP(↵, G
0
) is
almost surely discrete and takes the following form [Sethuraman, 1994]:
G =
+1X
k=1
⇡k ✓k (15)
where the ✓k are i.i.d. from the base distribution G0 and independent of the weights,
⇡ = (⇡k)k=1,2,..., which are drawn from a so-called "stick-breaking" distribution:
⇡
1
=  
1
and 8k > 1, ⇡k =  k
k 1Y
j=1
(1   j)
with  k
iid⇠ Beta(1,↵) for k = 1, 2, . . .. We write simply ⇡ ⇠ GEM(↵) after the Griffiths-
Engen-McCloskey (GEM) distribution [Pitman, 2006]. The base distribution G
0
tunes
the prior information available about the cluster locations. The parameter ↵ tunes the
prior distribution on the overall number of clusters K that will be discovered within C
data. In particular we have E[K|C] =PC 1c=0 ↵↵+C and V [K|C] =
PC 1
c=0
↵c
(↵+c)2
[Teh, 2010].
The DP carries conjugacy properties from the finite Dirichlet distribution, and we can
write the conditional distribution of ✓c given ✓ c = (✓1, . . . ,✓c 1,✓c+1, . . . ,✓c), known as
the Blackwell-MacQueen scheme:
✓c|✓ c ⇠ ↵
↵ + C   1G0 +
1
↵ + C   1
X
m 6=c
 ✓m (16)
where  ✓m denotes the probability distribution with all its mass in ✓m. Note that the
values of the drawn ✓ are repeated, with the probability of an already observed value
to be observed again proportional to the number of times it has already been observed.
This can be viewed as a "rich gets richer" property. The partition distribution induced
by the clustering can be interpreted as a Chinese Restaurant Process (CRP). This is a
metaphor of a Chinese restaurant with an infinite number of tables, and where customers
enter one by one and sit to any table they want (each table can also sit an infinite number
of customers). A new customer entering the restaurant can sit either at a table where
previous customers are already sitting, or sit alone at a new table. The most popular tables
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are the ones with the most customers already sat. In this metaphor, the customers are
the observations and the tables are in fact the clusters. The CRP describes a generative
process for the partition induced by a DP.
The model defined by Equations (12), (13) and (14) yields the following hierarchical
model known as a Dirichlet process mixture (DPM) model [Antoniak, 1974; Lo, 1984;
Escobar and West, 1995; Teh, 2010] with a Gamma hyperprior on the concentration
parameter ↵:
↵|a, b ⇠ Gamma(a, b) (17a)
⇡
  ↵ ⇠ GEM(↵) (17b)
for k = 1, 2, . . .
✓k
  G
0
⇠ G
0
(17c)
for c = 1, 2, . . . , C
`c
  
⇡ ⇠ Mult(⇡) (17d)
yc
   `c, {✓k} ⇠ f✓`c (17e)
where `c is an allocation variable indicating to which cluster is associated the observation
c. The parameter ↵ has a direct impact on the number of clusters in the posterior (Figure
4.3). In order to truly estimate the number of clusters in the posterior partition from the
data, it is important to specify a hyperprior on ↵.
4.4 Automated gating of flow cytometry data
This section is mainly part of an article that is in preparation for submission for pub-
lication in a peer reviewed scientific journal.
Analysis of flow cytometry data is usually performed manually. This results in analy-
ses: i) poorly reproducible [Aghaeepour et al., 2013], ii) expensive (highly time-consuming)
and iii) as a result of ii), focused on specific cell populations (i.e. specific combination
of markers), possibly missing out on cell populations. Efforts have been made in the
recent years to offer automated solutions to tackle these limitations [Aghaeepour et al.,
2013], and a lot of different methodological approaches have been proposed to perform
automated recognition of cell populations from flow cytometry data. First, clustering
methods related to the k-means methods such as L2kmeans [Aghaeepour et al., 2013],
89
DPM OF SKEW t-FOR FLOW CYTOMETRY DATA
−4 −2 0 2
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
theta
D
en
si
ty
●
●
●
●
●
● ● ●●● ●● ●● ●●● ● ●● ●● ●● ● ●● ●● ●● ● ● ●● ●● ● ●●●● ●● ● ●● ● ●●●● ●●● ●●● ●● ● ●●●● ●●● ● ●● ●●● ●● ●●● ● ●● ●● ●● ●● ● ●●● ●●●
● (truncated) sample G~DP(alpha=2, G0)
base distribution G0=N(0,1)
A: Example of a DP sampling with ↵=2
−4 −2 0 2
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
theta
D
en
si
ty
●
●
● ●
●
●
● ●
●
●
●
● ●●
●
●●
●●
●
●●●
●
●
● ●
●
●
●● ●●●●
●
●
●
● ● ●● ●● ●●
●
●● ● ● ●
●
●●●●● ● ● ● ● ●● ●●●● ●● ●● ●● ●●●● ●●● ● ●● ●●● ● ●●● ● ●● ●● ●●● ● ●●● ● ●● ● ●● ●●● ● ●● ●● ●●● ● ●●● ●●●
● (truncated) sample G~DP(alpha=20, G0)
base distribution G0=N(0,1)
B: Example of a DP sampling with ↵=20
Figure 4.3 – Impact of ↵ on the number of locations with a significant weight
flowMeans [Aghaeepour et al., 2011] were proposed. Model based clustering methods re-
lying on finite mixture models such as flowCust/merge [Lo et al., 2008; Finak et al., 2009],
FLAME [Pyne et al., 2009], SWIFT [Naim et al., 2014] were also proposed, as well as
dimension reduction methods such as MM and MMPCA [Sugár and Sealfon, 2010], Sam-
SPECTRAL [Zare et al., 2010], FLOCK [Qian et al., 2010]. All those approaches requires
the number of cell populations to be fixed in advance, and resort to various criteria to
find the optimal number of cell populations. Finally, CDP [Chan et al., 2008], and more
recently [Lin et al., 2013; Cron et al., 2013; Dundar et al., 2014], proposed nonparametric
Bayesian mixture models of Gaussian distributions. that directly estimate the number of
cell populations. All these methods, except those of Lin et al. [2013], of Cron et al. [2013]
and of Dundar et al. [2014], were evaluated in the FlowCAP-I Challenge whose results
are presented in Aghaeepour et al. [2013].
However, there is still room for improvement, especially in the definition of the num-
ber of cell population and the identification of rare cell populations. In addition, most
of those previous approaches have been proposed for a single sample analysis, except for
Cron et al. [2013] who recently proposed to use hierarchical Dirichlet process mixture
(DPM) of Gaussian distribution models to analyze multiple samples simultaneously. Yet
in the case of repeated measurements of flow cytometry data, it can be useful to perform
analysis as the samples are acquired (samples are often collected across several time points
in a population of patients, for instance included in a clinical trial). In such a case, one
would want to use previously acquired sample as informative prior information in the
analysis of a new sample. The approach proposed in this paper includes a strategy of se-
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quential approximations of the posterior distribution for multiple data samples, presented
in section 4.4.3.
The automated recognition of cell population from flow cytometry data is a difficult
task which can be seen as an unsupervised clustering problem. It is characterized by
two big challenges. First, the total number of cell populations to identify is unknown.
Second, the empirical distributions of the populations are heavily skewed, even when op-
timal transformation of the data is applied [Pyne et al., 2009; Finak et al., 2010], and the
data generally present many outliers. To address all these points together, our approach
consider a Bayesian nonparametric model-based approach, where the flow cytometry data
are assumed to be drawn from a DPM skew t-distributions. First, this approach enables
the number of cell populations to be inferred from the data, and avoids the challenging
problem of model selection. Second, it has been demonstrated that the Gaussian as-
sumption for the parametric shape of a cell population fits poorly flow cytometry data
[Mosmann et al., 2014]. Indeed, even after state-of-the-art transformation of raw cytom-
etry data, such as the biexponential transformation [Finak et al., 2010], cell population
distributions are typically skewed. Pyne et al. [2009] have showed the advantages of the
skew t-distribution [Azzalini and Capitanio, 2003] for modeling cell subpopulations in flow
cytometry data. The skew t-distribution is a generalization of the skewed normal distri-
bution, with a heavier tale which makes it more robust to outliers. Frühwirth-Schnatter
and Pyne [2010] proposed a finite mixture model of skew t-distributions. We extend this
model to the infinite mixture case in a Bayesian non parametric framework. Of inter-
est, quantifying the uncertainty around the estimated partition is straightforward in this
Bayesian paradigm, from the posterior distribution of the partition. Furthermore, the
use of a Bayesian framework allow the use of informative priors. In the case of repeated
measurements for instance, we propose to sequentially estimate the posterior partition
of flow cytometry using posterior information from time point t as prior information for
time point t+ 1.
4.4.1 A statistical model of Dirichlet process mixture of skew t-
distributions
In this section, only one single dataset is considered. The case of the sequential
estimation of multiple datasets will be addressed in section 4.4.3. Typically, the data
yc have been transformed from the raw data of measured fluorescence through a bi-
exponential or Box-Cox transformation [Finak et al., 2010].
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Multivariate skew t-distribution
First let’s consider the choice of the parametric density f✓ which is a skew t-distribution.
Skew normal distribution Frühwirth-Schnatter and Pyne [2010] present a parametriza-
tion of the multivariate skew Normal distribution defined by Azzalini and Valle [1996]
which leads to the following probability density function:
fSN (y; ⇠,⌦,⌘) = 2 (y   ⇠;⌦) (⌘0! 1(y   ⇠)) (18)
with  (·;⌦) the probability density function of the multivariate Normal distribution with
zero mean N (0,⌦) and  (·) the cumulative density function of the standard univariate
Normal distribution N (0, 1).
Frühwirth-Schnatter and Pyne [2010] propose a random-effects model representation
of such a skew Normal distribution, with truncated normal random effects:
Y = ⇠ + Z + " (19)
with Z ⇠ N
[0;+1[(0, 1) a truncated univariate standard Normal distribution and " ⇠
N (0,⌃) a multivariate Normal distribution with zero mean. The original parameters can
be recovered from:
⌦ = ⌃+  0, ⌘ =
1p
1  0⌦ 1 
!⌦ 1 (20)
The skew t-distribution Let X ⇠ SN (0,⌦, ⌘) and W ⇠ Gamma(⌫
2
, ⌫
2
). If Y has the
following stochastic representation:
Y = ⇠ +
1p
W
X (21)
then it follows a multivariate skew t-distribution Y ⇠ ST (⇠,⌦,⌘, ⌫) [Azzalini and Capi-
tanio, 2003]. Equation (21) can be expressed as the following random effect model
Y = ⇠ + 
Zp
W
+
✏p
W
(22)
Following the same parametrization as Frühwirth-Schnatter and Pyne [2010], we write
the density of a multivariate skew t-distibution as:
fST (y; ⇠,⌦,⌘, ⌫) =2fT (y; ⇠,⌦, ⌫) (23)
⇥ T⌫+d
 
⌘
0
!
 1
(y   ⇠)
s
⌫ + d
⌫ +Qy
!
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with ! =
p
Diag(⌦), Qy = (y ⇠)0⌦ 1(y ⇠), fT the multivariate Student t-distribution
probability density function, and T⌫ the cumulative distribution function of the scalar
standard Student t-distribution with ⌫ degrees of freedom. Figure 4.4 shows an example
of such distributions, highlighting the skewness of both the skew Normal and the skew t
and the heavier tail of the skew t distribution.
0.00
0.02
0.04
0.06
0.08
0 25 50 75 100
Y
D
en
si
ty
 Y~SN(0,1,10)      Y~ST(0,1,10,1.5)
Figure 4.4 – Density probability function of univariate skew Normal SN (⇠ = 0, =
10,   = 1) and skew t SN (⇠ = 0, = 10,   = 1, ⌫ = 1.5) distributions
4.4.2 Dirichlet process mixture of skew t-distributions
Let G
0
be the base distribution of a Dirichlet process in a DPM combining model
(17) with a random-effects model representation (22) of the skew t-distribution. G
0
is
the product of a structured inverse Wishart and of a prior on ⌫, the degree of freedom
of the skew t: G
0
= sNiW (⇠
0
, 
0
, B
0
,⇤
0
, 
0
)P
0,⌫ . Our proposed model is fully written as
follows:
↵|a, b ⇠ Gamma(a, b) (24a)
⇡
  ↵ ⇠ GEM(↵) (24b)
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for k = 1, 2, . . .
⇠k, k,⌃k, ⌫k ⇠ G0 (24c)
for c = 1, 2, . . . , C
`c
  
⇡ ⇠ Mult(⇡) (24d)
 c
   `c, (⌫k) ⇠ Gamma
⇣⌫`c
2
,
⌫`c
2
⌘
(24e)
sc
    c ⇠ N[0,+1[
✓
0,
1
 c
◆
(24f)
yc
   `c,  c, sc, (⇠k, k,⌃k) ⇠ N
✓
⇠`c + `csc,
1
 c
⌃`c
◆
(24g)
Discussion on the model assumptions
In model (24), the base distribution parameter G
0
conveys the prior information on
the cluster parametric shape. For the parameters ⇠k,  k and ⌃k, we have conditional
conjugacy with the random-effects model representation using joint priors taking the form
of a structured Normal-inverse-Wishart distribution[Frühwirth-Schnatter and Pyne, 2010].
See Appendix F page 157 for details. Frühwirth-Schnatter and Pyne [2010] pointed out
that the prior on ⌃k can have a big impact on the posterior number of clusters. Indeed,
setting the scale of the prior on ⌃k too small will give in an inflated number of clusters
in the posterior, whereas too large values tend to regroup all the observations together.
Adding a Wishart hyperprior on ⌃k, that carries on conjugacy with the inverse Wishart,
enables to relax this impact of the prior [Frühwirth-Schnatter and Pyne, 2010; Huang
and Wand, 2013]. Assuming prior independence between each ⌫k and also from the three
aforementioned parameters, we can use any of the three priors proposed in Juárez and
Steel [2010] for instance (such as an objective Jeffrey’s prior).
4.4.3 Statistical inference for a Dirichlet process mixture of skew
t-distributions model
Posterior inference via Gibbs sampling
For making inference on the model (24), MCMC methods allows to sample the parti-
tion {`
1:C} as well as the corresponding cluster parameters {✓⇤k} = {{⇠⇤k}, { ⇤k}, {⌃⇤k}, {⌫⇤k}}
from the marginal posterior distribution. Combining results from Frühwirth-Schnatter
and Pyne [2010] and Caron et al. [2014], it is possible to implement an efficient and valid
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partially collapsed Gibbs sampler with an Metropolis-Hastings step [van Dyk and Park,
2008; van Dyk and Jiao, 2013]. The use of slice sampling (the idea of sampling from a
distribution by uniformly sampling points uner its probability density curve) [Neal, 2003;
Walker, 2007; Kalli et al., 2011] enables the straightforward parallelization of the latent
allocation sampling (thanks to conditional conjugacy) in such an MCMC algorithm (even
in the skew normal and skew t cases). This can lead to substantial computation speed up
as the number of observations C (cells) per sample increases. Each iteration of our Gibbs
sampler proceeds in the following order (details are provided in supplementary material,
see Appendix F page 157):
1. Update the concentration parameter ↵ given the previous partition {`
1:C} using the
data augmentation technique from Escobar and West [1995].
2. Update the mixing distribution G given ↵, {⇠k}, { k}, {⌃k} and the base distri-
bution G
0
via slice sampling.
3. For c = 1, . . . , C update the individual skew parameter sc given {⇠k}, { k}, {⌃k}
and the new `c.
4. Update {⇠k}, { k}, {⌃k} given the base distribution G0, the updated partition
{`
1:C} and the updated individual skew parameters {s1:C}.
5. Finally jointly update the degrees of freedom and the individual scale factors ({⌫k},
{ 
1:C}) in an Metropolis-Hastings (M-H) within Gibbs step. First an M-H step
is performed to update the {⌫k} where the { 1:C} are integrated out, immediately
followed by a Gibbs step to sample the { 
1:C} from their full conditional distribution.
This ensures that the reduced conditioning performed in the M-H step does not
change the stationary distribution of the Markov chain [van Dyk and Jiao, 2013] –
see Appendix F page 157.
Sequential Posterior approximation
In flow cytometry experiments, it is common to actually have multiple datasets y(i)
(with i = 1, . . . , I) corresponding to multiple individuals, or repeated measurements of
the same individual. For instance in the case of clinical trials, longitudinal measurements
of flow cytometry data are often performed for the same patients. In such cases, it is of
interest to use previous time points or previous samples results as prior information. Spec-
ifying prior information to Dirichlet process mixture models not straightforward [Kessler
et al., 2015]. We propose to use the posterior MCMC draws obtained from previous
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dataset y(i) as prior information to analyze the next dataset y(i+1):
↵ ⇠ Gamma(a, b) (25a)
G|↵ ⇠ DP (↵, G
0
) (25b)
y
(i),y(i+1)|G ⇠iid
Z
⇥
f✓(·)dG(✓) (25c)
We are interested in estimating p(G|y(i),y(i+1)) / p(G|y(i))p(y(i+1)|G). The idea is to
first approximate p(G|y(i)) by a Dirichlet process through MCMC draws from the model
described in 4.4.1:
p(G|y(i)) '
Z
DP (G;↵, G
1
)Gamma(↵; a
1
, b
1
)d↵ (26)
where G
1
, a
1
, b
1
are parameters to be estimated from the MCMC approximation of
the true posterior: i) ba
1
and bb
1
can be taken as MLE estimates from the MCMC samples
↵(j); ii) cG
1
is a parametric approximation of the posterior. Indeed, the posterior of G
1
is
not suitable for being directly plugged in as a base distribution parameter of another DP .
In the case of a skew t-distributions mixture, G
1
is a joint distribution: G
1
= (sNiW, P
0,⌫)
where P
0,⌫ is the chosen prior for the skew t-distribution degrees of freedom. To estimate
G
1
, we estimate the Maximum a posteriori (MAP) from the posterior MCMC samples
(Appendix G page 163).
Using this posterior parametric approximation, we have the same hierarchical model,
conditional on y(i):
↵|y(i) ⇠ Gamma( ba
1
, bb
1
) (27a)
G|↵,y(i) ⇠ DP (↵,cG
1
) (27b)
y
(i+1)|G,y(i) ⇠iid
Z
⇥
f✓(·)dG(✓) (27c)
Note that under this approximate posterior model, the cluster parameters ✓(i)j are iid
from G
1
. Such an approach can be iterated numerous time if for instance several time
points are observed, approximating the successive posteriors.
Point estimate of the cell populations
Getting a representation of the partition posterior distribution is difficult. One can use
the maximum a posteriori, i.e. using the point estimation form the MCMC sample that
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maximize the posterior density. This approach loses any sense of the uncertainty conveyed
by the Bayesian approach. We rather consider a co-clustering probability matrix ⇣ on each
pair (k, l) of observations. Such a matrix can be estimated by averaging the co-clustering
matrices from all the explored partitions in the posterior MCMC draws:
b⇣cd =
1
N
NX
i=1
 
`
(i)
c `
(i)
d
(28)
where N is the number of MCMC draws from the posterior and  kl = 1 if k = l, 0
otherwise. The computational cost of this approach, though, is of the order O(Nn2).
An optimal partition point estimate {b̀
1:C} can then be derived in regard of this sim-
ilarity matrix by using a pairwise coincidence loss function [Lau and Green, 2007], such
as the one proposed by Binder [1978, 1981]:
{b̀
1:C} = argmin
{`(i)1:C}2
n
{`(1)1:C},...,{`
(N)
1:C }
o
C 1X
c=1
CX
d=c+1
2
⇣
 
`
(i)
c `
(i)
d
  b⇣cd
⌘
2
(29)
An optimal partition point estimate {˜`
1:C} can also be derived in regard of the F -
measure. The F -measure is widely used as a way to summarize the accordance between
2 methods, one being considered as a reference gold-standard. It is the harmonic mean
of the precision and recall:
F =
2PrRe
Pr +Re
(30)
In order to use the F -measure to evaluate our clustering method, we rely on the defi-
nition proposed in the online methods from Aghaeepour et al. [2013]. In this setting of
unsupervised clustering, the precision Pr is the number of cells correctly assigned to a
given cluster divided by the total number of cells assigned to this cluster. It can also be
called Positive Predictive Value. The recall Re is the number of cells correctly assigned
to a given cluster divided by the number of cells that should be assigned to this cluster
according to the gold-standard. Since in our problem the labels of the different clusters
are exchangeable, the F -measure is computed for each combination of the reference clus-
ters and the predicted clusters. Let G = {g
1
, . . . , gm} be a set of m reference clusters and
H = {h
1
, . . . , hn} be set of n predicted clusters. For each combination pair (q, r) of a
reference cluster gq and a predicted cluster hr, the F -measure is computed as follows:
Pr(hr, gq) =
|gq \ hr|
|hr| and Pr(hr, gq) =
|gq \ hr|
|gq| (31)
F (hr, gq) =
2Pr(gq, hr)Re(gq, hr)
Pr(gq, hr) +Re(gq, hr)
(32)
This F -measure is comprised in [0, 1], the closer it is to 1 the better agreement between the
predicted cluster and the reference cluster. The total F -measure for a predicted partition
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H given a gold-standard G is then define as the weighted sum of the best matched F -
measure:
Ftot(H,G) =
1Pm
q=1 |gq|
mX
q=1
|gq| max
r2{1,...,n}
F (hr, gq) (33)
This total F -measure is comprised in [0, 1], and the closer to 1 it gets, the closer the
predicted partition is from the gold-standard partition. The optimal partition point esti-
mate in regard of this thus defined F -measure can be derived by maximizing the average
F -measure over all the explored partitions in the posterior MCMC draws:
{˜`
1:C} = argmax
{`(i)1:C}2
n
{`(1)1:C},...,{`
(N)
1:C }
o
1
N
NX
j=1
j 6=i
Ftot
⇣
{`(i)
1:C}, {`(j)1:C}
⌘
(34)
4.4.4 Applications
Simulations
Two different simulations studies were conducted: first to evaluate the performance
of the Dirichlet process mixture of skew t distributions model in a simple clustering case,
and second to quantify the improvement of the sequential posterior approximation model
over the broad prior strategy in a more realistic scenario.
To assess the proposed model, 100 simulations in 2-dimensions were performed. 2000
observations were simulated. Three scenarios were used, in which observations were sim-
ulated from: i) the model thanks to the Chinese Restaurant process; ii) 4 clusters easily
separated clusters; iii) 4 overlapping clusters. inn the last two scenarios, the four clus-
ter represented respectively 50%, 30%, 15% and 5% of the data. After 10,000 MCMC
iterations (8,000 iterations burnt and a thining of 10 gave 200 partitions sampled from
the posterior; the chain was initialized with 30 clusters), the resulting mean F-measure
when comparing the point estimate obtained from our approach with the true original
clustering of the simulated data were, in the three scenarios respectively, 0.943, 0.999,
and 0.870. Figure 4.5 shows an example of the partition point estimate obtained for one
of those 100 simulations in both the "easy" and the "overlapping" scenarios.
To evaluate the sequential posterior approximation model, 100 simulations in 2-dimen-
sions were performed. For each simulation, two datasets were simulated, each of 2000
observations. First a learning simulated sample with 4 distinct clusters following skew t-
distributions, representing respectively 70%, 10%, 10% and 10% of the data. Second a test
simulated sample with 3 distinct clusters representing respectively 80%, 10% and 10% of
the data (Figures 4.6A. and 4.6B. for an example). The large cluster in the second sample
was actually the superposition of 3 different skew t-distributions at the same locations
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Figure 4.5 – Partition point estimate from one of the 100 2-dimensional simulations
as the lower left cluster of the learning sample. After 10,000 MCMC iterations (8,000
iterations burnt and a thining of 10 gave 200 partitions sampled from the posterior; the
chain was initialized with 30 clusters) the resulting mean F-measure was of 0.904 with a
broad prior but was improved to 0.983 with the sequential posterior approximation when
comparing the point estimate obtained from our approach with the true original clustering
of the simulated data. Figures 4.6C. and 4.6D. show an example of the partition point
estimate obtained for one of the 100 simulations. The informative prior lead to more
robust inference in this case: adding prior knowledge from the learning sample that there
is one large lower-left cluster enabled the model to fit only one cluster there (Figures
4.6C., 4.6D.). The posterior partition of the data shows much less variability when an
informative prior is used (Figures 4.6E. and 4.6F ). However, the prior knowledge that
there was one cluster in the lower right from the learning sample was not backed by the
data from the test sample, and the model correctly estimated no cluster located there
(in spite of this prior information). So the informative prior strategy seems to give more
robust estimations, for instance when the clusters are not stricly skew t-distributed.
Benchmark real experimental datasets analyses
Two real experimental datasets are analyzed with the proposed approach. Both were
used as benchmark data in Aghaeepour et al. [2013]. First the Graft versus Host Dis-
ease (GvHD) dataset, a public dataset was first analysed (manually gated) in Brinkman
et al. [2007], with the objective of identifying cellular signature that correlates or predict
Graft versus Host disease. Flow-cytometry data was collected for 12 samples. Second
the Hematopoietic Stem Cell Transplant (HSCT) dataset, which consists of 30 samples of
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Figure 4.6 – Example from one of the second 100 2-dimensional simulations
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bone marrow cells from the Terry Fox laboratory. For both datasets, their original man-
ual gates are being regarded as the true cell clustering, despite the reproducibility issues
with manual gating [Ge and Sealfon, 2012; Aghaeepour et al., 2013]. In order to compare
our method, we used the exact same data as in Aghaeepour et al. [2013], provided by
the FlowCAP project [http://flowcap.flowsite.org/] as part of the FLowCAP-I challenge
[http://ficcs.org/dataFiles/FlowCAP-I.zip]. Table 4.1 shows the performance of our pro-
posed approach NPflow on these two datasets, in the context of the other approaches
reviewed by Aghaeepour et al. [2013]. The F-measure is computed for all samples avail-
able for a given dataset and the mean over all samples is reported. The only algorithms
performing significantly better than NPflow in both benchmark datasets are flowMeans
[Aghaeepour et al., 2011] and FLAME [Pyne et al., 2009].
It is difficult to interpret the result of the sequential posterior approximation model
when applied to any of those 2 experimental datasets because to the lack of clinical
information. Indeed, in both case samples preceding the transplantation as well as samples
after the transplantation are considered. Samples before and after transplantation are
supposed to be very different, and thus question the hypothesis behind the sequential
posterior model.
4.4.5 Conclusion
We extend the classical Dirichlet process Gaussian mixture model to skew t-distribution
mixtures, based on Frühwirth-Schnatter and Pyne [2010] parametrization of such distri-
butions. Such a model is especially suited for model based unsupervised classification of
flow cytometry data. Automated gating of cell populations is an open research problem
and the proposed approach features three important characteristics for this task: i) it
avoids the difficult issue of model selection by estimating directly the number of com-
ponent in the mixture ; ii) it uses skew and heavy tailed distributions in the form of
skew t-distributions, of which the gaussian is a particular case, iii) it provides estimation
of the posterior co-clustering probabilities for each data pair that allows to quantify the
uncertainty about the partition. An efficient collapsed Metropolis within Gibbs sampler
has been developed for estimating such models. It has been implemented in as a
package NPflow, which is still under development but will soon be made available to the
community.
Some gain in computation time can be obtained through CPU parallelization and C++
implementation of key bottleneck within the sampler. Yet, computation times for such
models remains important. Depending on the number of data and the number of clusters
it ranges from a few minutes up to a couple hours (for around 100,000 observations). Since
101
DPM OF SKEW t-FOR FLOW CYTOMETRY DATA
Method GvHD HSCT
(n=12) (n=30)
NPflow 0.75 (0.70, 0.81) 0.82 (0.79, 0.85)
ADICyt 0.81 (0.72, 0.88) 0.93 (0.90, 0.96) +
CDP 0.52 (0.46, 0.58)   0.50 (0.48, 0.52)  
FLAME 0.85 (0.77, 0.91) + 0.94 (0.92, 0.95) +
FLOCK 0.84 (0.76, 0.90) 0.86 (0.83, 0.89)
flowClust/Merge 0.69 (0.55, 0.79) 0.81 (0.77, 0.85)
flowMeans 0.88 (0.82, 0.93) + 0.92 (0.90, 0.94) +
FlowVB 0.85 (0.79, 0.91) + 0.75 (0.70, 0.79)  
L2kmeans 0.64 (0.57, 0.72)   0.70 (0.65, 0.75)  
MM 0.83 (0.74, 0.91) + 0.73 (0.66, 0.80)
MMPCA 0.84 (0.74, 0.93) 0.91 (0.88, 0.94) +
SamSPECTRAL 0.87 (0.81, 0.93) + 0.85 (0.82, 0.88)
SWIFT 0.63 (0.56, 0.70)   0.59 (0.55, 0.62)  
All estimates except for our proposed NPflow approach are from Aghaeepour et al. [2013]. 95% Confi-
dence Intervals are calculated on 1,000 bootstrap samples of the F -measures. A   denotes the methods
significantly worse than the proposed NPflow model (according to a paired signed rank test at a 0.05
level), and a + denotes the methods with significantly better, in regards of the manual gating reference.
Table 4.1 – Mean F -measures across all samples on two benchmark experimental datasets
parallelized operation are very short, the gain in computation time is quickly overtaken
by time lost in communication between CPUs as their number increase.
In case of repeated measurement of flow cytometry data, such as in a clinical trial, the
proposed sequential analysis strategy enables to analyze each sample sequentially, as the
data are acquired. It requires neither to wait for the last sample to perform the automated
gating nor to analyze all data at once, but it still uses available prior knowledge. This
contrasts with hierarchical extensions of the Dirichlet Process Mixture Model such as
those proposed by Cron et al. [2013] or Dundar et al. [2014], where the complete dataset
must be analyzed at once. In our simulation study this sequential prior strategy improves
the fit of the model.
Manual gating is considered as the gold-standard when evaluating an automated gating
strategy on real flow cytometry data. Yet one should keep in mind that manual gating
has reproducibility issues, often resulting in a partial and subjective clustering [Ge and
Sealfon, 2012; Aghaeepour et al., 2013]. Therefore manual gating might not be actually
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the ideal way to assess the performance of automated gating algorithms, and consensus
clustering of manual or automated operators could be used instead.
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5 General discussion
This thesis covers various aspects of real world data encountered today in vaccine trials.
Thank to the technological improvements, the available data are now high-dimensional
and, above all, complex. In this work, we tried to present new tools to analyze such data,
and described a few ways to integrate different biological levels in a single analysis. The
key idea is to use the maximum information available. This is attempted in two ways:
i) the use of prior knowledge, that requires to transform expertise into mathematical
properties; ii) the use of all data at hand, hopefully in an integrated manner. We believe
that this addition of meaningful information will ease the separation of relevant signal from
noise, and will make the inference of interpretable biological results from high-dimensional
data easier and more consistent.
Longitudinal gene expression measurements are becoming more and more common in
clinical trials thanks to the decreasing cost of microarray technology. Such omics data are
prone to technical variability, and must analyzed carefully in order to differentiate signal
from noise. However, a lot of biological knowledge on gene pathways already exists. It
can be leveraged in order to enhance the sensitivity and the interpretability of such an
analysis. Taking into account this prior knowledge, we proposed to harness the power
linear mixed modeling coupled with a flexible control of the false discovery rate to model
gene expression over time. This modeling allowed us to unravel the impact of a therapeutic
vaccine against HIV on the state of gene expression in the blood of the vaccinated patients.
The signature thus highlighted had some overlap with signature derived in other vaccines
(namely the pneumococcal and flu vaccines). Compared to other methods available in
the literature [Subramanian et al., 2005; Efron and Tibshirani, 2007; Hummel et al., 2008;
Shahbaba et al., 2011; Wu and Smyth, 2012], we have underlined the usefulness of our
approach to answer the key questions: "Which gene sets have expression dynamics moving
significantly over time ?".
In gene set analyses, the gene sets’ definition is of utmost importance. Indeed, re-
gardless of the method (self-contained or competitive), a gene set analysis can be viewed
as hypothesis driven. The definition of the gene sets tested is therefore constitutive of
the hypotheses tested. In this thesis, two different strategies for gene sets definition are
considered: i) a priori defined gene sets (the Modules from Chaussabel et al. [2008]) in
the DALIA-1 trial; ii) gene sets directly inferred from the data itself [Furman et al., 2013]
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in the flu vaccine systems analysis. However, we did not tackle the issue of gene network
inference [Marbach et al., 2012; de la Fuente, 2013]. Gene network inference aims at
increasing biological knowledge on gene pathways from genomic data. It is usually per-
formed on time-course gene expression data. Recently, Wu et al. [2014] proposed sparse
ordinary differential equation modeling for gene network reconstruction from time-course
expression data in a very promising first attempt to adapt differential equation modeling
to high-dimensional data. Further developments are needed here to improve the identifi-
ability of parameters in such complex modeling approach. Other approaches such as the
Approximate Bayes Computation could be a good alternative [Ratmann et al., 2009].
RNA-seq is another technology to measure gene expression. It gives a more precise
measurement of the expression compared to microarrays, and it is increasingly used in
biological and medical studies. However, as a result of the increased precision, RNA-seq
data are count data. This makes modeling RNA-seq data more difficult, in particular,
it is not clear which statistical distribution is best suited for modeling such data (over-
dispersed Poisson distribution as well as the negative binomial distribution have been
proposed for instance [Auer and Doerge, 2011; Srivastava and Chen, 2010]). Instead,
Law et al. [2014] proposed to model logarithm transformed counts of RNA-seq reads
with Normal distribution while taking into accounts heteroskedasticity with in precision
weights. They argue that correct modeling of variance is the key to powerful statistical
tools of analysis. Such methodology would be directly applicable in TcGSA by including
precision weights in the mixed models. Consequently, our approach is easily extendable
to RNA-seq data.
But the longitudinal gene expression was not the only measurement available in this
particular therapeutic HIV vaccine trial. Along with it several other phenotypic variables
were measured including cytokine production, cell functionality, etc. Starting from the
signature identified with our proposed approach for analyzing time-course gene expres-
sion, we related gene expression to those phenotypic data thanks to sparse partial least
squares. It highlighted an association of low inflammatory pathway expression with lower
viral rebound. This association was consistent through a sensitivity analysis. In a dif-
ferent vaccine trial (against influenza), more traditional analyses revealed an association
between a testosterone modulated group of gene and the higher immune response to the
vaccine in females compared to males. In this study, high-dimensionality of the data was
dealt with by first aggregating gene expressions into gene modules, and then by correcting
for multiple testing. In both cases, integration of various data types cast a light on poten-
tial underlying biological explanations of the heterogeneity among the patients’ vaccine
response.
Finally, we developed a state-of-the-art nonparametric bayesian clustering was with
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a specific focus on automated processing of flow cytometry data. We proposed to ex-
tend the classical Gaussian Dirichlet process mixture model to the more general skew
t-distributions. Skew t-distribution are a class of probability distributions that are poten-
tially asymmetric and heavy tailed, of which the normal distribution is a particular case.
Given the shape of raw flow-cytometry fluorescence data, such properties are attractive.
We also proposed an efficient partially collapsed Metropolis within Gibbs sampler for es-
timating such models. Such a model performs similarly as other approach developed for
automated clustering of flow cytometry data. It has the advantage allowing the use of
informative prior specifications, in particular on the cluster locations. Such informative
priors can be used for instance in sequential posterior approximation for instance to take
advantage of repeated measurements. We expect in the near future that this type of
approach could be broadly used by immunologists who really need it to face to increasing
dimension of flow cytometry data.
Cron et al. [2013] proposed a hierarchical Gaussian Dirichlet process mixture model
closely related to our approach. They model between-sample heterogeneity by introduc-
ing a hierarchical layer in their model. Dundar et al. [2014] proposed a similar model
to identify outlier samples. Both models analyze all data simultaneously. Cron et al.
[2013] uses GPU parallelization in order to rapidly compute MCMC estimations of their
hierarchical Gaussian Dirichlet process mixture model on such a big amount of data. Our
approach takes a different approach by dealing with several samples sequentially. It is
currently implemented through CPU parallelization would likely benefit from switching
to GPU parallelization, which is more efficient when rapid computations have to be re-
peated a large number of times (such as in the cluster allocation step in our gibbs sampler,
see Appendix F page 157). However, as all dimensions (number of samples, number of
markers, number of cells) of flow-cytometry data increase, online data modeling (where
new observations become sequentially available) is appealing, especially in longitudinal
studies. In this context, other methods for estimating Dirichlet process mixtures models
such as Sequential Monte Carlo (SMC) samplers (or particle filters) [Doucet et al., 2001;
Del Moral et al., 2006] offer promising properties for dynamic modeling. Indeed, such
algorithms are naturally online and easily parallelized.
In the context of automated gating of flow cytometry data, manual gating is consid-
ered as the gold-standard. Of course, it is important that automated approaches exhibit
good performances compared to manual gating in order to convince immunologists that
they are good alternatives. However it has been shown that manual gating, among other
issues, is highly variable from one operator to another [Ge and Sealfon, 2012; Aghaeepour
et al., 2013]. This makes it difficult to assess automated gating algorithms because the
truth is unknown. In addition, due to the increase in the number of markers measured
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simultaneously, it now becomes impossible to manually look at all possible marker com-
binations in a manual gating strategy, whereas automated algorithms usually take into
account all dimensions. Simulating realistic flow-cytometry data is difficult, as those are
highly structured, sparse, high-dimensional data [Finak et al., 2009; Pyne et al., 2009].
To overcome this obstacle, one could use consensus clustering, either among automated
gating algorithms, like Aghaeepour et al. [2013], or among technical operator performing
manual gating (if several are available).
One of the perspective of automated gating of flow cytometry data is to improve the
reproducibility of the final subpopulation cell counts. This goal requires an extra step after
the gating of the cell population (regardless of wether a manual or automated method was
used): the annotation of the cell clusters. This task shares some similarities with gene
sets analyses, although the two are quite different. Very recently, Courtot et al. [2014]
proposed an algorithm using cell ontology [Diehl et al., 2011] to automatically annotate
cell populations based on a dichotomous split of each cellular marker. This next step of
the automated processing of flow cytometry data seems to be a new research area, whose
importance will likely increase as automated gating methods are becoming increasingly
performant.
Both the approach for the gene set analysis of longitudinal gene expression (TcGSA)
and the Dirichlet process mixture of skew t-distributions model have been implemented as
packages: TcGSA v0.9.8 is available on CRAN, whereas NPflow is still under develop-
ment (but will be made available to the community). Today, dissemination of statistical
developments requires their implementation in widely used softwares such as .
A next step for data integration would be to use the deconvolution in the spirit of Shen-
Orr et al. [2010] but for repeated measurements of gene expression (gene abundance) and
cell populations. It would be then of interest to disentangle the reason of changes in gene
abundance that can be due either to a real modification of the gene expression at the cell
level or to the circulation of some some specific cell populations.
The analysis of all of these data requires new methods that are still under development
and that need to be adapted according to the question asked, and consequently to the
data available. These complex data constitute the observations of a complex system, that
require sophisticated modeling, and preclude the use of intuitive simplistic statistics. This
opens a new area where biostatisticians has never been as much demanded, but where
collaborations have never been as much needed.
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Appendix A:
Multiple testing correction
A.1 Multiple testing
When several tests are performed simultaneously on the same data, there is an increase
of the global type I error. The type I error is the error of a false positive when testing H
0
and the type II error is the error of a false negative when testing H
0
, as depicted in table
A.1. Their respective probabilities are denoted by ↵ and  , defined as follow:
Definition. ↵ = P(H
0
is rejected | H
0
is true)
Definition.   = P(H
0
is not rejected | H
0
is False)
H
0
not rejected H
0
rejected
(H
0
) true
True Negative (TN) False Positive (FP)
correct type I error
(H
0
) false
False Negative (FN) True Positive (TP)
type II error correct
Table A.1 – Possible results of a test
The power of a test can be expressed as P(H
0
is rejected | H
0
is False)= 1     and is
linked to the type II error probability.
In a lot of applications, especially in biomedical sciences, one wants to control ↵ when
performing a test. When performing multiple tests however, the generalization of the
type I error probability is subject to discussion. If the Family Wise Error Rate (FWER)
seems the natural extension of the type I error, several other from the quantities defined
in table A.2, such as the False Discovery Rate (FDR) can be considered.
In the case of gene expression data, the number of tests performed is very large (sev-
eral). Controlling the FWER is usually too stringent in exploratory genome-wide studies,
and the FDR. FWER is more appropriate in confirmatory studies (in genomics, using
quantitative Polymerase Chain Reaction – qPCR– to precisely measure gene expression
of a few candidate probes).
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Reality H
0
not rejected H
0
rejected Total
H
0
True U V m
0
H
0
False T S m
1
Total W R m
Table A.2 – Cross table of reality and decision regarding m test of null hypothesis H
0
A.2 Family Wise Error Rate
The Family Wise Error Rate (FWER) is defined as the probability that at least one
of the m tests considered is wrongly rejecting H
0
:
Definition. FWER = P(V > 0)
Several procedures exists to control the FWER in an experiment [Dudoit and Van der
Laan, 2008]. Historically, a simple and widely used method is the Bonferroni method. If
each single test is controlled at the ↵⇤ level, then the FWER is bounded:
FWER  1  (1  ↵⇤)m
A taylor expansion gives:
FWER  m↵⇤  min(m↵⇤, 1)
Therefore, controlling each test at the level:
↵⇤ =
↵
m
ensures that FWER is controlled at level ↵.
A.3 False Discovery Rate
Another quantity of interest for multiple testing correction is the expected false positive
rate, called False Discovery Rate (FDR):
Definition. FDR = E
✓
V
R
◆
Controlling the FDR at a level ↵ is less stringent than controlling the FWER at the
same level ↵ since FDR  FWER [Dudoit and Van der Laan, 2008], with the limit case
being when all H
0
are true (m
1
= 0) [Foulkes, 2009]. So any procedure controlling the
FWER consequently controls the FDR.
Now several procedures exists to control the FDR in an experiment [Dudoit and Van
der Laan, 2008]. Especially, the Benjamini & Hochberg procedure for correcting p-values
in order to control this FDR is widely used. Let’s consider a vector of m raw p-values:
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1. the raw p-values are ordered by increasing order: p
(1)
. . . p
(m), where p(1) is the lowest
p-value obtained among the m tests performed, and p
(m) the highest
2. For the level ↵, one seeks the highest k so that: p
(k)  k
m
↵
3. All the null hypothesis H
0;(i) are rejected for i = 1 . . . k
Yekutieli and Benjamini [2001] proposed an extension that accounts for all kind of
dependencies (the previous procedure was only robust to specifyc type of dependencies
between the tests). The only change compared to the Benjamini-Hochberg procedure is
in step 2.:
2. For the level ↵, one seeks the highest k so that: p
(k)  k
m
↵
c(m)
where c(m) =
mX
i=1
1
i
123
APPENDIX A: MULTIPLE TESTING CORRECTION
124
Appendix B:
Hand-picked immune-related subsets of
KEGG and Gene Ontology databases
Comparison of TcGSA results on other gene sets databases for the DALIA-1
trial
In addition to utilizing the whole blood Illumina V2 modules from Chaussabel et al.
[2008] the DALIA-1 data were analyzed with two other databases: i) a subset of the
KEGG [Kanehisa and Goto, 2000] pathway database (table B.1) and ii) a subset of the
GO [Ashburner et al., 2000] database. Since the whole blood modules were derived from
multiple independent datasets that encompass a wide range of immune related diseases
(http://www.interactivefigures.com/dm3/vaccine-paper/faq.gsp for more infor-
mation), the 260 module gene sets are highly enriched in immune related annotations.
This facilitates the interpretation of TcGSA findings in terms of describing immune
changes in the blood associated with vaccination and viral rebound following treatment
interruption. This explains why the modules are more sensitive in pre-ATI during the
vaccination phase of the DALIA-1 trial (Figure B.1). However, the viral rebound is such
a cataclysm for the immune system that regardless of the database used, a large part of
the gene sets are activated. Indeed, during pre-ATI (vaccination phase of the DALIA-1
trial), 3 out of 75 gene sets were significant in the subset of KEGG, and 0 out of 131 in
the subset of GO. During post-ATI, 73 out of 75 gene sets were significant in the subset
of KEGG, and 101 out of 131 in the subset of GO. 2 gene sets the subset of KEGG and
20 from the subset of GO were automatically discarded because less than 10 probes or
more than 500 probes were observed.
Tables B.1 and B.2 two lists of hand-picked immune-related subsets of KEGG and
Gene Ontology databases respectively. The GO subset is transversal, that is to say that
each chosen gene set is exclusive of the others (if this exclusivity is true for KEGG and
Module by definition of their gene set, GO has a tree structure where numerous gene sets
are fully encompassed into others).
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Pre−ATI Post−ATI
KEGG
GO
Modules
0
20
40
60
80
100
Percentage of significant gene sets
4% 0%
27%
97%
77%
83%
Figure B.1 – Comparison of TcGSA results on DALIA-1 for the three gene sets databases
considered
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KEGG ID Description
1 path:hsa04910 † Endocrine System:Insulin signaling pathway
2 path:hsa04920 † Endocrine System:Adipocytokine signaling pathway
3 path:hsa03320 † Endocrine System:PPAR signaling pathway
4 path:hsa04912 † Endocrine System:GnRH signaling pathway
5 path:hsa04914 † Endocrine System:Progesterone-mediated oocyte maturation
6 path:hsa04916 † Endocrine System:Melanogenesis
7 path:hsa04614 † Endocrine System:Renin-angiotensin system
8 path:hsa04640 † Immune System:Hematopoietic cell lineage
9 path:hsa04610 † Immune System:Complement and coagulation cascades
10 path:hsa04620 † Immune System:Toll-like receptor signaling pathway
11 path:hsa04621 † Immune System:NOD-like receptor signaling pathway
12 path:hsa04622 † Immune System:RIG-I-like receptor signaling pathway
13 path:hsa04623 † Immune System:Cytosolic DNA-sensing pathway
14 path:hsa04650 † Immune System:Natural killer cell mediated cytotoxicity
15 path:hsa04612 † Immune System:Antigen processing and presentation
16 path:hsa04660 † Immune System:T cell receptor signaling pathway
17 path:hsa04662 † Immune System:B cell receptor signaling pathway
18 path:hsa04664 † Immune System:Fc epsilon RI signaling pathway
19 path:hsa04666 † Immune System:Fc gamma R-mediated phagocytosis
20 path:hsa04670 † Immune System:Leukocyte transendothelial migration
21 path:hsa04672 † Immune System:Intestinal immune network for IgA production
22 path:hsa04062 † Immune System:Chemokine signaling pathway
23 path:hsa04510 † Cell Communication:Focal adhesion
24 path:hsa04520 † Cell Communication:Adherens junction
25 path:hsa04530 † Cell Communication:Tight junction
26 path:hsa04540 † Cell Communication:Gap junction
27 path:hsa04110 † Cell Growth and Death:Cell cycle
28 path:hsa04114 † Cell Growth and Death:Oocyte meiosis
29 path:hsa04210 † Cell Growth and Death:Apoptosis
30 path:hsa04115 † Cell Growth and Death:p53 signaling pathway
31 path:hsa04144 † Transport and Catabolism:Endocytosis
32 path:hsa04145 † Transport and Catabolism:Phagosome
33 path:hsa04142*† Transport and Catabolism:Lysosome
34 path:hsa04146 † Transport and Catabolism:Peroxisome
35 path:hsa04140 † Transport and Catabolism:Regulation of autophagy
36 path:hsa04810 † Cell Motility:Regulation of actin cytoskeleton
37 path:hsa02010 † Membrane Transport:ABC transporters
38 path:hsa04010 † Signal Transduction:MAPK signaling pathway
39 path:hsa04012 † Signal Transduction:ErbB signaling pathway
40 path:hsa04310 † Signal Transduction:Wnt signaling pathway
41 path:hsa04330 † Signal Transduction:Notch signaling pathway
42 path:hsa04340 † Signal Transduction:Hedgehog signaling pathway
43 path:hsa04350 † Signal Transduction:TGF-beta signaling pathway
44 path:hsa04370 † Signal Transduction:VEGF signaling pathway
45 path:hsa04630 † Signal Transduction:Jak-STAT signaling pathway
46 path:hsa04064 † Signal Transduction:NF-kappa B signaling pathway
47 path:hsa04020 † Signal Transduction:Calcium signaling pathway
48 path:hsa04070 † Signal Transduction:Phosphatidylinositol signaling system
49 path:hsa04151 † Signal Transduction:PI3K-Akt signaling pathway
50 path:hsa04150 † Signal Transduction:mTOR signaling pathway
51 path:hsa04080 † Signaling Molecules and Interaction:Neuroactive ligand-receptor interaction
52 path:hsa04060 † Signaling Molecules and Interaction:Cytokine-cytokine receptor interaction
53 path:hsa04512 † Signaling Molecules and Interaction:ECM-receptor interaction
54 path:hsa03030 † Replication and Repair:DNA replication
55 path:hsa03410 † Replication and Repair:Base excision repair
56 path:hsa03420 † Replication and Repair:Nucleotide excision repair
57 path:hsa03430 † Replication and Repair:Mismatch repair
58 path:hsa03440 † Replication and Repair:Homologous recombination
59 path:hsa03450 Replication and Repair:Non-homologous end-joining
60 path:hsa03460 † Replication and Repair:Fanconi anemia pathway
61 path:hsa03060 † Folding, Sorting and Degradation:Protein export
62 path:hsa04141 † Folding, Sorting and Degradation:Protein processing in endoplasmic reticulum
63 path:hsa04130 † Folding, Sorting and Degradation:SNARE interactions in vesicular transport
64 path:hsa04120 † Folding, Sorting and Degradation:Ubiquitin mediated proteolysis
65 path:hsa04122 Folding, Sorting and Degradation:Sulfur relay system
66 path:hsa03050 † Folding, Sorting and Degradation:Proteasome
67 path:hsa03018 † Folding, Sorting and Degradation:RNA degradation
68 path:hsa03010*† Translation:Ribosome
69 path:hsa00970 † Translation:Aminoacyl-tRNA biosynthesis
70 path:hsa03013 † Translation:RNA transport
71 path:hsa03015 † Translation:mRNA surveillance pathway
72 path:hsa03008 † Translation:Ribosome biogenesis in eukaryotes
73 path:hsa03020 † Transcription:RNA polymerase
74 path:hsa03022 † Transcription:Basal transcription factors
75 path:hsa03040*† Transcription:Spliceosome
*: significant (FDR<0.05) in pre-ATI †: significant (FDR<0.05) in post-ATI
Table B.1 – Selected KEGG pathways for investigating DALIA-1
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Table B.2 – Selected GO pathways for investigating DALIA-1
GO ID Description
1 GO:0002218 † activation of innate immune response
2 GO:0006956 † complement activation
3 GO:0002429 † immune response-activating cell surface receptor signaling pathway
4 GO:0002758 † innate immune response-activating signal transduction
5 GO:0019883 † antigen processing and presentation of endogenous antigen
6 GO:0019884 † antigen processing and presentation of exogenous antigen
7 GO:0048002 † antigen processing and presentation of peptide antigen
8 GO:0002504 † antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
9 GO:0002475 antigen processing and presentation via MHC class Ib
10 GO:0002468 dendritic cell antigen processing and presentation
11 GO:0002578 negative regulation of antigen processing and presentation
12 GO:0002579 † positive regulation of antigen processing and presentation
13 GO:0002577 † regulation of antigen processing and presentation
14 GO:0002457 T cell antigen processing and presentation
15 GO:0002339 B cell selection
16 GO:0002263 † cell activation involved in immune response
17 GO:0051607 † defense response to virus
18 GO:0002432 granuloma formation
19 GO:0002434 immune complex clearance
20 GO:0043299 † leukocyte degranulation
21 GO:0001909 † leukocyte mediated cytotoxicity
22 GO:0019724 † B cell mediated immunity
23 GO:0002228 † natural killer cell mediated immunity
24 GO:0002707 † negative regulation of lymphocyte mediated immunity
25 GO:0002708 † positive regulation of lymphocyte mediated immunity
26 GO:0002706 † regulation of lymphocyte mediated immunity
27 GO:0002456 † T cell mediated immunity
28 GO:0002444 † myeloid leukocyte mediated immunity
29 GO:0002704 † negative regulation of leukocyte mediated immunity
30 GO:0002705 † positive regulation of leukocyte mediated immunity
31 GO:0002703 † regulation of leukocyte mediated immunity
32 GO:0002522 leukocyte migration involved in immune response
33 GO:0002698 † negative regulation of immune effector process
34 GO:0008228 opsonization
35 GO:0002699 † positive regulation of immune effector process
36 GO:0002697 † regulation of immune effector process
37 GO:0002679 † respiratory burst involved in defense response
38 GO:0002250 † adaptive immune response
39 GO:0002367 † cytokine production involved in immune response
40 GO:0006959 † humoral immune response
41 GO:0002418 † immune response to tumor cell
42 GO:0002437 † inflammatory response to antigenic stimulus
43 GO:0006957 † complement activation, alternative pathway
44 GO:0001867 complement activation, lectin pathway
45 GO:0002227 innate immune response in mucosa
46 GO:0045824 † negative regulation of innate immune response
47 GO:0045089 † positive regulation of innate immune response
48 GO:0045088 † regulation of innate immune response
49 GO:0034341 † response to interferon-gamma
50 GO:0034340 † response to type I interferon
51 GO:0050777 † negative regulation of immune response
52 GO:0002251 † organ or tissue specific immune response
53 GO:0052555 positive regulation by organism of immune response of other organism
involved in symbiotic interaction
54 GO:0002821 † positive regulation of adaptive immune response
55 GO:0002922 positive regulation of humoral immune response
56 GO:0002839 † positive regulation of immune response to tumor cell
57 GO:0002863 † positive regulation of inflammatory response to antigenic stimulus
58 GO:0002830 positive regulation of type 2 immune response
59 GO:0002765 † immune response-inhibiting signal transduction
60 GO:0002768 † immune response-regulating cell surface receptor signaling pathway
61 GO:0052552 modulation by organism of immune response of other organism
involved in symbiotic interaction
62 GO:0002819 † regulation of adaptive immune response
63 GO:0002718 † regulation of cytokine production involved in immune response
64 GO:0043309 regulation of eosinophil degranulation
65 GO:0002920 † regulation of humoral immune response
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66 GO:0002837 † regulation of immune response to tumor cell
67 GO:0002861 † regulation of inflammatory response to antigenic stimulus
68 GO:0033006 † regulation of mast cell activation involved in immune response
69 GO:0043380 regulation of memory T cell differentiation
70 GO:0043313 regulation of neutrophil degranulation
71 GO:0045622 † regulation of T-helper cell differentiation
72 GO:0002828 † regulation of type 2 immune response
73 GO:0042092 † type 2 immune response
74 GO:0002520 immune system development
75 GO:0002366 † leukocyte activation involved in immune response
76 GO:0050902 leukocyte adhesive activation
77 GO:0042113 † B cell activation
78 GO:0001767 establishment of lymphocyte polarity
79 GO:0001771 immunological synapse formation
80 GO:0002285 † lymphocyte activation involved in immune response
81 GO:0030098 † lymphocyte differentiation
82 GO:0046651 † lymphocyte proliferation
83 GO:0030101 † natural killer cell activation
84 GO:0051250 † negative regulation of lymphocyte activation
85 GO:0031294 † lymphocyte costimulation
86 GO:0050871 † positive regulation of B cell activation
87 GO:0045621 † positive regulation of lymphocyte differentiation
88 GO:0050671 † positive regulation of lymphocyte proliferation
89 GO:0032816 † positive regulation of natural killer cell activation
90 GO:0050870 † positive regulation of T cell activation
91 GO:0050864 † regulation of B cell activation
92 GO:0045619 † regulation of lymphocyte differentiation
93 GO:0050670 † regulation of lymphocyte proliferation
94 GO:0032814 † regulation of natural killer cell activation
95 GO:0050863 † regulation of T cell activation
96 GO:0050868 † negative regulation of T cell activation
97 GO:0046634 † regulation of alpha-beta T cell activation
98 GO:0046643 † regulation of gamma-delta T cell activation
99 GO:2001188 regulation of T cell activation via T cell receptor contact with antigen bound to MHC
molecule on antigen presenting cell
100 GO:0045580 † regulation of T cell differentiation
101 GO:0042129 † regulation of T cell proliferation
102 GO:0046631 † alpha-beta T cell activation
103 GO:0001768 establishment of T cell polarity
104 GO:0046629 † gamma-delta T cell activation
105 GO:0035709 memory T cell activation
106 GO:0002286 † T cell activation involved in immune response
107 GO:0030217 † T cell differentiation
108 GO:0042098 † T cell proliferation
109 GO:0002274 † myeloid leukocyte activation
110 GO:0002695 † negative regulation of leukocyte activation
111 GO:0002696 † positive regulation of leukocyte activation
112 GO:0043030 † regulation of macrophage activation
113 GO:0033003 † regulation of mast cell activation
114 GO:0030885 regulation of myeloid dendritic cell activation
115 GO:0001776 † leukocyte homeostasis
116 GO:0050900 † leukocyte migration
117 GO:0002262 † myeloid cell homeostasis
118 GO:0002683 † negative regulation of immune system process
119 GO:0050857 † positive regulation of antigen receptor-mediated signaling pathway
120 GO:0060369 positive regulation of Fc receptor mediated stimulatory signaling pathway
121 GO:0002253 † activation of immune response
122 GO:0002687 † positive regulation of leukocyte migration
123 GO:0070426 positive regulation of nucleotide-binding oligomerization domain containing
signaling pathway
124 GO:2000525 positive regulation of T cell costimulation
125 GO:0002645 † positive regulation of tolerance induction
126 GO:0034123 † positive regulation of toll-like receptor signaling pathway
127 GO:0002440 † production of molecular mediator of immune response
128 GO:0002682 regulation of immune system process
129 GO:0002200 † somatic diversification of immune receptors
130 GO:0045058 † T cell selection
131 GO:0002507 † tolerance induction
*: significant (FDR<0.05) in pre-ATI †: significant (FDR<0.05) in post-ATI
Table B.2: Selected GO pathways for investigating DALIA-1
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Appendix C:
Partial Least Squares methods
Partial Least Squares is an exploratory method that was originally proposed in the field
of chemometrics [Wold, 1966]. There exists numerous different algorithms implementing
the Partial Least Squares [Wegelin, 2000; Boulesteix and Strimmer, 2007]. Indeed, there
are several ways of presenting the method, mainly related to the application field. The
focus here is on the views presented in the works by Le Cao et al. [2008, 2009]; Le Cao
and Le Gall [2011], that are oriented toward genomics.
C.1 Partial Least Squares
C.1.2 Regression approach
Introduction
Let’s consider the following linear regression Y = X  + ✏ with:
• n observations
• Y n⇥q, q variables to be explained à expliquer
• Xn⇥p, p explicative variables
•  p⇥q, regression coefficients
• ✏n⇥q, errors
In the scope of such a regression model, X is assumed of full rank 1 in order to be able to
estimate its parameters according to the Ordinary Least Squares method 2 (OLS). Yet this
hypothesis is not always true. Indeed, in the high dimensional case where dim(X) > n,
or yet if some explicative variables are colinear, for instance, then X is not of full rank.
And OLS estimate is not unique. Partial Least Squares (PLS) methods are a way to solve
such problems.
1. Xn⇥p is said to be of full rank if and only if rank(X) = p
2. OLS estimates of   is: b  = (X 0X) 1X 0Y . Its computation requires therefore X 0X to be invertible.
If n << p or if there are colinearities in X columns, then X 0X is not invertible.
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PLS method principle
The PLS method seeks to construct latent variables or scores, orthogonal between
each other, which are linear combinations of the original explicative variables 1. It is
therefore important that those original explicative variables are centered to avoid to give
more weights to some of them in regards of others. It is also customary to reduce those
original explicative variables in order to for their coefficients to be comparable. However,
one must be careful because such an operation artificially increases the variability of
original explicative variables whose variance was originally very low. This leads to noise
amplification. To avoid such an issue, one must carefully pre-select explicative variables
(only take into account explicative variables with a significant variability).
PLS1 algorithm
For starters, let’s consider that Y contains only one column: q = 1. Thanks to the
PLS1 algorithm, the following linear model is fitted:
Y = T  + ✏H with
8
>>>>>>>>>>>>><
>>>>>>>>>>>>>:
T =
⇣
⇠
1
. . . ⇠H
⌘
  =
0
BB@
 
1
...
 H
1
CCA
✏H = P
(⇠1,...,⇠H)
?Y
where, by design, the ⇠h are orthogonal with one another. The ⇠h are called latent
variables of X, or X scores, h going from 1 to H, where H is the final number of scores
kept in the model.
PLS2 algorithm
Let’s consider now the case where there are q > 1 variables to explain: Y 2Mn⇥q.
PLS method’s idea is to seek latent scores (⇠
1
, . . . , ⇠H) of X which best explains Y , that
is to say which maximize covariance between X and Y . Therefore, latent scores of Y are
also computed and optimized:
(⇠h,!h) = argmax
⇠2{Xhu,kuk=1}
!2{Y hv,kvk=1}
< ⇠,! > = argmax
⇠2{Xhu,kuk=1}
!2{Y hv,kvk=1}
cov (⇠,!)
The equation to solve is thus: argmax
kuk=1, kvk=1
cov (Xhu,Y hv).
1. X columns
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PLS1 Algorithm
1. Step 1
X
1
= X and Y
1
= Y
⇠
1
= argmax
⇠2{X1u,kuk=1}
< ⇠,Y
1
>
Y
1
= ⇠
1
 
1
+ ✏
1
where  
1
is estimated by OLS
and ✏
1
= P⇠?1 Y 1 (orthogonal projec-
tion)
2. Step 2
X
2
= P⇠?1 X1 and Y 2 = ✏1
⇠
2
= argmax
⇠2{X2u,kuk=1}
< ⇠,Y
2
>
Y
2
= ⇠
2
 
2
+ ✏
2
where ✏
2
= P⇠?2 Y 2
...
3. Step h (h  dim(X))
Xh = P⇠?h 1Xh 1 and Y h = ✏h 1
⇠h = argmax
⇠2{Xhu,kuk=1}
< ⇠,Y h >
Y h = ⇠h h + ✏h where ✏h = P⇠?h Y h
...
H steps
We respectively name uh and vh the X and Y loadings. They are defined by ⇠h =
Xhuh and !h = Y hvh, where (!1, . . . ,!H) are the latent scores from Y .
Remark: In the regression perspective, only the ⇠h are of interest. The !h being not
orthogonal to one another, their interpretation is dubious and they are useful only in the
derivation of the ⇠h.
C.1.3 Canonical perspective
This can also referred be referred a symmetrical perspective [Tenenhaus et al., 2014]
or "mode A" [Vinzi et al., 2010]. In this case, there are two groums of variables, one
group in X and the other one in Y . There is no prior knowledge about the direction
of any potential association between variables from these two groups. As before, couples
of latent scores whose covariance is maximum are constructed from both X and Y :
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(⇠
1
,!
1
), . . . , (⇠H ,!H):
(⇠h,!h) = argmax
⇠2{Xhu,kuk=1}
!2{Y hv,kvk=1}
< ⇠,! > = argmax
⇠2{Xhu,kuk=1}
!2{Y hv,kvk=1}
cov (⇠,!)
The only difference resides in the deflation of the Y matrix in the iterative algorithm.
It is not deflated on the X scores (as in the regression perspective), but on the Y scores.
This has the effect of deriving successive !h that are orthogonal to one another this time.
Results exploitation One can then perform a communality analysis, which focus on
the correlations between the original data (X and Y ) and their latent scores ((⇠
1
, . . . , ⇠H)
et (!
1
, . . . ,!H)). One can also be interested in the relations between X and Y , for
example by representing their projections in the latent scores subspaces.
C.1.4 General PLS algorithm
The general PLS algorithm with q   1 can thus be written as follows:
PLS agorithm
1. X
0
= X and Y
0
= Y
2. For h = 1 . . . H
(a) solve: (uh,vh) = argmax
kuk=1, kvk=1
< Xh 1u,Y h 1v >
(b) ⇠h = Xh 1uh
!h = Y h 1vh
(c) Xh = Xh 1   ⇠h
✓
X
0
h 1
⇠h
k ⇠h k2
◆0
(d) Y h =
8
>>>>>>><
>>>>>>>:
Y h 1   ⇠h
✓
Y
0
h 1
⇠h
k ⇠h k2
◆0
regression
Y h 1   !h
✓
Y
0
h 1
!h
k !h k2
◆0
canonic
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C.2 The sparse Partial Least Squares method
C.2.1 sPLS algorithm
The sparse PLS (sPLS ) method objective is to get sparse loadings, that is to say
loadings with very few non zero elements, in order to ease the component interpretation.
Matrix Singular Value Decompostion (SVD)
Definition: 8 M 2 Mp⇥q of rank r, 9 U 2 Mp⇥r,   2 Dr⇥r, V 2 Mq⇥r so that
M = U V 0
•   is diagonal, its element  i are the singular value of M
•  i   0 , 8i = 1 . . . r
• U ’s columns are orthogonal to one another
• V ’s columns are orthogonal to one another
Property: M SVD decomposition is unique if the  i are ordered in a decreasing way
and if U and V ’s columns are normed.
The column vectors of U and V are respectively the left and right singular
vectors of M .
Property: If M = X 0Y and M = U V 0 its SVD decomposition, then the column
vectors of U and V are respectively the loadings of X and Y in the PLS
model.
Indeed (u
1
,  
1
v
1
) = argmin
u,v
kM uv0 k2
F
, where kM k2
F
= tr (MM 0) (the Frobenius
norm), and (u
2
,  
2
v
2
) = argmin
u,v
k (M   u
1
 
1
v
0
1
)   uv0 k2
F
. It follows that
Pk
i=1  iuiv
0
i
is the best M approximation of rank k in the sense of Frobenius norm k · k
F
[Shen and
Huang, 2008]. Hence:
argmax
kuk=1, kvk=1
< Xu,Y v > = argmin
kuk=1, kvk=1
kX 0Y    
1
uv
0 k2
F
where  
1
is the first singular value from M = X 0Y . This results allow to rewrite the
covariance maximization constraint in the PLS and sPLS algorithms [Shen and Huang,
2008].
Penalization
In order to perform sPLS objective (getting sparse loadings), penalties are added to
the maximization equation. Those penalties enforce the following idea: the more non
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zero coordinates there are on the loadings, the higher is the corresponding penalty. The
LASSO [Tibshirani, 1996] constraint (L
1
) fits this description, and has the advantage of
giving true zero coordinates on the loadings (not just very low coordinates as one can
get with classic PLS algorithms). Such a penalty is written: P (t) =
PH
i=1 2 |ti| (where
t = (t
1
, . . . , tH) and   is a threshold parameter) 1 . In practice, an approximate solution
to this LASSO constraint can be computed by using the soft-thresholding function [Le
Cao and Le Gall, 2011] (this approximation is exact in the case of independent predictors
as is the case in the canonic perspective).
sPLS algorithm
P 1(u) and P 2(v) penalization functions are defined as previously, constraining uh
and vh computation. The sPLS algorithm can be written as follows:
sPLS algorithm
1. X
0
= X and Y
0
= Y
2. For h = 1 . . . H
(a) Mh 1 = X 0h 1Y h 1
(b) solve (uh,vh) = argmin
kuk=1, kvk=1
kMh 1    (h)
1
uv
0 k2
F
+P 1(u) + P 2(v)
(c) ⇠h = Xh 1uh
!h = Y h 1vh
(d) Xh = Xh 1   ⇠h
✓
X
0
h 1
⇠h
k ⇠h k2
◆0
(e) Y h =
8
>>>>>>><
>>>>>>>:
Y h 1   ⇠h
✓
Y
0
h 1
⇠h
k ⇠h k2
◆0
regression
Y h 1   !h
✓
Y
0
h 1
!h
k !h k2
◆0
canonic
Remark: If P 1(u) = P 2(v) = 0, then one gets the standard PLS algorithm.
1. because |PHi=1 ti| 
PH
i=1 |ti|
136
APPENDIX C: PARTIAL LEAST SQUARES METHODS
Minimization : detail of step 2.(b) of the sPLS algorithm
Let’s consider the following function to be minimized:
kMh 1    (h)
1
uv
0 k2
F
+P 1(u) + P 2(v) (35)
The LASSO penalty can be approached by the soft-thresholding (with equivalence
reached in the case of orthogonal predictors). The minimization problem above (35) can
thus be solved by using the soft-thresholding until convergence is reached for cuh and cvh:
8
>>>>><
>>>>>:
c
uh
(k+1)
=
g (Mh 1cvh(k))
k g (Mh 1cvh(k)) k
c
vh
(k+1)
=
g (M
0
h 1cuh
(k)
)
k g (M 0h 1cuh(k)) k
with g (y) = sign(y) · (|y|   ) · 1{(|y|  )>0} the soft-thresholding function for each y
coordinate of the vectors. Indeed, for a fixed u in (35), one seeks bv that minimize:
kMh 1    (h)
1
uv
0 k2
F
+P 2(v) =
pX
i=1
qX
j=1
(mij   uivj)2 +
qX
j=1
P 2(vj) (36)
with mij = (Mh 1)ij
Since
pX
i=1
u2i = 1 (normed u), expanding the squares yields:
pX
i=1
(mij   uivj)2 =
pX
i=1
m2ij   2
pX
i=1
mijuivj +
pX
i=1
u2i v
2
j
=
pX
i=1
m2ij   2(M 0h 1u)jvj + v2j
and (36) then becomes:
qX
j=1
 
pX
i=1
m2ij   2(M 0h 1u)jvj + v2j + P 2(vj)
!
(37)
Thus, for a given u,
bv = argmin
kvk=1
qX
j=1
⇥ 2(M 0h 1u)jvj + v2j + P 2(vj)
⇤
(37) can be minimized for each coordinate j of bv independently, bv being standardized
once each of its coordinate is estimated, and then:
bvj = argmin v2j   2(M 0h 1u)jvj + P 2(vj) (38)
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What’s more, by derivation of (38) one gets:
d
dv
⇥
v2j   2(M 0h 1u)jvj + P 2(vj)
⇤
= 0
, vj = (M 0h 1u)j +
1
2
d
dv
[P 2(vj)] (39)
Let’s write z = (M 0h 1u)j, y = vj and   =  2. Then (39) becomes:
y = z +
1
2
d
dy
[P (y)] (40)
If P (v) = 2 |v|, then :
(40) , v =(z    ) · 1{v>0} + (z +  ) · 1{v<0}
=(z    ) · 1{z  >0} + (z +  ) · 1{z+ <0}
= sign(z)(|z|   ) · 1{z> } + sign(z)(|z|   ) · 1{z< }
= sign(z)(|z|   ) · 1{|z|> }
= g (z)
Finally, this applies also to u when v is fixed.
By initializing cuh(0) and cvh(0) with the first couple of singular vectors of Mh 1 SVD
decomposition (which is the solution for   = 0), convergence is rapidly reached towards
the sparse optimum.
The difference between canonical and regression perspectives
The difference between those 2 perspectives takes place during Y update, that is to
say at the steps (d) and (e) respectively of the PLS and sPLS algorithms.
• In the regression perspective, the Y matrix is deflated in regards of the X latent
scores subspace (by projecting Y onto the space orthogonal to the X latent scores):
Y h  Y h 1   ⇠h
✓
Y
0
h 1
⇠h
k ⇠h k2
◆0
• In the canonical perspective, the Y matrix is deflated in regards of its own la-
tent scores subspace (by projecting Y onto the space orthogonal to the Y latent
scores)):
Y h  Y h 1   !h
✓
Y
0
h 1
!h
k !h k2
◆0
• There exist a third perspective, the invariante perspective, where Y is never mod-
ified during the algorithm: Y h  Y h 1.
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Missing values
A simple way of dealing with missing values from either X or Y in PLS methods
is to replace those by 0 during the computation of the latent scores (since X has to be
centered and reduced, it is desirable that Y be too). But it seems more reasonable to
treat missing values before applying any PLS methods, for instance by using a multiple
imputation method [Schafer and Graham, 2002; Van Buuren and Groothuis-Oudshoorn,
2011].
C.2.2 Penalization parameters tuning
 
1
and  
2
are the two penalty parameter, enforcing the sparsity level on X and Y
respectively. There are various way of tuning those parameters [Le Cao et al., 2008]. A
common approach is to use cross validation to optimize a given criterion of model quality,
simultaneously for both  
1
and  
2
, one component at a time. For instance, one can
use a sequential cross-validated (preferably leave-one-out) optimization of the mean R2
between the Y variables selected by a given component explained by the corresponding X
component on a grid of explored values for  
1
and  
2
. Alternatively, the Mean Squared
Error of Prediction (MSEP) can be used instead of the R2. Often, instead of tuning
 
1
and  
2
, one tunes the number of variables selected (which is equivalent with the
soft-thresholding approximation of the LASSO solution). In practice, those penalization
criteria can also be tuned empirically depending on the application problem, so that
enough information is conveyed by each component for further interpretation (for instance
enrichment annotation of selected genes in genomics applications) [Le Cao and Le Gall,
2011].
C.2.3 Choice of the number of components
In a PLS (or sPLS) model, the maximum number of components possible to derive is p
if a regression perspective is adopted, and min(q, p) if a canonical perspective is adopted.
But often only a few number of components are analysed.
Let’s define:
Q2h = 1 
Pq
j=1 PRESS
j
hPq
j=1 RSS
j
h 1
with PRESSjh =
Pn
i=1(y
j
i   ŷjh( i))2 the PRediction Error Sum of Squares at step h 1
and RSSjh =
Pn
i=1(y
j
i   ŷjh)2 the Residual Sum of Squares at step h 1. ŷjh( i) refers to the
leave-one-out estimator of observation i. This Q2 criterion can be seen as the marginal
contribution of the latent score ⇠h [Le Cao et al., 2008]. A heuristic cutoff is to keep
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including the component h+ 1 as long as:
Q2h+1   (1  0.952) = 0, 0975
This limit corresponds to
p
PRESSh+1 < 0.95
p
RSSh.
The Q2 is only available in the regression perspective, and if Y latent scores are not
penalized (indeed, if the variables contributing to the PRESS are not the same as the
one selected at h  1 and contributing to the RSS, the Q2 criterion is not interpretable).
In such cases other empirical methods, for instance relying for instance on cross-validated
Root Mean Squared Error of Prediction (RMSEP), can be used.
C.3 Related approaches
Tenenhaus et al. [2014] proposed a general framework that encompass the case of the
sPLS method, and that also extend it both to the multi-block case and to an optimization
criterion for component that can depend on both the covariance and the correlation.
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Appendix D:
Supplementary information on the sys-
tems analysis of sex differences in the
response to influenza vaccination
D.1 Construction of the gene modules used in the flu
vaccination system analysis
First, gene probes were filtered by variance and normalized. Then, hierarchical ag-
glomerative clustering was performed to derive 109 modules. Those 109 are thus data
driven and based and co-expression.
In addition, for each gene module, a set of regulatory genes (regulatory program)
was assigned based on regression analysis of genes in the modules onto expression of
transcription factors. This was conducted using the LARS-EN algorithm [Zou and Hastie,
2005]. The LARS-EN algorithm provides fits of increasing numbers of predictors. To select
the best model among the outputs of LARS-EN, we assessed the quality of the resulting
models by the Akaike information criterion (AIC) [Akaike, 1974], with sample-specific
terms weighted by module variance. The fit with the best AIC score was selected for each
module. Detailed statistical procedures have been described [Furman et al., 2013].
D.2 Baseline sex differences
To determine the differences in the baseline’s immune measures in males versus fe-
males, we investigated univariate association of the 278 measured variables with sex,
while controlling the FDR (Appendix A page 121) at a 10% level. This association was
estimated using the Significant Analysis of Microarrays approach (SAM) from Tusher
et al. [2001]. This approach focus on estimating the signal-to-noise ratio between a two
conditions for an important number of covariates. It deals with high-dimensional setting
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(n = 87 and p = 278 in our case) by investigating univariate associations while controlling
the FDR.
Seven variables were found significantly associated with sex whith an FDR < 0.1,
six of which were increased in females. Strikingly, these included several known markers
of inflammation, such as LEPTIN, interleukin (IL)-1 receptor agonist (RA), C-reactive
protein (CRP), Granulocyte macrophage-colony stimulating factor (GM-CSF), and in-
terleukin IL-5, as well as the phosphorylation levels of STAT3 proteins in unstimulated
monocytes (M-pSTAT3). The last significant variable was the gene module 106. It was
up-regulated in males compared with females (a significant fraction of this gene module
is composed of genes located on the Y chromosome).
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Systems analysis of sex differences reveals an
immunosuppressive role for testosterone in the
response to influenza vaccination
David Furmana,1,2,3, Boris P. Hejblumb,1, Noah Simonc, Vladimir Jojicd, Cornelia L. Dekkere, Rodolphe Thiébautb,
Robert J. Tibshiranic,f, and Mark M. Davisa,g,h,3
aDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305-5323; bISPED-Epidemiologie-Biostatistique
and Institut National de la Santé et de la Recherche Médicale (INSERM), Centre INSERM U897, University of Bordeaux, and INRIA–Statistics in System Biology
and Translational Medicine Team, F-33000 Bordeaux, France; cDepartment of Statistics, Stanford University, Stanford, CA 94305-4065; dDepartment of
Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3175; eDepartment of Pediatrics, Division of Infectious Diseases, Stanford
University School of Medicine, Stanford, CA 94305-5208; fDepartment of Health Research and Policy, Stanford University School of Medicine, Stanford, CA
94305-5405; gInstitute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305-5124; and hHoward Hughes Medical Institute,
Stanford University School of Medicine, Stanford, CA 94305-5323
Contributed by Mark M. Davis, November 21, 2013 (sent for review September 23, 2013)
Females have generally more robust immune responses than
males for reasons that are not well-understood. Here we used
a systems analysis to investigate these differences by analyzing
the neutralizing antibody response to a trivalent inactivated
seasonal influenza vaccine (TIV) and a large number of immune
system components, including serum cytokines and chemokines,
blood cell subset frequencies, genome-wide gene expression, and
cellular responses to diverse in vitro stimuli, in 53 females and 34
males of different ages. We found elevated antibody responses to
TIV and expression of inflammatory cytokines in the serum of
females compared with males regardless of age. This inflamma-
tory profile correlated with the levels of phosphorylated STAT3
proteins in monocytes but not with the serological response to the
vaccine. In contrast, using a machine learning approach, we
identified a cluster of genes involved in lipid biosynthesis and
previously shown to be up-regulated by testosterone that corre-
lated with poor virus-neutralizing activity in men. Moreover, men
with elevated serum testosterone levels and associated gene
signatures exhibited the lowest antibody responses to TIV. These
results demonstrate a strong association between androgens and
genes involved in lipid metabolism, suggesting that these could be
important drivers of the differences in immune responses between
males and females.
aging | gender | immuno-endocrine | sexual dimorphism |
immunosenescence
The variability in the biology of human populations poses sig-nificant challenges in understanding different disease out-
comes and developing successful therapeutics. The sources of this
variation are likely the consequence of genetics, epigenetics, and
the history of antigenic exposure (1, 2). As therapies targeting
immune function are developed to improve clinical outcomes in
cancer, viral and bacterial infections, autoimmune diseases, and
transplantation, identifying the sources of immunological varia-
tion and finding biomarkers for immune health and dysfunction
are crucial for their success (3).
An important source of immunological variation is known to be
the sex of the individual. Males experience a greater severity and
prevalence of bacterial, viral, fungal, and parasitic infections than
females, who also exhibit a more robust response to antigenic
challenges such as infection and vaccination (4, 5). This stronger
immune response in females could also explain why they more
frequently develop immune-mediated pathologies during influenza
infection, such as an overproduction of cytokines (cytokine storm)
that contribute to an increase in capillary permeability and lung
failure (6). Furthermore, females are at a higher risk for de-
veloping autoimmune diseases. In this later context, it is interesting
to note that a recent study showed that females had, on average,
1.7 times the frequency of self-specific T cells as males (7). Despite
the fact that initial observations relating the sex of the individual
with the immune response were made many years ago (8), little is
known about the mechanisms underlying these differences.
Some sex-specific variations in the immune response can be di-
rectly attributed to sex hormones (9). In humans, sex steroids can
bind to intracellular receptors located in immune cells such as
monocytes, B cells, and T cells and activate hormone-responsive
genes, suggesting that they can directly affect sex-related differ-
ences in both innate and adaptive immune responses (10).Whereas
estrogens are associated with inflammation and can stimulate
proliferation and differentiation of lymphocytes and monocytes,
androgens suppress the activity of immune cells by increasing the
synthesis of anti-inflammatory cytokines (11, 12).
To date, no clear associations have been found between bi-
ological and clinical differences in the immune response between
Significance
There are marked differences between the sexes in their im-
mune response to infections and vaccination, with females
often having significantly higher responses. However, the
mechanisms underlying these differences are largely not un-
derstood. Using a systems immunology approach, we have
identified a cluster of genes involved in lipid metabolism and
likely modulated by testosterone that correlates with the
higher antibody-neutralizing response to influenza vaccination
observed in females. Moreover, males with the highest tes-
tosterone levels and expression of related gene signatures
exhibited the lowest antibody responses to influenza vaccina-
tion. This study generates a number of hypotheses on the sex
differences observed in the human immune system and their
relationship to mechanisms involved in the antibody response
to vaccination.
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males and females in humans. In one study, results from public
gene expression data (13) showed that many of the genes in-
duced by a yellow fever vaccine were preferentially activated in
females (14). However, whether these differences correlate with
poor antibody outcomes remains to be determined.
In this study, we sought to determine whether we could identify
biomarkers from peripheral blood that could explain the sex-related
differences in the serological response to the trivalent inactivated
seasonal influenza vaccine (TIV) in both young and older cohorts.
Young and older females had higher neutralizing antibodies
than age-matched males, consistent with previous reports (15).
Females also showed higher expression of inflammatory mark-
ers. However, none of these specific sex-related differences
correlated with the observed disparities in the antibody response
to TIV. Nevertheless, using a machine learning approach, we
identified a set of genes previously shown to be regulated by
testosterone and participating in lipid biosynthesis, whose ex-
pression was negatively associated with antibody responses to
TIV in the male subjects in our study. Moreover, males with high
levels of serum testosterone and expressing related gene sig-
natures in blood cells showed the lowest neutralizing responses
to TIV. These results suggest that testosterone might be immu-
nosuppressive in vivo in humans, and indicate that its effect on
an influenza vaccine and other immune responses could be due
to the regulation of genes implicated in the metabolism of lipids.
Results
Elevated Levels of Neutralizing Antibodies upon Influenza Vaccination
and Inflammatory Markers in Serum from Females Versus Males. To
study the differences in males’ versus females’ immune systems,
we used data from a vaccination and systems immunology study
conducted on 91 individuals (37 males and 54 females) of dif-
ferent ages (20–30 and 60–>89 y old) (Table 1) that we recently
reported (16). We studied a variety of immune parameters from
peripheral blood before vaccination, including cytokines, che-
mokines, and growth factors in serum, frequencies of diverse
blood cell subsets, phosphorylation levels of signal transducer
and activator of transcription (STAT) proteins in multiple cells
stimulated with a variety of cytokines or unstimulated (96 con-
ditions in total), and whole-blood gene expression. The gene
expression data were reduced to 109 gene modules by cluster
analysis and assignment of a set of transcription factors (regu-
latory program) to each gene module as described (16) (SI
Materials and Methods). Four individuals were removed from the
analysis: two outliers and two with incomplete datasets.
To determine the magnitude of the antibody response to
TIV, we performed virus microneutralization assays. The se-
roconversion rate (percent of individuals with a fourfold or
greater change in their post- versus prevaccination micro-
neutralization titer) was computed for each group and strain
in the vaccine (SI Materials and Methods). We conducted lo-
gistic regression analysis on each of the titer changes (corre-
sponding to the H1N1, H3N2, and B strains) and included the
age and sex variables in the model, because age was expected
to modify vaccine responses. Females had a greater response
than males to the H3N2 strain (P = 0.0027) and to a lesser
extent to the B strain (P = 0.02). In contrast, despite a strong
age effect (P = 0.0035), no differences according to sex were
found for the H1N1 strain (Table 2).
To determine the differences in the baseline’s immune measures
in males versus females, we conducted differential expression
analysis across a total of 278 parameters using significance analysis
of microarrays (SAM) (17) and found significant differences in 7
parameters [false discovery rate (FDR) Q < 0.1], 6 of which were
increased in females (Fig. 1). Strikingly, these included several
known markers of inflammation, such as LEPTIN, interleukin
(IL)-1 receptor agonist (RA), C-reactive protein (CRP), Gran-
ulocyte macrophage-colony stimulating factor (GM-CSF), and
Interleukin IL-5, as well as the phosphorylation levels of
STAT3 proteins in unstimulated monocytes (M-pSTAT3).
One parameter (gene module 106) was up-regulated in
males compared with females. A significant fraction of this gene
module is composed of genes located on the Y chromosome
(enrichment P < 10−9) (Table S1). Interestingly, genes partici-
pating in the activation of v-akt murine thymoma viral oncogene
homolog (Akt) and phospholipase C (PLC) proteins such as
mature T-cell proliferation 1 (MTCP1) and phosphatidylinositol-
specific phospholipase C, X domain containing 1 (PLCXD1),
respectively, clustered with Y chromosome-linked genes in
module 106. The regulatory program derived for module 106
(Fig. S1) included genes previously shown to be differentially
regulated in males versus females, such as CLOCK (18), ENY2
(19), and IRF1 and IRF7 (20).
It has long been noted that inflammatory markers, especially
IL-6, TNF-α, and IL-1β, among others, are increased in the el-
derly. Thus, we divided the individuals by age group (young, 20–
30 y old; old, 60–>89 y old) and investigated whether these
differences were also observed in our aging cohort. The serum
levels of LEPTIN, IL1-RA, CRP, GM-CSF, and IL-5 were all
higher in females regardless of age group (P < 0.05) (Fig. 2).
However, the differences for CRP, IL1-RA, and LEPTIN were
less pronounced in the older group due to an overall increase in
the levels of these proteins in older compared with younger
males (P = 0.007, by Fisher’s combined probability). Strikingly,
M-pSTAT3 levels were significantly higher in females among
young subjects (P = 0.002) but not in the elderly (P = 0.268),
where both sexes had similar levels to those found in young
females (Fig. 2). This suggested that other cytokines that signal
through STAT3 (e.g., IL-6, IL-11, and LIF, among others) were
elevated in both males and females in the older cohort. Because
IL-6 is one of the hallmark cytokines of aging, we directly
compared IL-6 levels in young versus older (without correction
for multiple comparisons) and noticed elevated levels in elderly
subjects (Fig. S2), consistent with multiple previous reports.
To identify associations between these sex-related features, we
generated correlation matrices and conducted unsupervised
clustering with or without IL-6. Interestingly, M-pSTAT3 clus-
tered with CRP and GM-CSF (Fig. S3A), or with CRP, IL-6, and
GM-CSF when IL-6 was incorporated in the clustering analysis
(Fig. S3B), suggesting that the intracellular levels of phosphorylated
Table 1. Subjects’ baseline characteristics
Males Females P value
Number of subjects 37 54 —
Age range (median), y 20–>89 (63) 20–>89 (68) 0.14
BMI range (median) 19–36 (25) 18–47 (24) 0.61
Cytomegalovirus (+), % 61 57 0.73
Epstein–Barr virus (+), % 70 54 0.13
BMI, body mass index.
Table 2. Age and sex effects on microneutralization antibody
titer responses to influenza vaccination
Beta SE z value P value
H1N1 (Intercept) −0.272 0.229 −1.190 0.234
Age −0.690 0.236 −2.919 0.004
Sex −0.011 0.234 −0.047 0.962
H3N2 (Intercept) −0.038 0.228 −0.166 0.868
Age −0.190 0.236 −0.804 0.421
Sex −0.716 0.239 −2.992 0.003
B (Intercept) −0.502 0.236 −2.128 0.033
Age −0.583 0.246 −2.367 0.018
Sex −0.594 0.256 −2.324 0.020
2 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1321060111 Furman et al.
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STAT proteins in monocytes likely represent a functional readout
corresponding to an inflammatory environment in vivo.
These results indicate that females have a stronger neutralizing
response to influenza vaccination and an increased inflammatory
serum profile, which correlates with the baseline levels of phos-
phorylated STAT3 proteins in peripheral monocytes.
Weaker Vaccine Responses in Males with High Expression of Genes
Involved in Lipid Metabolism. To identify features associated with
the observed sex differences in vaccine responsiveness, we fo-
cused on the neutralizing activity to H3N2 because the largest
differences between males and females were found for this
strain. Also, this influenza strain is important in a public health
context because it causes the highest rates of morbidity and
mortality during the influenza season (21). An individual was
considered a responder if they had the standard fourfold or
greater change in their post- versus prevaccination micro-
neutralization titer (seroconversion). For H3N2, 33 females and
10 males were responders and 20 females and 24 males were
nonresponders. We first searched for possible confounding fac-
tors by investigating which features could substantially modify
the observed sex effect. In brief, we performed forward stepwise
logistic regression with sex as the initial predictor. In stepwise
regression, each of the immune features was incorporated into
the model iteratively and statistics were computed to account for
modifications in the regression coefficient of sex (SI Materials
and Methods). The iterations were stopped when the added
feature did not modify the regression coefficient of sex to the
standard threshold 20%. By this procedure, we identified two
possible confounders: a gene module enriched for genes encoding
for ribosomal proteins (module 042) (enrichment P < 10−6) and
the acute-phase inflammatory marker CRP. Thus, we generated
a first model (model 1), which included the variables of sex,
module 042, and CRP. The resulting regression coefficient for sex
in model 1, after adjusting for confounders, was −2.03 compared
with −1.38 (sex variable alone) (Fig. S4).
We then searched for gene expression profiles that could ex-
plain the differences in vaccine responsiveness between males and
females, namely features having different effects in males or
females, while adjusting for confounding variables. To do so, we
used the Interact package (SI Materials and Methods), which
searches for significant interactions between predictors using
permutation methods. A significant interaction (FDR Q < 0.1)
was identified for a module enriched for genes participating in
lipid biosynthesis (enrichment P < 0.001) (module 052) (Table
S1). These genes included LTA4H, encoding for leukotriene A4
hydrolase, which converts leukotriene A4 (LTA4) to active LTB4;
MIF (macrophage migration inhibitory factor), which plays a role
in the anti-inflammatory effects of glucocorticoids (22); PDSS2
(decaprenyl-diphosphate synthase subunit 2), whose product syn-
thesizes the prenyl side chain of coenzyme Q; and PEX5 (perox-
isomal biogenesis factor 5), involved in fatty acid metabolism. The
gene regulators derived for module 052 (Fig. S1B) included
CLOCK (activator) and FBJ murine osteosarcoma viral oncogene
homolog (FOS), Jun B proto-oncogene (JUNB), and Jun D proto-
oncogene (JUND) (repressors), among others. Interestingly, the
CLOCK gene is involved in the regulation of circadian rhythms, as
well as in lipid metabolism (23).
We then generated a second model (model 2), which included
the variables of sex and module 052, the interaction term (sex ×
module 052), and the covariates CRP and module 042. The
resulting odds ratio (OR) estimate for vaccine response based on
the expression of module 052 in model 2 was 0.39 [confidence
interval (CI), 0.18–0.84] for males and 2.25 (CI, 1.08–4.67) for
females (Fig. 3A). This indicates that the probability of being
a high responder to TIV decreases significantly with an elevated
expression of module 052 in males and with decreased expres-
sion of module 052 in females. To determine the extent to which
module 052 and its interaction with sex contribute to the
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Fig. 1. Significant differences in baseline immune parameters between
females and males. Expression of a total of 278 immune features and gene
modules was compared between females (F) (n = 53) and males (M) (n = 34)
of different age groups, including serum cytokines, chemokines, and growth
factors; frequencies of over 15 blood cell subsets; phosphorylation events in
multiple immune cells; and whole-genome gene expression using SAM. A
cutoff of Q < 0.1 and absolute score(d) > 2 was considered significant (vol-
cano plot; Top, Left). Inflammatory markers including LEPTIN, IL-1RA, and
CRP and other serum proteins were elevated in females compared with
males. mono.Unstimulated.STAT3, baseline levels of pSTAT3 in isolated
monocytes. A single gene module (module 106) (Bottom, Right) was dif-
ferentially expressed (and up-regulated in males). Module 106 is enriched for
genes located on the Y chromosome (P < 10−9). Lower whisker represents the
minimum value, lower hinge the first quartile, upper hinge the third quartile,
and upper whisker the maximum value. Outliers are represented by circles.
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classification model, we computed a cross-validated area under
the curve (cvAUC) for model 1 and model 2. The cvAUC was
0.712 for model 1, and 0.761 for model 2. Furthermore, direct
comparison of the two models shows that model 1 is significantly
better than model 2 (P = 0.0019, by likelihood ratio test).
These results suggest that the observed sex differences in the
neutralizing antibody responses to vaccination could be medi-
ated by the expression of genes involved in lipid metabolism.
Blunted Vaccine Response in Males with High Levels of Testosterone
and Elevated Expression of Genes Involved in Lipid Metabolism. Our
results showing that augmented expression of module 052 cor-
related with weaker vaccine responsiveness in males but not in
females suggested that sex hormones could be involved in ex-
pression of this gene module. Indeed, results from chemical–
gene interaction analysis (http://ctdbase.org) (24) show that ex-
pression of a significant fraction of genes in module 052 can be
modulated by testosterone (P < 0.005, by hypergeometric test).
Thus, we measured free (unbound, bioactive form) testosterone
in the sera from the individuals in our study with the hypothesis
that, in males, the observed effect of module 052 on vaccine
response was dependent on the circulating levels of testosterone.
We stratified the male subjects into testosterone high (Thi) or
low (Tlo), if they were above or below the median for all of the
male subjects (4.06 pg/mL; range, 0.58–24.78 pg/mL), and gen-
erated a third model (model 3) for vaccine-neutralizing response,
in which male subjects were replaced by Thi (n = 17) and Tlo
(n = 17). The median testosterone level in Thi subjects was 9.55
pg/mL (range, 4.25–24.78 pg/mL), and 2.34 pg/mL (range, 0.58–
3.89 pg/mL) in Tlo subjects. The median age for Tlo and Thi
males was 77 and 24 y, respectively. Thus, model 3 included the
interaction terms module 052 × Thi and module 052 × Tlo, and
was also adjusted for age, because of the effect of aging on
testosterone levels. Strikingly, the interaction between testos-
terone levels and module 052 was significant only for the Thi
group (P < 0.005) and not for Tlo males (P = 0.18), and the
corresponding OR estimates for vaccine response, according to
module 052, were 0.87 (CI, 0.28–2.69) for Tlo and 0.19 (CI,
0.04–0.80) for Thi males. We also tested testosterone levels as
a continuous measure by replacing the interaction terms module
052 × Thi and module 052 × Tlo with module 052 × testoster-
one; the model was also adjusted by sex and age. Consistent with
model 3, the interaction of module 052 and testosterone levels
was significant (P = 0.012) (Fig. S5). This indicates that module
052 has a significant effect on vaccine response in males with
high levels of testosterone but not in those with lower levels.
Together, these results show that in males with higher levels of
testosterone and elevated expression of genes that participate in
lipid metabolism, the antibody response to vaccination is severely
down-regulated, whereas in those with low levels of testosterone,
or in females, the contribution of module 052 is not detrimental
and the responses to the vaccine remain intact.
Discussion
In this study, we have used a systems approach to the analysis of
sex differences in the immune system in humans. These data re-
inforce and extend previous reports, and point toward a mecha-
nistic hypothesis that may drive the sex disparities observed in
responses to vaccination. Differences in vaccine responsiveness
in males versus females have been reported for most commercially
available vaccines including yellow fever, influenza, measles, mumps,
rubella, and hepatitis, among others (5). As in these studies, we find
stronger responses to influenza vaccination and significantly in-
creased serum levels of proinflammatory molecules in females
compared with males, specifically LEPTIN (25), IL-RA (26), and
CRP (27). In addition, we find differences in GM-CSF and IL-5
and in the baseline pSTAT3 levels in monocytes, which correlate
with serum CRP, IL-6, and GM-CSF. Consistent with this,
LEPTIN and IL-6 activate STAT3 in monocytes, which results in
the secretion of CRP and IL1-RA (28, 29). We also find that these
sex differences in monocyte pSTAT3 are observed only in young
IL
5
3
2
1
0
1
2
3
4
Young Old
F M F M
m
on
o.
U
ns
tim
ul
at
ed
.S
TA
T
3
3
2
1
0
1
2
3
4
Young Old
F M F M
m
od
_1
06
3
2
1
0
1
2
3
4
Young Old
F M F M
LE
P
T
IN
3
2
1
0
1
2
3
4
Young Old
F M F M
IL
1r
a
3
2
1
0
1
2
3
4
Young Old
F M F M
C
R
P
3
2
1
0
1
2
3
4
Young Old
F M F M
G
M
C
S
F
3
2
1
0
1
2
3
4
Young Old
F M F M
Fig. 2. Differences in baseline immune parame-
ters between females and males by age group.
The individuals were first divided by age group
(58 older and 29 young), and the significant dif-
ferences identified between all females (yellow
bars) and males (blue bars) using SAM (seven in
total; Fig. 1) were used to investigate differences
in expression by age group. With the exception of
mono.Unstimulated.STAT3, all significant differences
between all males and females identified previously
were also observed in both age groups (P < 0.05).
However, the differences in LEPTIN, IL-1RA, and CRP
were less pronounced in older individuals due to an
overall increase in the levels of these proteins in the
serum of older males compared with young males
(P < 0.05). F, females; M, males. mono.Unstimulated.
STAT3, baseline levels of pSTAT3 in isolated mon-
ocytes; mod_106, module enriched for Y chromo-
some genes.
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Fig. 3. Odds ratio for vaccine responses in males and females based on
expression of module 052. Interaction analysis was conducted for sex and
gene expression modules on the serological (microneutralization) responses
to TIV (seroconversion to the H3N2 strain). A significant interaction was
found between the variables sex and gene module 052. (A) Odds ratio for
vaccine response given module 052 in females (red line) and males (blue
line). (B) No significant interaction between sex and module 052 is ob-
served for males with low levels of testosterone [Tlo (n = 17), brown line],
although a significantly negative effect of module 052 is observed for
males with high levels of testosterone [Thi (n = 17), blue line] (adjusted for
confounders including age).
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subjects, possibly due to increased levels of other cytokines
signaling through STAT3 in both sexes from the older cohort (e.g.,
IL-6). Therefore, the level of pSTAT3 in monocytes likely reflects
the sum of diverse inflammatory stimuli targeting STAT3. Con-
sistent with these observations, the phosphorylation levels of
STAT3 and other STAT proteins have been found to be increased
in asthma (30) and in other inflammatory conditions (31).
With respect to the influenza vaccine response, our results
indicate that the natural variation in circulating free testosterone
could drive many of the differences observed in the response to
vaccines. In particular, males with elevated levels of serum tes-
tosterone and high expression of genes participating in lipid
metabolism were significantly less likely to respond to TIV.
These results are in agreement with previous findings showing an
immunosuppressive role of testosterone in animals and in vitro
(11, 32) with an increase in the synthesis of anti-inflammatory
cytokines such as IL-10 (12). Consistently, men with androgen
deficiencies have higher levels of inflammatory cytokines than
healthy controls (33). However, we did not find an association
between the proinflammatory cytokines that are differentially
expressed in females and males and the response to vaccination.
Rather, our data indicate that other molecules, such as those
involved in lipid biosynthesis, are likely affected by testosterone
and modulate the antibody response. In particular, our results
suggest that testosterone could act by decreasing expression of
transcription factors such as FOS, JUNB, and JUND that, in turn,
repress the expression of gene module 052 (Fig. S1B). Consistent
with this hypothesis, androgen receptor signaling antagonizes NF-
κB and represses AP-1 (FOS/JUN), which mediates the pro-
duction of proinflammatory and antiviral cytokines (34, 35).
A particularly interesting gene found in module 052 is LTA4H,
one of the members of the epoxide hydrolase family. The product
of this gene catalyzes the conversion of LTA4 (originating from
arachidonic acid) to LTB4, a lipid mediator that has both proin-
flammatory (via surface receptors) and anti-inflammatory (via
activation of peroxisome proliferator-activated receptors and de-
creased NF-κB expression) activities. Furthermore, LTB4 seems
to participate in the differentiation of suppressor cells both from
the myeloid (36) as well as from the lymphoid (37) compartments.
More generally, several studies in both humans and mice have
shown the ability of LTB4 precursors, such as omega-3 and -6
fatty acids, to suppress inflammatory responses (38, 39).
Other potentially relevant genes in module 052 are MIF,
PDSS2, and PEX5. MIF participates in the synthesis of prosta-
glandin E2, a lipid compound that originates from arachidonic
acid, binds to immune cells (T cells and dendritic cells), and
suppresses inflammatory cytokine production (40, 41). A less
clear association is observed for PDSS2, an enzyme that medi-
ates isoprenoid biosynthesis and the incorporation of lipids in
proteins. Last, PEX5 participates in the biogenesis of perox-
isomes, which regulate various metabolic activities including the
degradation of very long chain fatty acids. Peroxisomes have also
been implicated in the innate immune system, with a significant
reduction observed in inflammation, apparently related to the
suppressive effect of TNF-α on peroxisome function (42).
Recent studies have also focused on the possibility that genes
located on the X and Y chromosomes also affect the response to
vaccination. Polymorphisms in genes on the X chromosome that
encode for immunological proteins can influence immune
responses to vaccines. For example, Toll-like receptor 7, located
on the X chromosome, can escape X inactivation, resulting in
higher expression in females than in males (43). Y chromosome
genes have also been shown to affect sex-dependent suscepti-
bility to autoimmune disease and possibly to other immune
functions (44). However, our results indicate that the expression
of genes on the Y chromosome might not be involved in the
immune response to vaccines, because the sex-related gene
module 106 was not associated with the differences in the re-
sponse to TIV despite the observation that genes regulating
important immune functions such as the activation of Akt and
PLC proteins by MTCP1 and PLCXD1, respectively, are clus-
tered together with Y chromosome genes in this module.
In conclusion, our results are consistent with a large body of work
in animals showing that testosterone is immunosuppressive in vivo
and extend this to humans responding to a seasonal influenza
vaccine and exhibiting typical variations in testosterone levels. We
suggest that testosterone acts directly on immune cells by repressing
transcription factors (such as FOS, JUN, and others) implicated in
immune activation; these transcription factors would in turn repress
the expression of genes involved in lipid metabolism with immu-
nosuppressive activities, creating a negative feedback loop.
From an evolutionary perspective, the immunosuppressive effects
of testosterone could be advantageous as a possible homeostatic
mechanism to turn off the immune response. For instance, experi-
ments with highly pathogenic viruses reconstructed from isolates
from the 1918 influenza pandemic (which killed over 50 million
people) show that infection with this strain in animal models results
in an uncontrolled, deadly cytokine storm (45). Furthermore, sup-
pression of this inflammatory response in infected mice ameliorates
immunopathology and decreases mortality (6, 46). It has also been
noted that testosterone treatment of castrated male mice made
them less susceptible to LPS-induced shock (32). Because males of
many species are more likely to experience trauma than females,
this positive effect of testosterone may also help to balance out the
consequences of reduced immunity to infection.
In summary, we have identified unique proinflammatory markers
that are differentially expressed in females compared with males, as
well as genes that participate in lipid metabolism that could be
modulated by the levels of free testosterone in normal pop-
ulations and correlate with the sex-related bias in the re-
sponsiveness to influenza vaccination.
Materials and Methods
Subjects, Specimens, and Vaccination Protocol. With the exception of the
neutralizing antibody response to the vaccine and the determination of
testosterone measurements from serum, this study used baseline-level data
from a previously published work conducted in 91 healthy donors who were
enrolled in an influenza vaccine study at the Stanford-Lucile Packard
Children’s Hospital (LPCH) Vaccine Program during the 2008–2009 influenza
season (16). Thus, only a brief description of the methods is included here.
The protocol of the study was approved by the Institutional Review Board of
the Research Compliance Office at Stanford University. Blood samples were
obtained prevaccination and 28 ± 7 d after receiving a single dose of TIV
Fluzone (Sanofi Pasteur). Whole blood was used for gene expression analysis
as described (16). Peripheral blood mononuclear cells (PBMCs) were obtained
by density gradient centrifugation (Ficoll-Paque) and frozen at −80 °C before
transferring to liquid nitrogen. Serum was separated by centrifugation of
clotted blood and stored at −80 °C before use. Whole blood, PBMCs, or serum
from the first visit (baseline, day 0) was processed and used for determination
of gene expression, leukocyte subset frequency, signaling responses to stim-
ulation, serum cytokine and chemokine levels, testosterone levels, and CMV
and EBV serostatus by ELISA (Calbiotech). Serum samples from day 0 and day
∼28 were used for virus microneutralization titer determination.
Virus Microneutralization Assay. A standard plaque reduction virus micro-
neutralization assay was performed. In brief, serum samples were heat-inacti-
vated for 30 min at 56 °C, serially diluted (twofold) in virus diluent (DMEM, 1%
BSA, antibiotics, and 25 mM Hepes), and mixed with 100 median tissue culture
infective doses each of the H1N1, H3N2, and B strains (kind gift of George
Kemble, MedImmune). Plates were incubated 1 h at 37 °C and 5% CO2, and
1.5 × 104 exponentially growing Madin–Darby canine kidney-London cells
(kind gift of David Lewis, Stanford University) were added in 100 μL of virus
diluent. Cell cultures were then incubated overnight at 37 °C and 5% CO2,
and washed and fixed with ice-cold acetone for 10 min at room tempera-
ture. Fixative was discarded and plates were air-dried. After several washes
with washing buffer (PBS, 0.1% Tween-20), wells were incubated for 1 h at
room temperature with an anti-influenza A or B nucleoprotein mouse
monoclonal antibody (KPL) at 1:4,000 in blocking buffer (PBS, 1% BSA,
0.1% Tween-20). After washing, a secondary antibody (goat anti-mouse
IgG, HP-conjugated; KPL) was added at 1:2,000 in blocking buffer and
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incubated 1 h at room temperature before revealing with HRP substrate.
Absorbance (OD) was read at 490 nm.
Whole-Blood Microarray Analysis of Gene Expression. The procedures for RNA
extraction, quantification, hybridization, and scanning were described pre-
viously (16). The original microarray probe-level data files can be accessed at
the Gene Expression Omnibus repository under accession number GSE41080.
Leukocyte Subset Frequency Determination. PBMCs were thawed, washed
with FACS buffer (PBS supplemented with 2% FBS and 0.1% Na azide), and
stained with three separate anti-human antibody mixtures containing (i)
anti-CD3 AmCyan, CD4 Pacific Blue, CD8 allophycocyanin (APC) H7, and
CD28 APC; (ii) CD3 AmCyan, CD4 Pacific Blue, CD8 APCH7, CD27 PE, and
CD45RA PE-Cy5; and (iii) CD3 AmCyan, CD19 Alexa Fluor 700, CD56 PE, CD33
PE-Cy7, and TCR APC, all reagents from BD Biosciences. After incubation,
cells were washed several times and data were collected using DIVA soft-
ware on an LSR II instrument (BD Biosciences) and analyzed using FlowJo
8.8.6 (Tree Star).
Phosphorylation of Intracellular Proteins by Phosphoflow. Cells were thawed
with FACS buffer and stimulatedwith the indicated cytokines for 15min inwarm
media (RPMIwith 10%FBS). Cellswerewashedand fixedwith paraformaldehyde
and permeabilized with 95% ice-cold methanol. Different stimulus conditions
were bar-coded using a 3 × 3 matrix with Pacific Orange and Alexa Fluor 750
(Invitrogen). Cell mixtures were stained with an antibody mixture as described
previously (16). Data were collected using DIVA software and analyzed with
FlowJo 8.8.6.
Serum Cytokine-Level Determination. Cytokines were measured on a Luminex
system. Fifty-plex kits were purchased from Millipore and used according to
the manufacturer’s recommendations with some modifications.
Testosterone-Level Determination. Serum levels of free testosterone were
measured using the Free Testosterone ELISA Kit (Calbiotech) as recom-
mended by the manufacturer.
Statistical Analysis. Statistical procedures for gene module construction, in-
teraction analysis, and modeling of vaccine responsiveness can be found in SI
Materials and Methods.
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SI Materials and Methods
Serological Response to Trivalent Inactivated Seasonal Influenza
Vaccine. The seroconversion rate (percent of individuals with
a fourfold or greater change in their post- versus prevaccination
microneutralization titer) was computed for each strain and for
each group of individuals. The largest differences between males
and females were observed for the H3N2 strain. Thus, the vac-
cine response was modeled as a binary variable (fold increase ≥4
to the H3N2 strain) in logistic regression analyses.
Gene Module Construction. First, gene probes were filtered by
variance and normalized. Hierarchical agglomerative clustering
wasperformedtoderive109modules.Foreachgenemodule,a setof
regulatory genes (regulatory program) was assigned based on re-
gression analysis of genes in the modules onto expression of tran-
scription factors.Thiswas conductedusing theLARS-ENalgorithm
(1). The LARS-ENalgorithmprovides fits of increasing numbers of
predictors. To select the best model among the outputs of LARS-
EN, we assessed the quality of the resulting models by the Akaike
information criterion (AIC) (2), with sample-specific terms weighted
by module variance. The fit with the best AIC score was selected for
eachmodule.Detailed statistical procedures havebeendescribed (3).
Interaction Analysis and Modeling of Vaccine Responsiveness. Po-
tential confounders were identified if they modified the estimates
of the sex effect on the vaccine response by more than 20%. A
forward strategy was performed starting with a basic model in-
cluding the sex covariate only.
To identify possible gene module candidates that explain the
differences observed in vaccine response, we tested for marginal
interactions between gene modules and the sex variable that as-
sociate with the neutralization antibody titer outcome (above). To
do so, we used the Interact package (http://cran.r-project.org/web/
packages/Interact/index.html), which searches for interactions in
a binary response model using permutation methods to estimate
false discovery rates (FDRs). The significance threshold was set
at an FDR of <10% (Q < 0.1).
For the estimation of the regression coefficients and odds
ratios in the response to vaccination, we conducted simple
logistic regression with the categorical variable corresponding
to the seroconversion to the H3N2 strain. The following for-
mulas were used in the different models.
Model 1.
logitðyiÞ= μ+ βsmalei + βccrpi + βm42mod_42i + «i
Model 2.
logitðyiÞ= μ+ βsmalei + βccrpi + βm42mod_42i + βm52mod_52i
+ βs:m52male : mod_52i + «i
Model 3.
logitðyiÞ= μ+ βccrpi + βm42mod_42i + βm52mod_52i + βaagei
+ βTlomaleTloi + βThimaleThii+ βTlo:m52maleTlo:mod_52i
+ βThi:m52maleThi : mod_52i + «i;
where yi is the binary response to H3N2 for the ith individual,
μ is the average response for females, malei is a dichotomic
variable (1 for male, 0 for female), crpi is the CRP level of the
ith individual, mod_42i is the 42nd module median expression
level of the ith individual, mod_52i is the 52nd module expres-
sion level of the ith individual, maleTloi is a dichotomic vari-
able (1 for males with low levels of testosterone, that is, below
the median of the male group; 0 for females and males with
high levels of testosterone; see below), maleTloi:mod_52i
is the interaction term of mod_52i and maleTloi for the ith
individual, maleThii is a dichotomic variable (1 for males with
high levels of testosterone, that is, above the median of
the male group; 0 for females and for males with low levels
of testosterone), maleThii:mod_52i is the interaction term of
mod_52i and maleThii, and ei is the error term for the ith
individual.
1. Zou H, Hastie T (2005) Regularization and variable selection via the elastic net. Journal
of the Royal Statistical Society, Series B 67:301–320.
2. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat
Contr 19(6):716–723.
3. Furman D, et al. (2013) Apoptosis and other immune biomarkers predict influenza
vaccine responsiveness. Mol Syst Biol 9:659.
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Fig. S1. Profile of gene regulators of modules 52 and 106. The initial gene expression data were reduced to gene modules by clustering analysis and as-
signment of a set of transcription factors (regulatory program) to each gene module. We used hierarchical agglomerative clustering to derive 109 modules.
Using a set of candidate regulators composed of known signaling and transcription factors, for each gene module a set of regulatory genes (regulatory
program) was assigned based on regression analysis of genes in the modules onto expression of transcription factors using the AIC (1). The regulatory program
of module 52 contains FOS, JUNB, and JUD, among others, which is consistent with the suppressing effect of testosterone signaling on the AP-1 complex (FOS/
JUN) (2). The regulatory program of sex-related gene module 106 contains transcription factors known to be differentially regulated in males versus females,
such as CLOCK (3, 4), ENY2 (5), and IRF1 and IRF7 (6). Module profile, median expression of genes in the module.
1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr 19(6):716–723.
2. Kallio PJ, Poukka H, Moilanen A, Jänne OA, Palvimo JJ (1995) Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element.
Mol Endocrinol 9(8):1017–1028.
3. Gómez-Abellán P, et al. (2012) Sexual dimorphism in clock genes expression in human adipose tissue. Obes Surg 22(1):105–112.
4. Lim AS, et al. (2013) Sex difference in daily rhythms of clock gene expression in the aged human cerebral cortex. J Biol Rhythms 28(2):117–129.
5. Xiao R, et al. (2012) In utero exposure to second-hand smoke aggravates adult responses to irritants: Adult second-hand smoke. Am J Respir Cell Mol Biol 47(6):843–851.
6. Haslinger C, et al. (2004) Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol
22(19):3937–3949.
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Fig. S2. Serum levels of IL-6 are increased in the elderly. To test for possibly explanatory variables of the elevated baseline levels of pSTAT3 proteins in blood
monocytes in the elderly, we compared the serum IL-6 levels in all young (Y) versus older (O) individuals (A) or divided by sex (B). Significant differences are
observed in all subjects (A), as well as in male individuals and to a lesser extent in females (B).
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Fig. S3. Heat map of the correlation structure for sex-related immune features. A correlation matrix (Spearman method) was computed for all seven sex-
related immune features in all individuals without (A) or with IL-6 (B), and hierarchical clustering (with Ward’s method and Euclidian distance) was conducted.
mono.Unstimulated.STAT3 clustered with CRP and to a lesser extent with GM-CSF (A, dendrogram), as well as with CRP and to a lesser extent with IL-6 and GM-
CSF (B, dendrogram).
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Fig. S4. Modifications in sex effect on vaccine response after adjusting for confounding factors. Forward stepwise logistic regression analysis was conducted
to identify candidate confounders. (A) Regression coefficient of sex before adjustments. (B) Regression coefficient estimate for sex after adjusting for gene
module 042. (C) Regression coefficient of sex after adjusting for gene module 042 and CRP levels. Negative values (x axis) indicate higher vaccine response in
females.
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Fig. S5. Odds ratio for vaccine response based on expression of module 052 and testosterone levels. Logistic regression analysis was conducted on the an-
tibody-neutralizing activity based on expression of genes in module 052 and the testosterone levels as a continuous measurement. The estimated odds ratio
(OR) for the antibody-neutralizing response is shown (black continuous line). Red, light blue, blue, and dark blue dashed lines indicate the median testosterone
levels in females and first, second, and third quartiles of testosterone levels for males. CI, confidence interval.
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Table S1. Official gene symbol, Entrez ID, and module
assignments for construction of gene modules 042, 052, and 106
Gene symbol Entrez ID Module assignment
RPS26P39 100128168 042
RPS26P38 100129552 042
RPS26P54 100131971 042
ZNF511 118472 042
SYT11 23208 042
GZMB 3002 042
RPS26P6 392256 042
RPS26P47 400156 042
ASCL2 430 042
RPS26P35 441377 042
RPS26P11 441502 042
ABI3 51225 042
CPSF3 51692 042
EXOSC10 5394 042
TRIT1 54802 042
PNPO 55163 042
RPS26 6231 042
RPS26P20 644166 042
RPS26P8 644191 042
RPS26P15 644928 042
RPS26P50 644934 042
RPS26P31 645979 042
RPS26P2 646753 042
RPS26P53 728823 042
RPS26P25 728937 042
CHRNA2 1135 052
FAM83F 113828 052
SPATA2L 124044 052
COX6C 1345 052
ZNF358 140467 052
CCDC140 151278 052
ADRA2C 152 052
AIM1 202 052
NAT9 26151 052
BSCL2 26580 052
GPR162 27239 052
C17orf60 284021 052
DHRS4L2 317749 052
HSPB1 3315 052
ANKRD33 341405 052
ARAF 369 052
FLJ41423 399886 052
RPS15P4 401019 052
LTA4H 4048 052
FAM116B 414918 052
MIF 4282 052
LOC440313 440313 052
LOC440993 440993 052
AURKAIP1 54998 052
USE1 55850 052
PDSS2 57107 052
PEX5 5830 052
RPS19 6223 052
BDKRB1 623 052
HSPBL2 653553 052
RPS19P3 728953 052
SPRYD3 84926 052
FIBCD1 84929 052
PIGQ 9091 052
NR1D1 9572 052
MTCP1NB 100272147 106
RPS4Y2 140032 106
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Table S1. Cont.
Gene symbol Entrez ID Module assignment
CYorf15A 246126 106
NAAA 27163 106
NFU1 27247 106
GTF3A 2971 106
MTCP1 4515 106
PPA1 5464 106
PID1 55022 106
PLCXD1 55344 106
PRKY 5616 106
RPS4Y1 6192 106
CYorf15B 84663 106
ACCS 84680 106
DDX3Y 8653 106
EIF1AY 9086 106
KIAA0020 9933 106
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Appendix F:
Gibbs sampler for Dirichlet process mix-
ture of skew t-distributions models
— K is the number of different unique values taken by c (i.e. the number of clusters).
This number of clusters K is not set and its value may change at each iteration.
— `c is the latent variable indicating which cluster the observation c belongs to. {`1:C}
refers to a whole partition of the data.
— sc is the skew parameter for the observation c.
—  c is the scale parameter (skew t only) for the observation c.
F.1 Skew Normal distributions mixture
Our Gibbs sampler proceeds with each of the following updates in turn:
1. update concentration parameter ↵ given {`
1:C} using the data augmentation tech-
nique from West [1992]:
↵ / p(↵|{z
1:C}, G0, {⇠k}, { k}, {⌃k}, {`1:C}, {wk}, {s1:C}) / p(↵|{`1:C})
(↵, x|{`
1:C}) ⇠ p(↵)↵K 1(↵ + C)x↵(1  x)C 1
(x|↵, {`
1:C}) ⇠ Beta(↵ + 1, C)
(↵|x, {`
1:C}) ⇠ ⇡xGamma(a+K, b  log(x))+(1 ⇡x)Gamma(a+K 1, b  log(x))
with p(↵) / Gamma(a, b) and ⇡x
1 ⇡x =
a+k 1
C(b log(x))
2. update G given ↵, {⇠k}, { k}, {⌃k} and G0 via slice sampling:
{wk}, {`1:C} / p ({wk}, {`1:C}|{z1:C},↵, G0, {⇠k}, { k}, {⌃k}, {s1:C})
(a) sample the weights:
(w
1
, . . . , wK , w⇤|{`1:C}) ⇠ Dirichlet(card({`c = 1}), . . . , card({`c = K}),↵)
(b) for c = 1, . . . , C: uc ⇠ Unif([0, w`c [)
(c) Set j = K. While
Pj
k=1 wk < (1 min(u1:C)):
— set j = j + 1
— sample ⇡j ⇠ Beta(1,↵)
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— set wj = w⇤⇡j
Qj 1
k=K+1(1  ⇡k)
— sample (⇠j, j,⌃j|G0) ⇠ G0
(d) for c = 1, . . . , C sample `c given {⇠k}, { k}, {⌃k}, {wk} from:
p(`c = k) / 1{wk>uc}fSN (zc, ⇠k, k,⌃k)
3. for c = 1, . . . , C update sc given `c , {⇠k}, { k}, {⌃k}:
p(sc|zc,↵, G0, {⇠k}, { k}, {⌃k}, {`1:C}, {wk}) / p(sc|zc, {⇠k}, { k}, {⌃k}, `c)
(sc|zc, {⇠k}, { k}, {⌃k}, `c) ⇠ N[0,+1[(ac, Ac)
with Ac = 1
1+ 0`c⌃
 1
`c
 `c
and ac = Ac 0`c⌃
 1
`c
(zc   ⇠`c)
4. for k = 1, . . . , K update ⇠k,  k and ⌃k given G0, {`1:C} and {s1:C} from
p({⇠k}, { k}, {⌃k}|{z1:C},↵, G0, {`1:C}, {wk}, {s1:C}):
(a) update Gk given {z1:C}, G0, {`1:C} and {s1:C}:
— G
0
= sNiW (b⇠
0
, b 
0
,B
0
,⇤
0
, 
0
) with b
0
= (b
⇠
0
0
b
 
0
0
)
0 and B
0
= diag(D⇠
0
, D 
0
)
— Gk = sNiW (b⇠k, b
 
k ,Bk,⇤k, k) with bk = (b
⇠
k
0
b
 
k
0
)
0
— let Xk be a matrix of dimension card({c|`c = k})⇥ 2: Xk = (1 sc|`c=k)
— let Bk = (X 0kXk + diag(D0) 1) 1
— bk =
⇣
zc|`c=k Xk +
⇣
1
D⇠0
b
⇠
0
1
D 0
b
 
0
⌘⌘
Bk
—  k =  0 + card({c|`c = k})
— ⇤k = ⇤0 +
X
c|`c=k
"c"
0
c +
1
D⇠
0
(b
⇠
k   b⇠0)(b⇠k   b⇠0)0 +
1
D 
0
(b
 
k   b 0 )(b k   b 0 )
with "c = zc   b⇠k   scb k
(b) sample (⇠k, k,⌃k|Gk) ⇠ Gk
— ((⇠k, k)|⌃k, {`1:C}, {s1:C}, Gk) ⇠ N2d
⇣
(b
⇠
k, b
 
k ),Bk ⌦⌃k
⌘
— (⌃k|{`1:C}, {s1:C}, Gk) ⇠W 1( k,⇤k)
F.2 Skew t-distributions mixture
Our Gibbs sampler for non parametric skew t-distributions mixture proceeds with each
of the following updates in turn:
1. update concentration parameter ↵ given {`
1:C} using the data augmentation tech-
nique from West [1992]:
↵ / p(↵|{z
1:C}, G0, {⇠k}, { k}, {⌃k}, {⌫k}, {`1:C}, {wk}, {s1:C}, { 1:C}) / p(↵|{`1:C})
(↵, x|{`
1:C}) ⇠ p(↵)↵K 1(↵ + C)x↵(1  x)C 1
(x|↵, {`
1:C}) ⇠ Beta(↵ + 1, C)
(↵|x, {`
1:C}) ⇠ ⇡xGamma(a+K, b  log(x))+(1 ⇡x)Gamma(a+K 1, b  log(x))
with p(↵) / Gamma(a, b) and ⇡x
1 ⇡x =
a+k 1
C(b log(x))
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2. update G given ↵, {⇠k}, { k}, {⌃k}, {⌫k} and G0 via slice sampling:
{wk}, {`1:C} / p({wk}, {`1:C}|{z1:C},↵, G0, {⇠k}, { k}, {⌃k}, {⌫k}, {s1:C}, { 1:C})
(a) sample the weights:
(w
1
, . . . , wK , w⇤|{`1:C}) ⇠ Dirichlet (card({`1:C} = 1), . . . , card({`1:C} = K),↵)
(b) for c = 1, . . . , C: uc ⇠ Unif([0, w`c ])
(c) Set j = K. While
Pj
k=1 wk < (1 min(u1:C)):
— set j = j + 1
— sample ⇡j ⇠ Beta(1,↵)
— set wj = w⇤⇡j
Qj 1
k=K+1(1  ⇡k)
— sample (⇠j, j,⌃j|G0) ⇠ structured-Normal-invWishart(G0)
— sample ⌫j ⇠ p(⌫j)
(d) K = j
(e) for c = 1, . . . , C sample `c given {⇠k}, { k}, {⌃k}, {wk} from:
p(`c = k) / 1{wk>uc}fSN (zc, ⇠k, k,⌃k)
3. for c = 1, . . . , C update sc given `c , {⇠k}, { k}, {⌃k}:
(sc|zc, {⇠k}, { k}, {⌃k}, `c) ⇠ N[0,+1[(ac, Ac)
with Ac = 1
1+ 0`c⌃
 1
`c
 `c
and ac = Ac 0`c⌃
 1
`c
(zc   ⇠`c)
4. for k = 1, . . . , K update ⇠k,  k and ⌃k given G0, {`1:C} and {s1:C} from:
p({⇠k}, { k}, {⌃k}|{z1:C},↵, G0, {⌫k}, {`1:C}, {wk}, {s1:C}, { 1:C})
/ p({⇠k}, { k}, {⌃k}|{`1:C}, {s1:C}, G0):
(a) update the hyper parameters of the cluster distribution given {z
1:C}, G0, {`1:C}
and {s
1:C}:
— G
0
= sNiW (b⇠
0
, b 
0
,B
0
,⇤
0
, 
0
) with b
0
= vec(b⇠
0
, b 
0
) and B
0
= diag(D⇠
0
, D 
0
)
— Gk = sNiW (b⇠k, b
 
k ,Bk,⇤k, k) with bk = vec(b
⇠
k, b
 
k )
— let Xk be a matrix of dimension card({c|`c = k})⇥ 2: Xk = (1 sc|`c=k)
— let Bk = (X 0kXk + (B0) 1) 1
— bk =
⇣
zc|`c=k Xk +
⇣
1
D⇠0
b
⇠
0
1
D 0
b
 
0
⌘⌘
Bk
—  k =  0 + card({`c = k})
— ⇤k = ⇤0 +
X
c|`c=k
"c"
0
c +
1
D⇠
0
(b
⇠
k   b⇠0)(b⇠k   b⇠0)0 +
1
D 
0
(b
 
k   b 0 )(b k   b 0 )
with "c = zc   b⇠k   scb k
(b) sample (⇠k, k,⌃k|bk,Bk,⇤k, k) from a sNiW (bk,Bk,⇤k, k)
— ((⇠k, k)|⌃k, {`1:C}, {s1:C}, Gk) ⇠ N2d
⇣
(b
⇠
k, b
 
k ),Bk ⌦⌃k
⌘
— (⌃k|{`1:C}, {s1:C}, Gk) ⇠W 1( k,⇤k)
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5. update the degrees of freedom {⌫k} and the scale factors { 1:C} from the random
effects representation given {⇠k}, { k}, {⌃k}, {s1:C} and {`1:C}, sampling from:
p(⌫k, { 1:C}|{⇠k}, { k}, {⌃k}, {s1:C}, {`1:C})
(a) for k = 1, . . . , K update ⌫k, given ⇠k,  k, ⌃k, {s1:C} and {`1:C}, integrating
out the { 
1:C}, sampling from:
p(⌫k|{⇠k}, { k}, {⌃k}, {`1:C}, {wk}, {s1:C},↵, { 1:C})
/ p(⌫k|{⇠k}, { k}, {⌃k}, {`1:C}, {s1:C}, { 1:C})
/ p(⌫k|{⇠k}, { k}, {⌃k}, {`1:C}, {s1:C}) (reducing conditioning on the { 1:C})
A Metropolis-Hastings step is required to sample from the above distribu-
tion. We use a uniform log random-walk proposal as proposed in Frühwirth-
Schnatter and Pyne [2010]:
log(⌫newk   1) ⇠ Unif([log(⌫k   1)  c⌫k , log(⌫k   1) + c⌫k ]
where c⌫k is a fixed parameter of the algorithm (that can be tuned to improve
the acceptance rate of this MH step). Acceptance probability for ⌫newk is as
follow:
min
✓
1,
p(y|{⇠k}, { k}, {⌃k}, ⌫ k, ⌫newk , {`1:C})p(⌫newk )(⌫newk   1)
p(y|{⇠k}, { k}, {⌃k}, {⌫k}, {`1:C})p(⌫k)(⌫ k 1)
◆
(b) for c = 1, . . . , C update  c given {⇠k}, { k}, {⌃k}, {⌫k}, sc and `c sampling
from:
p( c|{⇠k}, { k}, {⌃k}, {⌫k}, sc, `c) ⇠ Gamma
 
⌫`c + d+ 1
2
,
⌫`c + z
2
c + tr(⌘c⌘
0
c⌃
 1
`c
)
2
!
with ⌘c = zc   ⇠`c   sc `c
F.3 Skew t-distributions mixture with informative mix-
ture of priors
Now we consider the case where the prior G
0
is actually a mixture of different priors
given by :
G
0
=
JX
j=1
sNiW (b⇠
0j, b
 
0j,B0j,⇤0j, 0j)
Let Uk = (⇠k, k,⌃k). The base measure over the cluster locations is then
p(Uk, ⌫k) = p(Uk)p(⌫k)
=
 
JX
j=1
!jfj(Uk)
!
p(⌫k)
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where fj is a structured Normal inverse Wishart distribution of parameters  j = {b⇠
0j, b
 
0j,
B
0j,⇤0j, 0j}:
fj(·) = sNiW (·; b⇠
0j, b
 
0j,B0j,⇤0j, 0j)
Let yAk where Ak = {c|`c = k} is the data in a given cluster k. Conditional on ⌫k, we
have
p(U k|yAk , ⌫k) =
p(yAk |U k, ⌫k)p(U k|⌫k)
p(yk|⌫k)
=
p(yAk |U k, ⌫k)p(U k)R
p(yAk |U, ⌫k)p(U)dU
Now
p(yAk |U k, ⌫k)p(U k) =
JX
j=1
!jp(yAk |U k, ⌫k)fj(U k)
Let’s write
pj(U k|yAk) =
p(yAk |U k, ⌫k)fj(U k)R
p(yAk |U , ⌫k)fj(U )dU
and pj(yAk) =
Z
p(yAk |U , ⌫k)fj(U )dU =
p(yAk |U k, ⌫k)fj(U k)
pj(U k|yAk)
As we are in a conjugate setting, pj(U k|yAk) is a sNiW whose probability density
function can be evaluated analytically, and pj(yAk) can be evaluated analytically. Thus
we have
p(U k|yAk , ⌫k) =
JX
j=1
!jpj(yAk)PJ
j0=1 !j0pj0(yAk)
pj(U k|yAk)
So the update for each cluster k in step 4 of the sampler becomes:
(a) For each j = 1, . . . , J , compute the sufficient statistics bjk, Bjk, ⇤kj,  jk, and
the associated pj(yAk)
(b) Sample an index m 2 {1, . . . , J} from the discrete distribution
 
!
1
p
1
(yAk
)
PJ
j0=1 !j0pj0(yAk)
, . . . ,
!JpJ(yAk)PJ
j0=1 !j0pj0(yAk)
!
(c) Sample U k|m ⇠ pm(U k|yAk)
The update for ⌫k in step 5 remains the same.
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F.4 MH within collapsed Gibbs
As an MH is used in the skew t sampler to sample {⌫k}, it is very important to never
integrate out those {⌫k} in the previous steps of the Partially Collapsed Gibbs sampler
[van Dyk and Jiao, 2013]. Otherwise, there is no guaranty that the stationary distribution
of the Markov chain remains unchanged (correlation structure of the {⌫k} with the other
parameters is likely not to be estimated properly). Besides, the reduced conditioning on
the { 
1:C} does not change the stationary distribution as those marginalized out { 1:C}
are sampled right after the MH step from their full conditional distribution [van Dyk and
Jiao, 2013].
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Appendix G:
Parameter estimation for Normal inverse-
Wishart and structured Normal inverse-
Wishart distributions
G.1 Maximum Likelihood Estimation
G.1.1 Maximum Likelihood estimators for Normal inverse-Wishart
Let observations (µi,⌃i) follow a Normal inverse-Wishart distribution for i = 1 . . . n:
(µi,⌃i) ⇠ NiW (µ0,0,⇤0, 0)
The likelihood is:
p ({µ
1:n}, {⌃1:n}|µ0,0,⇤0, 0) =
nY
i=1
(
(2⇡) 
d
2 |⌃i| 
 0+d+1
2
2
  0d2 |⇤
0
| 02
 d(
 0
2
)
    
1

0
⌃i
    
  12
exp

 1
2
tr
 
⇤
0
⌃ 1i
   0
2
(µi   µ0)0⌃ 1i (µi   µ0)
 )
The loglikelihood is then:
log (p ({µ
1:n}, {⌃1:n}|µ0,0,⇤0, 0)) = 
d
2
log(2⇡)   0 + d+ 2
2
nX
i=1
log (|⌃i|)  n 0d
2
log(2)
+
n 
0
2
log (|⇤
0
|)  n log
✓
 d(
 
0
2
)
◆
+
nd
2
log (
0
)
  1
2
tr
 
⇤
0
nX
i=1
⌃ 1i
!
  0
2
nX
i=1
(µi   µ0)0⌃ 1i (µi   µ0)
Taking the partial derivatives in respect of the four parameters µ
0
,
0
,⇤
0
, 
0
and setting
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each of them to zero gives the following system:
8
>>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>>:
µ
0
=
1
n
nX
i=1
µi
1

0
=
1
nd
nX
i=1
(µi   µ0)0⌃ 1i (µi   µ0)
⇤
0
= n 
0
 
nX
i=1
⌃ 1i
! 1
0 =  1
2
nX
i=1
log (|⌃i|)  nd
2
log(2) +
n
2
log (|⇤
0
|)  n
2
zd
✓
 
0
2
◆
where zd(x) =
d
dx
log( d(x)) is the d-dimensional digamma function (the derivative of
the logarithm of the d-dimensional Gamma function).
NB: The above solution are obtained using the two following identities:
d
dX
log(|X|) =
X
 1 and
d
dX
tr(XA) = A0 if X is definite-positive
Hence the MLE solutions verify:
8
>>>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>>>:
c
µ
0
=
1
n
nX
i=1
µi
b
0
= nd
 
nX
i=1
(µi  cµ0)0⌃ 1i (µi  cµ0)
! 1
zd
 
b 
0
2
!
=   1
n
nX
i=1
log (|⌃i|) + d log
 
n b 
0
2
!
  log
      
nX
i=1
⌃ 1i
     
!
c⇤
0
= n b 
0
 
nX
i=1
⌃ 1i
! 1
under the constraint b 
0
> d+ 1 (in which case there should a unique solution b 
0
).
G.1.2 Maximum Likelihood estimators for structured Normal inverse-
Wishart
Let observations (⇠i, i,⌃i) follow a structured Normal inverse-Wishart distribution
(sNiW ) for i = 1 . . . n:
(⇠i, i,⌃i) ⇠ sNiW (⇠0, 0,B0,⇤0, 0)
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The likelihood is:
p ({⇠
1:n}, { 1:n}, {⌃1:n}|µ0,B0,⇤0, 0) =
nY
i=1
(
(2⇡) 
d
2 |⌃i| 
 0+d+1
2
2
  0d2 |⇤
0
| 02
 d(
 0
2
)
  
B
 1
0
⌦⌃i
    12
exp
h
  1
2
tr
 
⇤
0
⌃ 1i
 
  1
2
(µi   µ0)0
 
B
0
⌦⌃ 1i
 
(µi   µ0)
i)
where µi = (⇠
0
i  
0
i)
0 and µ
0
= (⇠
0
0
 
0
0
)
0
The loglikelihood is then:
log (p ({µ
1:n}, {⌃1:n}|µ0,B0,⇤0, 0)) = 
nd
2
log(2⇡)   0 + d+ 1
2
nX
i=1
log (|⌃i|)  n 0d
2
log(2)
+
n 
0
2
log (|⇤
0
|)  n log
✓
 d(
 
0
2
)
◆
  1
2
nX
i=1
log
   
B0
 1 ⌦⌃i
     1
2
tr
 
⇤
0
nX
i=1
⌃ 1i
!
  1
2
nX
i=1
(µi   µ0)0
 
B0 ⌦⌃ 1i
 
(µi   µ0)
Taking the partial derivatives in respect of the four parameters µ
0
, B
0
,⇤
0
, 
0
and setting
each of them to zero gives the following system:
8
>>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>>:
µ
0
=
1
n
nX
i=1
µi
0 =
nX
i=1
✓
d
dB0
 
log
   
B0
 1 ⌦⌃i
    
+
d
dB0
 
(µi   µ0)0
 
B0 ⌦⌃ 1i
 
(µi   µ0)
 ◆
⇤
0
= n 
0
 
nX
i=1
⌃ 1i
! 1
0 =  1
2
nX
i=1
log (|⌃i|)  nd
2
log(2) +
n
2
log (|⇤
0
|)  n
2
zd
✓
 
0
2
◆
where zd(x) =
d
dx
log( d(x)) is the digamma function (the derivative of the logarithm of
the Gamma function).
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nX
i=1
✓
d
dB0
 
log
   
B0
 1 ⌦⌃i
    
+
d
dB0
 
(µi   µ0)0
 
B0 ⌦⌃ 1i
 
(µi   µ0)
 ◆
=
nX
i=1
d
dB0
⇣
log
⇣
|B0| d |⌃i|2
⌘⌘
+
nX
i=1
d
dB0
 
(µi   µ0)0
 
B
0
⌦⌃ 1i
 
(µi   µ0)
 
=  nd d
dB0
(log (|B0|)) +
nX
i=1
d
dB0
 
(µi   µ0)0
 
B
0
⌦⌃ 1i
 
(µi   µ0)
 
=  ndB0 1 +
nX
i=1
d
dB0
 
(µi   µ0)0
 
B
0
⌦⌃ 1i
 
(µi   µ0)
 
=  ndB0 1 +
nX
i=1
d
dB0
 
tr
 
(µi   µ0)0
 
B
0
⌦⌃ 1i
 
(µi   µ0)
  
=  ndB0 1 +
nX
i=1
⇣
⇠i   ⇠0  i   0
⌘0  
⌃ 1i
  ⇣
⇠i   ⇠0  i   0
⌘
=  ndB0 1 +
nX
i=1
 
⇠
0
i   ⇠00
 
0
i   00
!
 
⌃ 1i
  ⇣
⇠i   ⇠0  i   0
⌘
So if the above expression is zero, we get:
c
B
0
= nd
 
nX
i=1
 
⇠
0
i   ⇠00
 
0
i   00
!
 
⌃ 1i
  ⇣
⇠i   ⇠0  i   0
⌘! 1
So MLE solution for sNiW are:
8
>>>>>>>>>>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>>>>>>>>>>:
b
⇠
0
=
1
n
nX
i=1
⇠i
c
 
0
=
1
n
nX
i=1
 i
c
B
0
= nd
0
@
nX
i=1
0
@ ⇠
0
i   ⇠00
 
0
i   00
1
A ⌃ 1i
  ⇣
⇠i   ⇠0  i   0
⌘
1
A
 1
zd
 
b 
0
2
!
=   1
n
nX
i=1
log (|⌃i|) + d log
 
n b 
0
2
!
  log
      
nX
i=1
⌃ 1i
     
!
c⇤
0
= n b 
0
 
nX
i=1
⌃ 1i
! 1
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G.2 Expectation-Maximization algorithms (MLE & MAP)
G.2.1 MLE estimation via an E-M algorithm
The latent variables used in the EM [Dempster et al., 1977] algorithm for estimating
a finite mixture model over the MCMC draws for the parameters ⇠i,  i and ⌃i are the
allocation variables `i, with i = 1..N the number of (MCMC) observations. An (MCMC)
observation is then xi = (⇠i, i,⌃i). Let K be the number of components in the mixture
model:
p(xi|K, {✓1:K}) =
KX
k=1
⇡kf✓`i (xi|`i, {✓1:K}) for i = 1 . . . N
where f✓k is the parametric density function of a cluster: a sNiW density function
with parameters ✓k = (⇠k, k,Bk,⇤k, k).
At iteration t, the EM algorithm maximizes Q
⇣
{✓
1:K}
   {✓(t 1)
1:K }
⌘
for {✓
1:K} with:
Q
⇣
{✓
1:K}
   {✓(t 1)
1:K }
⌘
= E
h
log
 
p(x{1:n}, `{1:N}|K, {✓1:K})
    {✓(t 1)
1:K }
i
=
X
`{1:N}
log
⇣
p(x{1:n}, `{1:N}|K, {✓(t 1)
1:K })
⌘
=
KX
k=1
nX
i=1
r
(t 1)
ik log(⇡k) +
KX
k=1
nX
i=1
r
(t 1)
ik log (p(xi|K, {✓1:K}))
=
KX
k=1
nX
i=1
"
r
(t 1)
ik log(⇡k) 
 k + d+ 1
2
r
(t 1)
ik log(|⌃i|)
   kdr
(t 1)
ik
2
log(2)  r(t 1)ik log( d(
 k
2
)) +
r
(t 1)
ik  k
2
log(|⇤k|)
  r
(t 1)
ik
2
log(|B 1k ⌦⌃i|) 
r
(t 1)
ik
2
tr(⇤k⌃
 1
i )
  r
(t 1)
ik
2
(µi   µk)0(Bk ⌦⌃ 1i )(µi   µk)
#
with r(t)ik = p(`i = k|xi, {✓(t)1:K}) =
⇡kf✓(t)k
(xi)
PK
j=1 ⇡jf✓(t)j
(xi)
1. Initialization
✓
(0)
k is initialized randomly (⇡k are initialized at 1/K)
2. E step at iteration t
Compute the membership weights r(t 1)ik for each observation i = 1 . . . N for each
cluster k = 1 . . . K:
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r
(t 1)
ik = p
⇣
`i = k
   xi, {✓(t 1)
1:K }
⌘
=
⇡kf✓(t 1)k
(xi)
PK
j=1 ⇡jf✓(t 1)j
(xi)
3. M step at iteration t
Update the parameters:
• ✓(t)k are updated with their weighted Maximum Likelihood Estimators for each
k:
8
>>>>>>>>>>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>>>>>>>>>>:
b
⇠k =
1
Nk
nX
i=1
r
(t 1)
ik ⇠i
c
 k =
1
Nk
nX
i=1
r
(t 1)
ik  i
c
Bk = Nkd
0
@
nX
i=1
r
(t 1)
ik
0
@ ⇠
0
i   b⇠k
0
 
0
i   c k
0
1
A ⌃ 1i
  ⇣
⇠i   b⇠k  i   c k
⌘
1
A
 1
zd
 
b k
2
!
=   1
Nk
nX
i=1
r
(t 1)
ik log (|⌃i|) + d log
 
Nk b k
2
!
  log
      
nX
i=1
r
(t 1)
ik ⌃
 1
i
     
!
c⇤k = Nk b k
 
nX
i=1
r
(t 1)
ik ⌃
 1
i
! 1
• ⇡(t)k are updated with Nk/n, Nk =
Pn
i=1 rik
4. Repeat 2. and 3. until convergence
Convergence is reached when the incomplete log-likelihood l(t) is unchanged between
two consecutive iterations t and t+ 1 of the 2. and 3. steps:
l(t) = log
⇣
p({x
1:N}|K, {✓(t)
1:K})
⌘
=
nX
i=1
log
 
KX
k=1
⇡kp(xi|K, {✓(t)
1:K})
!
G.2.2 MAP estimation via E-M algorithm
In order to avoid degenrate covariance matrices (for instance when K is set to too
many clusters in the EM algorithm), it can be useful to replace MLE estimation with
Maximum A Posteriori (MAP) estimations [Fraley and Raftery, 2007].
To perform a MAP estimation instead of a MLE estimation as in section G.2.1, the
E-step of the algorithm is unchanged, but the M-step now maximizes the following Q
function:
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Q
⇣
{✓
1:K}
   {✓(t 1)
1:K }
⌘
=E
h
log
 
p({✓
1:K})p(x{1:n}, `{1:n}|K, {✓1:K})
    {✓(t 1)
1:K }
i
=
X
`{1:N}
⇣
log
⇣
p(x{1:n}, `{1:n}|K, {✓(t 1)
1:K })
⌘⌘
+ log(p({✓
1:K}))
= log(p({✓
1:K})) +
KX
k=1
nX
i=1
r
(t 1)
ik log(⇡k)
+
KX
k=1
NX
i=1
r
(t 1)
ik log (p(xi|K, {✓1:K}))
We use the following priors :
— a Dirichlet prior over the cluster weigths ⇡{1:K} with all parameters equal to the
same ↵ ( if ↵ = 1, then this is equivalent to a uniform prior over the K 1 simplex):
(⇡
1
, . . . , ⇡K) ⇠ Dir(↵)
And for each k:
— a Normal-Wishart empirical bayes prior on (µk,Bk):
(µk,Bk) ⇠ NW (m,0,C, 4)
µk|m,0,Bk,⌃{1:n} ⇠N
0
@
m,
1

0
 
Bk ⌦ 1
n
nX
i=1
⌃ 1i
! 11
A
Bk|C ⇠W (C, 4)
with m = µ{1:n}, C = 100I2 and L = (S(⇠)+S( ))/2 (where S(⇠) = diag(var({⇠1:n}))
and S( ) = diag(var({ 
1:n}))) and 0 = 0.01 for instance. The harmonic mean is
used as an empirical bayes prior for the bloc variance matrix.
One can also specify a vague prior on µk: µk ⇠ U2d
] 1,+1[ (which simplifies the ⇠
and  MAP estimators, as long as no cluster has an exactly null 0 contribution
Nk)
— a Wishart priors on ⇤k:
⇤k ⇠W (L, d+ 2)
with L = (S(⇠)+S( ))/2 (where S(⇠) = diag(var({⇠
1:n})) and S( ) = diag(var({ 1:n})))
— an Exponential prior on  k under the constraint that  k   d+ 1 :
 k   (d+ 1) ⇠ Exp(1)
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The Q function is then:
Q(✓|✓(t 1)) =
KX
k=1
"
  1
2
log
0
@
      
Bk ⌦
 
nX
i=1
⌃ 1i
! 1      
1
A
  0
2n
(µk  m)0
 
Bk ⌦
nX
i=1
⌃ 1i
!
(µk  m)
+
1
2
log(|Bk|)  1
2
tr
 
C
 1
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 
+
1
2
log(|⇤k|)  1
2
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 
L
 1⇤k
    k
#
+
KX
k=1
nX
i=1
"
r
(t 1)
ik log(⇡k) 
 k + d+ 1
2
r
(t 1)
ik log(|⌃i|)
   kdr
(t 1)
ik
2
log(2)  r(t 1)ik log( d(
 k
2
)) +
r
(t 1)
ik  k
2
log(|⇤k|)
  r
(t 1)
ik
2
log(|Bk ⌦⌃i|)  r
(t 1)
ik
2
tr(⇤k⌃
 1
i )
  r
(t 1)
ik
2
(µi   µk)0(Bk ⌦⌃ 1i )(µi   µk)
#
+ constant
and its partial derivatives yields:
dQ(✓|✓(t 1))
d k
=  Nk
2
zd
 
b k
2
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  1
2
nX
i=1
r
(t 1)
ik log (|⌃i|) +
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Nk b k
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  Nk
2
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 1
i
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=
d
2
Bk +
Nkd
2
Bk  
nX
i=1
r
(t 1)
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⇠
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0
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0
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1
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2
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The MAP estimators of ✓k|✓(t 1)k are thus:
8
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>:
b⇡kMAP =
Nk + ↵  1
n+K(↵  1)
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+
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(t 1)
ik
0
@ ⇠
0
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0
i   c k
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A ⌃ 1i
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 i   c k
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⌘
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+
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Nk b k
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!
+Nk log
   Pn
i=1 rik⌃
 1
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   
+ 2
c⇤k
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⇣
Nk b k
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L
 1
+
nX
i=1
r
(t 1)
ik ⌃
 1
i
! 1
with Nk =
Pn
i=1 r
(t 1)
ik .
The corresponding E-M algorithm for MAP estimation can therefore be written as
follows:
1. Initialization
✓
(0)
k are initialized randomly (⇡k are initialized at 1/K)
2. E step
Compute the membership weights r(t 1)ik for each observation i = 1 . . . N for each
cluster k = 1 . . . K:
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3. M step
Update the parameters:
• ✓k are updated with their MAP estimation for each k:
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• ⇡(t)k are updated with Nk/n, Nk =
Pn
i=1 rik
4. Repeat 2. and 3. until convergence
Convergence is reached when the incomplete log-likelihood l(t) is unchanged between
two consecutive iterations t and t+ 1 of the 2. and 3. steps:
l(t) = log
⇣
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1:N}|K, {✓(t)
1:K})
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Résumé
Analyse intégrative de données de grande dimension
appliquée à la recherche vaccinale
Les données d’expression génique sont reconnues comme étant de grande dimension, et
nécessitant l’emploi de méthodes statistiques adaptées. Mais dans le contexte des essais
vaccinaux, d’autres mesures, comme par exemple les mesures de cytométrie en flux, sont
également de grande dimension. De plus, ces données sont souvent mesurées de manière
longitudinale. Ce travail est bâti sur l’idée que l’utilisation d’un maximum d’informa-
tion disponible, en modélisant les connaissances a priori ainsi qu’en intégrant l’ensemble
des différentes données disponibles, améliore l’inférence et l’interprétabilité des résultats
d’analyses statistiques en grande dimension. Tout d’abord, nous présentons une méthode
d’analyse par groupe de gènes pour des données d’expression génique longitudinales. En-
suite, nous décrivons deux analyses intégratives dans deux études vaccinales. La première
met en évidence une sous-expression des voies biologiques d’inflammation chez les patients
ayant un rebond viral moins élevé à la suite d’un vaccin thérapeutique contre le VIH. La
deuxième étude identifie un groupe de gènes lié au métabolisme lipidique dont l’impact
sur la réponse à un vaccin contre la grippe semble régulé par la testostérone, et donc lié
au sexe. Enfin, nous introduisons un nouveau modèle de mélange de distributions skew t à
processus de Dirichlet pour l’identification de populations cellulaires à partir de données
de cytométrie en flux disponible notamment dans les essais vaccinaux. En outre, nous
proposons une stratégie d’approximation séquentielle de la partition a posteriori dans le
cas de mesures répétées. Ainsi, la reconnaissance automatique des populations cellulaires
pourrait permettre à la fois une avancée pratique pour le quotidien des immunologistes
ainsi qu’une interprétation plus précise des résultats d’expression génique après la prise
en compte de l’ensemble des populations cellulaires.
Mots clés : Analyse intégrée ; Analyse par groupe de gènes ; Bayesien non paramétrique ;
Connaissance a priori ; Cytométrie en flux ; Dimorphisme sexuel ; Distribution skew t ; Don-
nées de grande dimension ; Fenêtrage automatisé ; Grippe ; Génomique ; Modèle de mélange ;
Processus de Dirichlet ; Vaccin ; VIH.
Abstract
Integrative analysis of high-dimensionnal data
applied to vaccine research
Gene expression data is recognized as high-dimensional data that needs specific statis-
tical tools for its analysis. But in the context of vaccine trials, other measures, such as
flow-cytometry measurements are also high-dimensional. In addition, such measurements
are often repeated over time. This work is built on the idea that using the maximum of
available information, by modeling prior knowledge and integrating all data at hand, will
improve the inference and the interpretation of biological results from high-dimensional
data. First, we present an original methodological development, Time-course Gene Set
Analysis (TcGSA), for the analysis of longitudinal gene expression data, taking into ac-
count prior biological knowledge in the form of predefined gene sets. Second, we describe
two integrative analyses of two different vaccine studies. The first study reveals lower
expression of inflammatory pathways consistently associated with lower viral rebound fol-
lowing a HIV therapeutic vaccine. The second study highlights the role of a testosterone
mediated group of genes linked to lipid metabolism in sex differences in immunological
response to a flu vaccine. Finally, we introduce a new model-based clustering approach for
the automated treatment of cell populations from flow-cytometry data, namely a Dirichlet
process mixture of skew t-distributions, with a sequential posterior approximation strat-
egy for dealing with repeated measurements. Hence, the automatic recognition of the
cell populations could allow a practical improvement of the daily work of immunologists
as well as a better interpretation of gene expression data after taking into account the
frequency of all cell populations.
Key words: Automated gating; Dirichlet process; Flow cytometry; Flu; Gene set analysis; High-
dimensional data; HIV; Integrative analysis; Mixture model; Nonparametric Bayesian; Prior
knowledge; Sexual dimorphism; Skew t-distribution; Statistical genomics; Vaccine.
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